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Abstract 
Many spinal cord injuries (SCI) are incomplete, variable numbers of spared fibres 
passing the lesion level and supporting some residual function below the injury. 
One approach to improving function following injury is to develop therapies that 
maximise the potential of these spared fibres. The aim of the work in this thesis 
was to investigate the spontaneous plasticity that occurs in spinal cord pathways 
following injury and then determine whether olfactory ensheathing cell (OEC) 
transplants or treatment with antibodies blocking the function of the myelin 
inhibitors Nogo and MAG could enhance this plasticity. 
An electrophysiological approach was used to investigate these questions in rats 
which were subjected to a lesion of the dorsal columns at the C4/5 segmental 
level. This lesion interrupts the main component of the corticospinal tract which 
descends in the ventromedial dorsal column and also interrupts the ascending 
collaterals of sensory fibres from forelimb nerves. In this study, changes in the 
function of both of these pathways were assessed by recording cord dorsum 
potentials (CDPs) after stimulation in the pyramids (corticospinal activation) or 
of the radial nerve (sensory fibre activation). To enable plasticity in the 
corticospinal system to be investigated a method was developed for maximally 
activating the corticospinal projection on one side of the pyramids, whilst 
avoiding activation of the opposite pyramid and structures surrounding the 
pyramids. It was found that this could be achieved by careful positioning of 
bipolar stimulating electrodes. 
Before investigating the effect of potential plasticity inducing agents, the 
degree to which plasticity occurs in the absence of treatments was first assessed 
in F344 rats. The function of corticospinal and sensory pathways was compared 
in normal animals, acutely lesioned animals, and at 1 week and 3 months after a 
dorsal column lesion. Corticospinally-evoked CDPs above the lesion were not 
altered following an acute lesion but were larger in 1 week and 3 month dorsal 
column lesioned animals than in normal animals. The increase in amplitude was 
similar in both lesioned animal groups. This suggests that plasticity occurs at the 
intact connections formed by corticospinal fibres axotomised more distally, that 
it occurs within a week of the lesion and persisits for at least 3 months. 
 3
Corticospinally-evoked CDPs were almost abolished below an acute dorsal 
column lesion and remained of minimal amplitude 1 week after lesioning. 
However, there was some recovery of CDPs between 1 week and 3 months. This 
suggests plasticity either at the connections formed by spared fibres of the 
minor non-dorsal column components of the corticospinal tract or in 
propriospinal pathways originating above the lesion. This plasticity has a longer 
time-course than that at the connections of axotomised fibres above the lesion. 
Plasticity of the connections formed by larger diameter sensory fibres in the 
radial nerve was also seen below the level of the dorsal column lesion. This had 
a similar time course to the plasticity of corticospinal connections above the 
lesion CDPs being larger both 1 week and 3 months after injury compared to 
normal animals. A modest enhancement of transmission in both corticospinal and 
sensory systems therefore occurred following a dorsal column lesion. 
To investigate whether OEC transplants enhance plasticity after spinal cord 
injury, OECs were transplanted such that they became distributed within the 
spinal cord for several mm either above or below the lesion. Electrophysiological 
methods were then used, as above, to investigate whether transmission in the 
corticospinal and sensory fibre systems following a dorsal column lesion was 
improved in transplanted animals compared to 3 month survival animals. 
However, corticospinal actions rostral to the lesion were not enhanced by OEC 
transplants above the lesion and sensory transmission caudal to the lesion was 
not enhanced by cells below the lesion. OEC transplants are therefore unlikely to 
support recovery by promoting plasticity in the spinal cord after injury. 
To investigate whether antibodies designed to block the function of the myelin 
inhibitors Nogo and MAG would enhance plasticity following spinal cord injury, 
antibodies were delivered intrathecally via implanted osmotic minipumps over a 
period of six weeks following a dorsal column lesion. Vehicle treated and normal 
animals were investigated for comparison. Placement of the cannula and/or 
delivery of vehicle alone was found to have a detrimental effect on corticospinal 
actions above the lesion when compared to normal animals. Treatment with an 
anti-Nogo antibody (GSK577548) raised against a human Nogo-A fragment and 
targeting the amino-Nogo terminal was found to enhance transmission of 
corticospinal actions both above and below the dorsal column lesion. 
Corticospinal actions above the lesion were significantly greater than in the 
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vehicle treated controls but did not exceed those in normal animals because of 
the detrimental effect of the intrathecal cannulae/vehicle treatment. 
Transmission at the terminals of sensory afferent fibres below the level of the 
lesion was also enhanced by anti-Nogo treatment. In this case the actions of 
sensory pathways were significantly greater than those in both vehicle treated 
and normal animals. The fact that enhanced transmission occurs on the ‘wrong 
side’ of the lesion to be explained by axonal regeneration and the sensory 
transmission is enhanced over normal, strongly suggests that anti-Nogo induces 
plasticity in spinal pathways. In contrast, treatment with the anti-MAG antibody 
(GSK249320A) had no effect on either corticospinal or sensory-evoked activity in 
the spinal cord above or below the lesion, CDPs evoked by these pathways being 
comparable to that in vehicle treated controls. Anti-MAG does not appear to 
induce plasticity but may have neuroprotective actions which cannot be 
adequately tested in this lesion model. 
The results show that both corticospinal and sensory fibre systems show modest 
spontaneous plasticity following a dorsal column lesion. Plasticity at the 
terminations of axotomised fibres occurs relatively rapidly (within one week) 
while plasticity in spared systems occurs more slowly. This spontaneous 
plasticity does not appear to be enhanced by transplants of OECs, so that 
improvements in spinal cord function previously demonstrated in transplanted 
animals are probably due to a neuroprotective mechanism. The results obtained 
using function blocking antibodies targeting myelin inhibitors suggest that anti-
Nogo but not anti-MAG treatment may enhance plasticity in the spinal cord after 
injury. This observation adds to the accumulating evidence that interfering with 
Nogo-A signalling may be a useful approach for improving function after spinal 
cord injury. 
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1.1 Spinal cord injury 
The spinal cord is a caudal extension of the brain and its function is the 
transmission and integration of sensory, motor and autonomic signals. It receives 
sensory information from skin, muscles, joints and visceral organs, and 
distributes motor signals to the muscles of the body. Spinal Cord Injury (SCI) 
interrupts ascending and descending pathways in the white matter of the spinal 
cord that carry sensory and motor signals to and from the brain. It also damages 
grey matter in the central part of the spinal cord which causes segmental loss of 
interneurons and motoneurons. As a consequence, severe SCI can lead to deficits 
of sensory, motor and autonomic functions, which are usually permanent 
because the injured spinal cord has a very limited capacity for repair. 
It is estimated that the annual incidence of SCI, not including those who die at 
the scene of the accident, is approximately 1,000 new cases each year, and 
there are thought to be 40,000 people living with SCI in the UK alone (Spinal 
Injuries Association, http://www.spinal.co.uk). In the United States, the 
incidence of SCI has been estimated to be about 40 cases per million of 
population per year, or approximately 12,000 new spinal cord injuries per year, 
not including those who die at the scene of the accident. The number of people 
living with SCI has been estimated to be approximately 259,000 persons in 2008 
in the United States, with a range of 229,000 to 306,000 persons (Spinal Cord 
Injury Information Network, http://www.spinalcord.uab.edu). In China, the 
incidence of SCI was recently estimated to be as high as 65 cases per million of 
population per year in urban areas. If so, assuming a population of 1.3 billion, 
this would suggest an incidence of 84,500 per year. The annual global incidence 
of SCI in developed countries varies from 11.5 to 57.8 per million when only 
patients that survived before hospital admission were included (Reviewed by 
Ackery et al. 2004), and since the long-term survival is improved in developed 
countries, there are a large number of people who are chronically disabled by 
SCI.  
A SCI can be caused by a number of factors, from traffic accidents through to 
sporting activities and diseases. However, traffic accidents including motor 
vehicle, bicycle, and pedestrian, account for approximately half of reported SCI 
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cases (Lenehan et al. 2009). The majority of patients are 20–40 years old at the 
time of the injury. Recently, it appears that developed countries have higher 
mean ages at the time of SCI because of higher life expectancies and advance 
medical care, compared to less developed countries. It has been well 
documented that SCI in males is more prevalent than in females (Reviewed by 
Ackery et al. 2004; Lenehan et al. 2009).  
The majority of injuries lead to paralysis, and the effects of such an injury can 
be a disaster to individuals living with SCI and their families who are faced with 
not only the challenge of coming to terms with the injury, but also rebuilding 
their lives with a disability. Apart from the physical, emotional and social costs 
of SCI, the actual monetary costs are relatively high. The average yearly health 
care and living expenses and the estimated lifetime costs that are directly 
attributable to SCI vary greatly according to severity of the injury (Harvey et al. 
1992). Moreover, indirect costs have to be considered, such as losses in wages, 
fringe benefits and productivity. 
Mortality rates are significantly higher during the early stage after injury than 
during subsequent years (Reviewed by Strauss et al. 2006). Age, level of injury, 
and neurological grade are the most important premorbid factors for survival 
after SCI. Before World War Ⅱ , most people with SCI died within a few weeks 
after injury because of respiratory infection, urinary dysfunction or bedsores, 
and other complications (DeVivo et al. 1999). With the advent of modern 
medicine and better procedures for dealing with SCI, life expectancy for people 
with SCI continues to increase, and is now approaching that for the general 
population. Recent studies show that the leading cause of death after SCI is now 
respiratory complications (Strauss et al. 2006; DeVivo et al. 1999).  
1.2 General anatomy of the spinal cord 
The spinal cord is contained within the vertebral column which supports and 
protects the vulnerable cord. In addition, the spinal cord is covered by three 
meninges (the outer dura mater, the arachnoid mater, and the innermost pia 
mater) and surrounded by cerebral spinal fluid which acts as a cushion to protect 
the delicate cord (Figure 1-1).  
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Figure 1-1 Structure of the spinal cord 
The spinal cord is protected by the vertebral column and three meninges: the 
dura mater, the arachnoid mater, and the pia mater. The anterior roots (motor 
nerve roots) exit from ventral aspect of the spinal cord while the posterior roots 
(sensory nerve roots) enter the dorsal aspect. These two roots join to form 
paired spinal nerves. In cross section, the spinal cord is composed of a centrally 
placed butterfly- or H-shaped area of grey matter surrounded by white matter. 
The grey matter of the cord contains primarily the cell bodies of neurons and 
glia. The white matter of the cord contains primarily fibre tracts (adapted from 
online information www.mmi.mcgill.ca). 
The human spinal cord is divided into 31 segments: 8 cervical segments, 12 
thoracic segments, 5 lumbar segments, 5 sacral segments and 1 coccygeal 
segment (Afifi and Bergman 2005). The segmental levels of the spinal cord do 
not relate exactly to that of the corresponding vertebral bones at all levels of 
the cord. For example, the sixth cervical spine corresponds to the level of the 
seventh spinal cord segment in the cervical region, the fourth thoracic spine 
corresponds to the sixth cord segment in the thoracic region, and the tenth 
thoracic spine corresponds to the first lumbar cord segment in the lower 
thoracic and lumbar regions (Afifi and Bergman 2005) (Figure 1-2). 
There are two enlargements along the spinal cord: the cervical enlargement 
(third cervical to second thoracic segments) and the lumbosacral enlargement 
(first lumbar to third sacral segments). These two enlargements are sites of 
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neurons that innervate the upper and lower limbs respectively (Afifi and 
Bergman 2005).  
 
Figure 1-2 The relationships of spinal cord segments and spinal nerves to 
vertebral column levels 
The spinal cord is segmentally arranged: 8 cervical segments, 12 thoracic 
segments, 5 lumbar segments, 5 sacral segments and 1 coccygeal segment. It is 
encased in vertebral bone. In the 3-month foetus, the spinal cord and vertebral 
canal are the same length but the vertebral canal grows more rapidly so that in 
the adult the cord extends from the foramen magnum to the level of the first or 
second lumbar vertebra. Thus, the adult spinal cord occupies only the upper 
two-thirds of the vertebral canal. 31 pairs of spinal nerves emerge from the cord 
and, since the adult spinal cord is shorter than the vertebral canal, these nerve 
roots descend in the canal, with increasing obliquity and length, to reach their 
appropriate intervertebral foramina, through which they exit the canal. The 
lumbar and coccygeal nerves are the longest and descend beyond the end of the 
spinal cord as the cauda (adapted from Bradbury and McMahon 2006).  
The spinal cord, which consists of millions of nerve fibres, is the major pathway 
for transmitting information to and from the limbs, trunk and organs of the 
body. The motor nerve roots exit from the ventral aspect of the spinal cord 
while the sensory nerve roots enter the dorsal aspect. These two roots join to 
form paired spinal nerves (Figure 1-1). A pair of spinal nerves exits from each 
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segment of the spinal cord and they are numbered according to the 
corresponding spinal segment. Spinal nerves carry information from the spinal 
cord to the rest of the body. Cervical nerves are responsible for movement of, 
and feeling in, the arms, neck and upper trunk. Thoracic nerves transmit signals 
to and from the trunk and abdomen, while lumbar and sacral nerves carry 
information to and from the legs, the bladder, bowel and sexual organs (Afifi 
and Bergman 2005) (Figure 1-2). 
1.3 SCI type and level 
The exact effects of a SCI depend on the type and level of the injury. SCIs can 
be divided into two types depending on neurological evidence of sparing of 
sensory and/or motor functions: complete and incomplete injuries. In a 
complete injury, there is no sensation or voluntary movement below the level of 
the injury which is defined as the lowest level that has normal neurological 
function. An incomplete injury means that there is some sort of functionality 
below the level of the injury, which could be sensory or motor or both.  
According to the American Spinal Cord Injury Association’s (ASIA) International 
Standards for Neurological Functional Classification of Spinal Cord Injury (revised 
2002) (http://www.asia-spinalinjury.org), SCIs can be classified into five 
different degrees from A to E based on neurological levels, touch and pinprick 
tests of sensory function and strength of key muscles on both sides of the body 
after injury. A=complete: no motor or sensory function is preserved in the sacral 
segment S4-S5. B=incomplete: sensory but not motor function is preserved below 
the neurological level and includes the sacral segments S4-S5. This is usually a 
transient phase and if there is any motor function recovered below the 
neurological level, it becomes a motor incomplete, i.e. ASIA C or D. 
C=incomplete: motor function is preserved below the neurological level, and 
more than half the key muscles below the neurological level have a muscle 
grade less than 3. D=incomplete: motor function is preserved below the 
neurological level, and at least half the key muscles below the neurological level 
have a muscle grade of 3 or more. E=normal: motor and sensory functions are 
normal. 
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Based on the ASIA scale, approximately two thirds of SCIs were complete forty 
years ago. Nowadays, incomplete SCIs are becoming more common with 
approximately 55% of injuries being of this type because of the improved initial 
care and retrieval systems, greater awareness of the importance of 
immobilization after injury, use of air bags in vehicles, and hospital treatments 
to limit secondary injury such as administration of steroid drugs to reduce 
inflammation (Strauss et al. 2006). 
The part of the body from which function may be lost can determine the level of 
a SCI. SCIs occurring in the cervical region account for a relatively high 
percentage of approximately 51%; while SCIs in every other region, i.e. thoracic 
region, thoracolumbar region and lumbosacral region, contribute approximately 
equally (Lenehan et al. 2009). Cervical SCIs usually result in quadriplegia while 
thoracic level injuries or below result in paraplegia (Figure 1-3). Quadriplegia, 
also known as tetraplegia, is a symptom in which a person suffers paralysis 
affecting all four limbs after SCIs, although not necessarily complete paralysis or 
loss of function. In addition to the arms and legs being paralyzed, the abdominal 
and chest muscles will also be affected resulting in breathing deficits and 
inability to cough properly. Paraplegia is when the injury occurs below the level 
of the first thoracic spinal nerve. The degree of paralysis can vary from the 
impairment of leg movement to complete loss function of the legs and abdomen 
up to the nipple line. However, paraplegics have full function of their arms and 
hands (Figure 1-3). 
Lumbar and sacral injuries (L1-S5) result in a decreased control of the legs and 
hips, urinary system, and anus. Partial paralysis of lower body and legs can be 
seen in lower thoracic injuries (T9-T12). However, unlike lower thoracic injuries, 
upper thoracic (T1-T8) injuries result in poor trunk control as the result of lack 
of abdominal muscle control. In addition, the function of sympathetic nervous 
system may be compromised. People with injuries at the thoracic level or below 
usually have full control of the hands. Individuals with C7-T1 injuries may have 
arm control but not complete control of hands and fingers. C7 is generally the 
highest injury level where the patients are able to live relatively independently. 
C6 injuries allow wrist control but no hand and finger function. A passive key 
grip may be present by flexing the wrist backwards, but will be weak. C5 injuries 
usually result in only shoulder and biceps control, no control at the wrist or 
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hand. Individuals with C4 injuries may have some use of biceps and shoulders, 
but weaker. In higher cervical injuries, above the C3 level, patients typically 
lose diaphragm function and require a ventilator to breathe. The head and neck 
movements usually are affected depending on residual muscle strength 
(International Standards for Neurological and Functional Classification of Spinal 
Cord Injury 2002) (Figure 1-3). In addition to these symptoms, people with SCI 
will often suffer other complications such as spasticity and neuropathic pain 
(Burchiel and Hsu 2001). 
 
Figure 1-3 Functional deficits at different levels of SCI  
The symptoms of SCI depend on two factors: where the damage occurs and how 
serious it is. Cervical spinal cord injuries usually result in quadriplegia while 
thoracic level injuries or below result in paraplegia. Quadriplegia is a symptom 
in which a person suffers paralysis affecting all four limbs after SCI, although not 
necessarily complete paralysis or loss of function. Paraplegia is when the injury 
occurs below the level of the first thoracic spinal nerve, which leads paralysis of 
the lower half of the body. Paraplegics have full function of their arms and 
hands. The area of paralysis is indicated in red (taken from Thuret et al. 2006). 
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Depending on the mechanical mechanisms of the injury, several physically 
distinct types of injuries are recognized. When sudden and violent jolts injure 
the nearby tissues of the spinal cord, a temporary spinal concussion occurs. This 
type of injury stays only for a few hours. If the violent force injures the spinal 
cord directly, a contusion or bruise may happen. It causes bleeding in the spinal 
canal and a range of further secondary damage, details which are described 
below. A spinal compression occurs when an object, such as a tumour, occupies 
some space in the bony vertebral column and gives pressure to the spinal cord. 
The spinal cord can be cut such as following a knife injury. Spinal transection 
describes the complete severing of the cord (Bohlman et al. 1992).  
1.4 Experimental animal models 
The need to be able to investigate the mechanisms and possible treatments for 
SCI has led to the development of different types of animal models. Since there 
is no particular model that completely addresses all aspects of traumatic SCI, a 
number of models ranging from sharp transections to blunt contusions have been 
developed in a variety of animal species.  
Among animal species used for SCI models, the rat and mouse are the most 
common animals because of cost, accessibility, ease of care, low susceptibility 
to infections and well-established techniques for functional analysis (Onifer et 
al. 2007; Rice et al. 2007; Toft et al. 2007). The mouse is becoming more 
popular because of its transgenic potential (Carter et al. 2008; Simonen et al. 
2003; Kim et al. 2003; Zheng et al. 2003). Larger mammals such as dogs, pigs, 
and cats, (Blight and Young 1989; Blight 1991) have also been used occasionally 
and primate experiment may be necessary to prove safety and efficacy before 
clinical trials (Freund et al. 2006; 2007).  
1.4.1 Contusion 
After the first well-documented weight drop model by Allen in 1911, a range of 
animal models in different species have been developed to produce a blunt 
contusive force to the spinal cord, which simulates the evolution of 
neuropathology after SCIs in humans (Wrathall et al. 1985; Soblosky et al. 2001). 
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The contusion model provides a good setting for evaluating neuroprotective 
strategies, plasticity and demyelination. However, it is not an ideal model for 
investigation of regeneration due to the incomplete nature of the injury and the 
complexity of the tracts. With continuous refinements, current contusion 
models, including New York University Impactor (NYU device) (Gruner 1992), 
Ohio State University Impactor (OSU device) (Noyes 1987) and Infinite Horizon 
Impactor (IH) (Scheff et al. 2003), can optimize the consistency and precision of 
the mechanical forces applied during the injury, generate different degrees of 
injury severity and functional outcomes by monitoring injury parameters such as 
impact velocity and tissue displacement, and also are relatively easy to perform 
because of highly refined devices. The contusion model has become one of the 
most commonly used and well developed injury models. 
1.4.2 Compression 
Because most contusion devices deliver a rapid impact to the spinal cord, they 
do not simulate ongoing cord compression secondary to residual spinal column 
displacement. A clip compression model was developed to produce static 
compression injuries, in which a relation between the severity of neurological 
injury and the duration of compression was illustrated (Rivlin and Tator 1978). 
Blight (1991) developed a moderate-severity injury technique in the guinea pig 
using modified forceps which produces a relatively larger volume of tissue 
compression and displacement than the clips. As in the contusion model, the 
compression model can also produces different severities of SCI by adjusting the 
closing force of the clips or forceps and/or duration. The compression model is 
valuable for investigation of the acute pathophysiology after cord injury, the 
timing of decompression, and potential therapies such as neuroprotective 
agents.  
1.4.3 Transection 
Partial or complete transections of the spinal cord have also been frequently 
used to model SCI. Because these models can effectively disconnect designated 
axonal pathways at required levels of the cord, they mainly are applied for 
testing axonal regeneration that is impossible to assess from contusion or 
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compression models, in which many axons are invariably spared (Liu et al. 1999; 
Gauthier et al. 2002; Polentes et al. 2004). Transection models produce 
relatively consistent injuries compared to contusion and/or compression models. 
In a complete transection model, the completeness of the injury provides an 
easy way to determine the degree of the axonal regeneration and functional 
recovery (López-Vales et al. 2006; Steward et al. 2006; Coumans et al. 2001). In 
a partial transection model produced by a variety of techniques, a selected tract 
is cut in order to collect information about this specific tract (Toft et al. 2007; 
Lu et al. 2006). Compared to a complete transection, a partial transection is 
milder and therefore the postoperative animal care is easier, especially 
regarding bladder care. A unilateral partial transection model also allows 
comparison of the responses in a particular tract with its uninjured counterpoint 
on the contralateral side (Xu et al. 1999).   
1.4.4 Chemical-mediated SCI 
Chemically-mediated SCI models also exist. They are not so widely used but can 
be employed to model specific aspects of the secondary injury cascade, 
demyelination, or to induce ischemia (Cameron et al.1990; von Euler et al 2002).  
1.5 Pathological events following SCI 
Information from clinical injuries on the pathological events following SCI is 
relatively limited so that most of our understanding of this area comes from 
experiments on animals. Injury to the spinal cord triggers a complex series of 
biological events which are summarized in Figure 1-4. 
SCI includes two stages: primary and secondary injury processes. The primary 
injury process, initial mechanical injury due to local deformation and energy 
transformation, is quickly followed by a series of time-dependent 
pathophysiological changes, i.e. the secondary injury process, including blood 
flow changes, excitotoxicity, oedema, inflammation, demyelination, axotomy, 
axonal degeneration and dieback, and apoptotic cell death (Dumont et al. 
2001a) (Figure 1-4). Most participating cells reside in the spinal cord while others 
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are recruited from the circulatory system to the injury site (Schwab and 
Bartholdi 1996). 
 
Figure 1-4 Pathological events following SCI 
SCI includes two stages: primary and secondary injury processes. The primary 
injury process, initial mechanical injury due to local deformation and energy 
transformation, is quickly followed by a series of time-dependent 
pathophysiological changes, i.e. the secondary injury process, including blood 
flow changes, excitotoxicity, oedema, inflammation, demyelination, axotomy, 
axonal degeneration and dieback, and apoptotic cell death (taken from Bareyre 
and Schwab 2003). 
1.5.1 Blood flow alterations 
SCI disrupts the blood flow at the actual injury site and also changes blood flow 
in the vicinity of the injury site. The damage of the regional blood vessels is vital 
for the evolution of destructive events during the secondary injury process 
(Mautes et al. 2000). Breakdown of the blood brain barrier that normally helps 
protect the central nervous system (CNS) at the site of SCI results in the influx of 
inflammatory cells (see below; Bareyre and Schwab 2003). 
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Haemorrhage occurs when injury disrupts blood vessels, which is a common 
feature in both experimental models and in human SCIs (Mautes et al. 2000; 
Tator and Koyanagi 1997). Haemorrhage is usually found in the central region of 
the injured cord, especially the grey matter (Mautes et al. 2000). The majority 
of these haemorrhages are relatively small. Occasionally, major bleeding termed 
as haematoma can be seen in the cord following contusion or laceration injuries.  
Vasospasm, which is a narrowing of the blood vessels that can often decrease 
blood flow by up to 80 percent (Anthes et al. 1996) and small vessel thrombosis, 
can lead to ischemia, which deprives neurons and other cells of the oxygen and 
other nutrients they need to survive (Tanaka et al. 2005). Most cell types 
produce reactive oxygen species and other free radicals during the ischemic 
period, which have been shown to be crucial in the progressive death of cells 
after SCIs (Cayli et al. 2004; Usul et al. 2004). Inadequate flow of oxygen and 
nutrients into the spinal tissue can contribute to spinal shock, which is a stage of 
failure of the spinal cord to function within the first few weeks after injury 
(Krassioukov and Claydon 2006).  
Complete cervical injuries can cause systemic changes to the cardiovascular 
system including bradycardia and hypotension that can lead to further damage 
to the cord (Krassioukov and Claydon 2006; Guízar-Sahagún et al. 2004).  
1.5.2 Oedema 
Rapid bleeding into the normal fluid-filled spaces of the spinal cord contributes 
to local oedema, which can be easily observed at the injury site very soon after 
SCI (Griffiths and Miller 1974) and reaches maximum in the first days after 
injury. Oedema starts from the central portion of the cord and then spreads into 
white matter of the cord (Noble and Wrathall 1989). It can also spread for a 
considerable distance rostrally and caudally from the injury site in both 
experimental models and clinical patients (Wang et al. 1993). The most 
important of the various factors contributing to oedema is the increased 
permeability of blood vessels around the injury site. It is suggested that oedema 
exerts deleterious effects probably by providing an abnormal environment and 
compressing the local tissue (Balentine 1985). 
  30 
1.5.3 Inflammatory response 
The inflammatory response, which involves four major categories of immune 
cells: neutrophils, monocytes, microglia, and T-lymphocytes, begins within hours 
after SCI and reaches its peak within the first few days (Schnell et al. 1999; 
Bareyre and Schwab 2003). This complex process includes the release of 
chemical mediators, epithelial damage, changes of vascular permeability, 
oedema, activation of microglia, and recruitment of peripheral inflammatory 
cells. The inflammatory cells recruited in the CNS after SCI are much higher and 
have been infiltrated into wider areas (i.e. not restricted to the lesion site) 
compared to those following brain injury (Schnell et al. 1999; Donnelly and 
Popovich 2008). 
It is commonly believed that inflammation has both destructive and constructive 
effects to the cord (Bethea 2000). On the one hand, improved functional 
recovery can be observed by reducing inflammatory response (Stirling et al. 
2004). On the other hand, cellular debris and breakdown products can be 
eliminated through inflammation events (Rice et al. 2007; Fleming et al. 2006).  
Macrophages are one of the most active cellular factors in the inflammation and 
have both detrimental and beneficial roles in the progression of SCI and 
following repair (Bethea 2000). A large number of macrophages produce and 
secrete cytokines that contribute to further cell death and maintain the 
inflammatory process. They also produce reactive oxygen species that eventually 
lead to severe membrane damage. However, the macrophages are also active in 
constructive events by secreting factors that could promote axonal growth, 
stimulate Schwann cells proliferation and remove cellular debris after injury, 
which might improve functional recovery later (Schwartz and Yoles 2005).  
Local microglia are also activated in the vicinity of lesion and within tracts that 
undergo Wallerian degeneration, which represents the anterograde 
disintegration of axons and their myelin sheaths that have been damaged 
following injury. These activated microglia secrete various cytokines, nitric 
oxide, superoxide anions, glutamate, and proteases (Banati et al. 1993), which 
indirectly induce apoptosis. Moreover, microglia can cause oligodendrocyte 
death (Li et al. 2005). However, many of the cytokines released by microglia 
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may have beneficial actions, including inducing neurite sprouting, stimulating 
the production of nerve growth factor, facilitating CNS regeneration, and 
neuroprotective actions (DeKosky et al. 1996; Banati et al. 1993; Li et al. 2005). 
Activation of macrophages and microglia is sustained over the course of weeks. 
1.5.4 Apoptosis and excitotoxicity 
The mechanical injury to the cord causes some cells to die instantaneously by 
necrosis, which is a process of cell swelling and then cell membrane rupture. 
Later on, apoptosis (programmed cell death), another type of cell death in 
which cells condense and break apart into small fragments in a very orderly 
process, afflicts many cell types including neurons, oligodendrocytes, astrocytes, 
and other cells of the spinal cord (Reviewed by Beattie et al. 2000). Injury-
induced rush of calcium into cells is the major trigger for apoptosis after injury. 
Apoptosis has been reported to last for about one month in experimental animals 
(Crowe et al. 1997), and has also been detected in humans (Emery et al. 1998).  
Oligodendrocyte death may occur at the injury site and distant from the impact 
site after SCI in both humans (Emery et al. 1998) and in experimental animals (Li 
et al. 1999). As mentioned above, microglia are one important cause of 
oligodendrocyte death. Along with microglia, loss of trophic supports due to 
degeneration of axons and an increase in nerve growth factor after injury are 
causes of oligodendrocyte apoptosis (Beattie et al. 2002; Krenz and Weaver, 
2000). 
Injury induces the accumulation of the excitatory amino acids glutamate and 
aspartate with peak levels within the very first minutes (Farooque et al. 1997). 
All sorts of neural cells in the injured cord are susceptible to excitotoxic cell 
death. Over-excitation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid 
receptors and N-methyl-D-aspartate receptors may cause the death of neurons 
(Das et al. 2005). Oligodendrocytes are the most vulnerable cell type, while 
other glial cells are also susceptible to excitotoxic cell death via α-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid and kainite receptors (Rosin et al. 
2004). 
  32 
1.5.5 Axonal degeneration and demyelination 
Following injury, the axons may have simply been disrupted, or may be still 
intact anatomically in the early stage and then degenerate afterwards. Those 
spared axons are commonly dysfunctional. Lack of vascular and glial support 
after injury, an ionic imbalance with an influx of calcium, and the inherent 
reaction of neurons to injury all contribute to the progress of axonal 
degeneration (Iwata et al. 2004; Araki et al. 2004). The dieback of the severed 
axons may lead to loss of collateral connections, and therefore minimise residual 
functions and reduce the degree of ensuing plasticity (see 1.6 spontaneous 
recovery).  
Demyelination is a process whereby myelin has been damaged while the axons 
are still relatively intact following SCI (Waxman 1989) (Figure 1-5). Literature 
suggests that primary demyelination occurs early following SCI in experimental 
animals (Salgado-Ceballos et al. 1998). However, it seems only isolated axons 
have been affected in human SCIs (Norenberg et al. 2004). The ensuing 
demyelination has strong negative effects on the normal function of surviving 
axons, which contributes to the functional deficits of SCI.  
1.5.6 The glial scar  
The formation of the glial scar after injury is a complex event in which various 
cell types may be involved such as activated astrocytes, microglial cells, 
oligodendrocytes, inflammatory cells and connective tissue (Reviewed by 
Fawcett and Asher 1999) (Figure 1-5). Astrocytes are the most commonly found 
and important cell type in the evolution of CNS scars. Following injury, 
astrocytes become activated and proliferate to form a solid network surrounding 
the lesion site (Faulkner et al. 2004).  
The glial scar is not only a physical barrier for regeneration, but also can release 
inhibitory factors which inhibit axon outgrowth. The extracellular matrix 
molecules associated with the glial scar have potent growth inhibitory properties 
in vitro and therefore may contribute to the non-permissive environment of the 
glial scar (Fawcett and Asher 1999; Davies et al. 1999). It has been shown that 
the impairment of axonal regeneration by the glial scar also occurs in immature 
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CNS. However, scar formation is much less severe than in the adult system 
(Firkins et al. 1993).  
In addition to the non-permissive effects on axonal regeneration, the glial scar 
might have some beneficial effects such as repair of the blood-brain barrier, 
limiting cellular degeneration and inflammation (Faulkner et al. 2004; Rolls et 
al. 2009). Moreover, the glial scar isolates the injury site from surrounding 
healthy tissue (Figure 1-5).   
1.5.7 Cavity  
Over time, the lesion site begins to form a fluid-filled cavity in the centre. In 
animal models, it may extend several segments above and below the site of 
injury within a few weeks (Figure 1-5). The injury may develop a single, 
multiloculated or multiple cavities in humans. These cavities are filled with 
extracellular fluids which contain residual macrophages, small pieces of 
connective tissue and blood vessels (Norenberg et al. 2004).The cavity 
represents the final healing phase of the necrotic process and provides a physical 
gap that impedes axon regeneration. About 4% of individuals with SCI develop 
syringomyelia, which results from the extension of a cavity or coalescence of a 
few small cavities in the centre of the spinal cord over time from as early as 2 
months to as late as 30 years after injury (Schurch et al. 1996).  
SCIs are usually relatively stable after a period of weeks to months. The injury 
site following SCI develops typically characterized by axotomized nerve fibres, a 
fluid-filled cavity surrounded by a glial scar which engulfs inhibitory molecules, 
and variable amounts of intact tissue surrounding the lesion. In this peripheral 
rim of intact tissue harbours spared fibres that are either uninjured or 
demyelinated (Figure 1-5).  
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Figure 1-5 Main pathological features of a SCI 
Following SCI, large numbers of nerve fibres become axotomized, interrupting 
communication in the long ascending and descending pathways responsible for 
normal motor, sensory and autonomic functions. Axotomized fibres are 
prevented from regenerating by inhibitory molecules associated with myelin 
debris and the glial scar, which is composed of reactive astrocytes and a variety 
of other cell types. Over time, a fluid-filled cyst can develop at the site of 
injury, forming a physical barrier to regeneration. If the injury is incomplete, 
spared fibres can provide some residual function. Impulse conduction along some 
of these fibres might, however, be compromised by demyelination (taken from 
Barnett and Riddell 2007). 
1.6 Spontaneous recovery 
SCI causes obvious functional deficits in the early stage of the course of lesion 
evolution in clinical patients. Although spontaneous regeneration of lesioned 
fibres is very limited in the adult CNS, some functional recovery below the initial 
spinal injury level can be observed in almost all SCIs during a period of days, 
weeks or even years after the injury (Reviewed by Fawcett et al. 2007; Burns et 
al. 1997).  
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The spontaneous recovery of motor function in people with complete SCIs is 
limited and predictable (Fisher et al. 2005; Brown et al. 1991). However, it is 
relatively substantial and highly variable in incomplete SCI patients (i.e. ASIA C 
and ASIA D) (Ditunno et al. 2000; Burns et al. 1997). The extent of this motor 
functional recovery is nearly complete in some but very limited in others. The 
rate of spontaneous motor recovery is rapid during the first few months, and 
almost reaches the peak by 9 months. However, a small amount of ongoing 
recovery can persist for up to 18 months or occasionally longer. Some sensory 
recovery can also be seen after the initial injury over the same time course as 
motor recovery. Once there is no further improvement in functional capacity, 
the injury is considered to be stable (Fawcett et al. 2007).  
The severity of the initial injury has a strong impact on the following 
spontaneous recovery. Data from US Model systems Sygen and EMSCI databases 
show that the majority of ASIA A patients remain as ASIA A, with about 10% 
regaining some sensory function (ASIA B) and about 10% converting to ASIA C 
(some motor function) over the first year after SCI. However, patients initially 
classed ASIA B or C showed greater spontaneous recovery compared to ASIA A 
patients; about 15-40% of ASIA B patients showed a conversion to ASIA C, and 
40% to ASIA D. ASIA C conversion to D was between 60-80% of all the patients 
examined. Very few ASIA D patients converted to ASIA E (reviewed by Fawcett et 
al. 2007). 
Spontaneous functional recovery can also be seen in experimental animal models 
of incomplete SCI (McKenna and Whishaw 1999; Weidner et al. 2001; Bareyre et 
al. 2004; Courtine et al. 2005; Ballermann and Fouad 2006; Gulino et al. 2007). 
However, the degree and time course of spontaneous functional recovery vary 
from species to species. It also depends on the level and severity of the lesion 
(Noble and Wrathall 1989). 
In rats, a number of behavioural tests and electrophysiological techniques are 
available to evaluate function outcomes. Different tests are applied for assessing 
different functions in different models of SCI. A pellet retrieval test may be 
chosen to assess reaching and grasping functions in cervical SCI models (McKenna 
and Whishaw 1999; Weidner et al. 2001). The cylinder test is used to examine 
forelimb and forepaw usage for support during spontaneous vertical exploration 
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after cervical SCIs (Liu et al. 1999). Gait analysis tests such as catwalk may be 
chosen for obtaining quantitative information on a range of parameters relating 
to gait (Hamers et al. 2001). There are also studies for evaluating limb placing 
and footfalls while the rat walks on a grid, ladder, and beam or rope (Onifer et 
al. 2007). 
The Basso, Beattie, and Bresnahan open-field locomotor rating scale (BBB scale) 
(Basso et al. 1995) is one of the most commonly used tests to assess locomotion 
in rats. The BBB scale has a range from zero (no hindlimb movements) to 21 
(normal coordinated gait) by analysing paw placement, joint movement, and 
trunk stability. Scores from zero to 7 focus on joint movement in the hindlimbs, 
scores from 8 to 13 relate to paw placement and coordination, and scores from 
14 to 21 are determined by trunk stability, tail position, and paw placement.   
As mentioned above, spontaneous functional recovery also depends on the 
severity of the original injury. One study suggests that even though spontaneous 
recovery can be observed in both mild and moderate contusion groups in rats, 
the differences of average BBB scores between them can be as high as 5 
(Collazos-Castro et al. 2006). Another study reported that the BBB score is 0 on 
post-operative day 1 after spinal hemisection, and then rapidly reaches 11 on 
post-operative day 7 (Gwak et al. 2004). The prognosis for functional return may 
be better in experimental animals than in humans because quadruped animals 
adapt trunk, forelimb and hindlimb movements to compensate for deficits. 
Therefore, they can walk satisfactorily although probably with poor balance or 
coordination (Rossignol et al. 2004; Ballermann and Fouad 2006). 
The mechanisms behind this spontaneous functional recovery are not fully 
understood. It has been proved that CNS axons have the intrinsic capacity for 
regrowth over long distances (David and Aguayo 1981). However, they are 
inhibited by the unfriendly environment after injury (Davies et al. 1999). The 
local expression of neurotrophic factors are increased after SCI, but apparently 
not sufficiently to overcome inhibitory factors and maintain regenerative axonal 
response (Brown et al. 2004; Oyesiku et al. 1997; Satake et al. 2000). Therefore, 
axonal regeneration can be excluded from the mechanisms of spontaneous 
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recovery. Remyelination and plasticity may contribute to this spontaneous 
functional recovery. 
A degree of spontaneous remyelination within the spinal cord probably 
contributes to functional recovery in experimental animals. Remyelination can 
occur in two different ways, i.e. by Schwann cells and oligodendrocyte 
precursors. Schwann cells normally myelinate fibres of the peripheral nervous 
system (PNS), but migrate into the spinal cord after injury, and then myelinate 
demyelinated axons (Takami et al. 2002; Imaizumi et al. 2000). Blight and Young 
(1989) have reported that remyelination by Schwann cells is prevalent in a cat 
contusion model. Their electrophysiological assessment also showed that the 
remyelination by Schwann cells is capable of restoring effective action potential 
conduction in mammalian spinal cord sensory tracts. Oligodendrocyte precursors 
in the spinal cord also migrate to the site of injury, and differentiate into 
mature oligodendrocytes and produce myelin (Gensert and Goldman 1997; Yang 
et al. 2006). The remyelination of spared projections by newly generated 
oligodendrocytes could contribute to functional recovery. 
Plasticity is a generic term that denotes the capacity of the nervous system to 
change. Neuronal plasticity has been traditionally associated with learning and 
memory processes in the hippocampal regions of the brain (DeFelipe 2006). It is 
now generally accepted that plasticity is also associated with cellular changes 
and modifications occurring in all areas of the CNS after injury including SCI. 
This reorganization might happen with two different main mechanisms: synaptic 
plasticity which occurs in pre-existing circuits by modifications of synaptic 
strength (Gulino et al. 2007) and anatomical plasticity in which new connections 
arise through sprouting and anatomical reorganization (Bareyre et al. 2004). A 
number of experiments have been done to investigate plasticity after SCI 
(reviewed by Raineteau and Schwab 2001; Edgerton and Roy 2002). These 
experiments show that plasticity has been seen in different types of injuries and 
different animal models during hours to months after injury. They also show that 
the CNS is capable of reorganising the circuitry in different levels under certain 
conditions, i.e. cortical level (Jain et al. 1997), subcortical level and local spinal 
cord, based on unlesioned fibres in incomplete SCI. Furthermore, it has been 
proved that this plasticity can contribute to functional recovery in both animal 
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models and humans (reviewed by Raineteau and Schwab 2001; Edgerton and Roy 
2002).  
At the cortical level, it is observed that cortical territories controlling intact 
body parts tend to enlarge and invade cortical regions that have lost their 
peripheral target regardless of different species, i.e. in experimental and 
clinical SCI. The structure of the dense network that interconnects the different 
subregions of the primary motor cortex provides the basis of rapid cortical 
reorganization. This cortical reorganization includes physiological change and 
anatomical change. Jain et al (1997) reported that massive cortical 
reorganization was observed in monkeys with a dorsal column SCI. Some studies 
(Bareyre et al. 2004; Fouad et al. 2001) also proved that rearrangement of the 
motor cortical area can be seen following SCI in rats. A reorganization of axonal 
connections has also been described at the subcortical level (Kaas et al. 1999; 
McKenna and Whishaw 1999). Bruehlmeier et al (1998) showed that patients with 
SCI exhibit extensive changes in the activation of cortical and subcortical brain 
areas during hand movements, irrespective of normal or impaired hand function. 
The strong activation changes suggest that a reorganization of neuronal activity 
occurs in patients with SCI. The cortical plasticity was also investigated by using 
functional magnetic resonance imaging in SCI patients (Jurkiewicz et al. 2007).   
Injury induced reorganization has also been seen at the level of spinal cord. Aoki 
et al (1986) reported that newly formed synapses have been observed on the 
side of spinal cord hemisection in monkeys. Brus-Ramer et al. (2007) suggested 
that there is a significant increase in the length of spared ipsilateral 
corticospinal tract (CST) axons after injury in rats. They also reported that 
electrical stimulation of spared corticospinal axons augments connections with 
ipsilateral spinal motor circuits. Weidner et al (2001) reported that spontaneous 
sprouting of the minor unlesioned ventral CST can be observed after the 
transection of the main dorsal CST component in rats, and this sprouting 
correlates with functional recovery. Bareyre et al (2004) reported that a new 
intraspinal circuit spontaneously formed in rats with incomplete mid-thoracic 
dorsal hemisection, and confirmed the functionality of this new circuit by 
electrophysiological and behavioural testing. They also demonstrated that 
transection of the main dorsal CST component resulted in spontaneous sprouting 
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of the unlesioned dorsolateral and ventral CST components in a transgenic 
mouse (Bareyre et al. 2005).  
Like the CST, Ballermann and Fouad (2006) showed that spared reticulospinal 
fibres sprouted caudal to the lesion in rats with lateral thoracic hemisection, 
and this change correlated to improved locomotor function. However, they did 
not find changes in the projection of injured fibres rostral to the lesion. 
Lawrence DG and Kuypers (1968) demonstrated that the unlesioned rubrospinal 
tract could take over some of the functions of the lesioned CST which is one of 
the main descending motor tracts in monkeys. Furthermore, indirect 
propriospinal connections can mediate the functional recovery after severe SCI 
(Courtine et al. 2008). In addition, spontaneous sprouting of the lesioned axons 
has been observed in other partial transection models (Fouad et al. 2001), 
contusion model (Hill et al. 2001), and ischemic injury model (von Euler et al. 
2002). 
However, it should be kept in mind that plasticity in the injured spinal cord does 
not always result in a positive outcome. For instance, sprouting of uninjured 
sensory afferents is thought to contribute to two serious and debilitating 
consequences of SCI in humans, i.e. autonomic dysreflexia (Weaver et al. 2006) 
and pain (Finnerup and Jensen 2004).  
The central pattern generator is a network of locomotor neurons in the spinal 
cord, which can produce the basic pattern of neural activities required for 
walking. It can do so even in the absence of inputs from the brain and the 
peripheral sensory system. Experiments performed by Grillner and Zangger 
(1979) proved the existence of a central pattern generator in mammalian 
species. Gulino and co-worker (2007) believed that the rhythmic activity of a 
central pattern generator could be the early component of functional recovery 
(Gulino et al. 2007). Although a clear demonstration of a central pattern 
generator existence in humans has remained difficult because only data from an 
entirely deafferented and complete SCI patient would satisfy all criteria, some 
data strongly suggested that humans possess a central pattern generator within 
the spinal cord that is capable of generating stepping (Dimitrijevic et al. 1998; 
Gurfinkel et al. 1998; Calancie et al. 1994). 
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However, there are limitations to the extent of this spontaneous functional 
recovery. Understanding these limitations and investigating the mechanisms 
behind them may aid understanding of SCI, and therefore the development of 
new therapeutic strategies that facilitate these mechanisms of recovery. 
1.7 Repair Strategies 
As mentioned above, many patients show some spontaneous recovery following 
injury. However, the degree of this kind of recovery is normally too limited to 
retrieve the lost functions completely. Therefore, the functional deficits are 
usually permanent after SCI. Currently, damage to the spinal cord can not be 
repaired by any therapy.  
SCI leads to a series of biological events as listed before. Most of them have 
detrimental effects on the injured cord and therefore hamper the repair process 
of the cord. Repair of the injured spinal cord in the adult is more than a simple 
matter of damaged tissue rebuilding itself but, rather, it is a highly complex 
multi-step process. First of all, the injured neuron must survive, and then the 
damaged axon must extend its cut processes to its original neuronal targets. 
Once contact is made, the axon needs to be remyelinated and functional 
synapses need to form on the surface of the targeted neurons. Consequently, 
treatments strategies are designed to tackle those problems following injury. 
The targets of curing SCI, therefore, are to minimize secondary damage 
progression and preserve residual functions (i.e. neuroprotection strategy), 
supply a permissive environment to axonal regeneration (i.e. regeneration 
strategy), and promote axonal sprouting (i.e. plasticity strategy) and repair 
demyelination and conduction deficits (i.e. remyelination strategy). 
1.8 Therapeutic approaches 
Ongoing research to test possible new treatments for SCI is progressing rapidly, 
and a number of therapeutic strategies are being examined in clinical trials 
(Hawryluk et al. 2008). However, there is no cure for SCI in clinic so far. Current 
medical interventions focus on two conservative aims. The first is to administer 
high dose steroids and/or surgical procedures if necessary to prevent further 
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damage shortly after injury. The other one is to help patients and family with 
rehabilitative training in order to optimize residual function and minimise 
problems like poor ventilation, bladder infections, joint fixation, and muscle 
wastage. 
Although individual therapy developed to solve one specific aspect of SCI might 
restore important functions, a multidisciplinary approach probably will be the 
solution for SCI treatment. The interventional therapies may involve treatments 
to prevent secondary damage and protect residual neurons, overcome myelin 
inhibition and combine with neurotrophic factors to prevent neuronal atrophy 
and promote axonal regeneration, reduce non-permissive effects of the glial 
scar, enhance plasticity to maximize the spontaneous recovery, and form 
remyelination. At the late stage, intensive rehabilitative training programmes 
will help the patient to regain independence.        
1.8.1 Neuroprotection 
Neuroprotection counts all the therapeutic strategies aiming at counteracting 
secondary injury mechanisms and/or minimising the extent of damage caused by 
destructive cellular and tissue events and preserving residual functions. On the 
basis of co-existence of several different injury mechanisms, a large number of 
potentially neuroprotective substances are being investigated in animal studies.  
Methylprednisolone sodium succinate is the most extensively studied agent and 
it has been reported that a high dose of methylprednisolone sodium succinate 
administration during early acute stage (<8h) can help to improve energy 
metabolism, anti-inflammation (Fu ES and Saporta S 2005), reduce the formation 
of cytotoxic oedema, and the release of glutamate and free radicals (Farooque 
et al. 1996; Cayli et al. 2004). It is commonly applied clinically in the United 
States (Bracken and Holford 1993; Bracken et al. 1998; Aito et al. 2005) 
(National Acute Spinal Cord Injury Study, NASCIS 2 and 3). However, this therapy 
is still controversial because of inadequate evidence of efficacy and a higher 
rate of complications in clinic (Sayer et al. 2006; Suberviola et al. 2008). 
Erythropoietin, a potent neuroprotective cytokine, has recently been discovered 
as a potential treatment for SCIs (Reviewed by Brines and Cerami 2008). 
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Erythropoietin functions not only as an anti-inflammatory and anti-apoptotic 
role, but also as a mediator of neuroprotective hypoxic preconditioning. 
Erythropoietin plays its beneficial role by apoptosis blockage (Arishima et al. 
2006), reduction of inflammation, restoration of vascular integrity, and neuronal 
regeneration (Reviewed by Brines and Cerami 2008). However, Erythropoietin 
has a rheological disadvantage of causing an increased aggregation of 
thrombocytes and augmented hematocrite (Reviewed by Brines and Cerami 
2008). Erythropoietin analogues such as asialoerythropoietin (Erbayraktar et al. 
2003) and carbamylated erythropoietin (Kirkeby et al. 2008) have been 
generated as mutants of erythropoietin. They still have the same 
neuroprotective properties but without the rheological problems. 
CD95 is a member of the tumour necrosis factor receptor family, and CD95 
ligand can initiate cell death. Inhibition of the CD95 pathway has been proved to 
limit neuronal and glial apoptosis after SCI in mice (Demjen et al. 2004; Casha et 
al. 2005). Systemic application of minocycline, a synthetic tetracycline, has 
been shown to reduce apoptotic cell death of oligodendrocytes and the gliotic 
response with concomitant improvement in neurological function (Stirling et al. 
2004; Beattie 2004). However, it is still not clear whether the altered cell, which 
is forced to survive, is still functional, and how long it can survive.  
Furthermore, a remaining problem for all possible pharmacological treatments in 
the acute stage is still unclear: therapeutic windows. Even though the pre-
clinical results are very promising, almost all phase II/III clinical neuroprotection 
trials have failed to achieve a consistently improved outcome for SCI patients 
(Dumont et al. 2001b; Hawryluk et al. 2008).  
Besides these pharmacological interventions, early decompression also has been 
claimed to contribute to neuroprotection (Mirza et al. 1999). This non-
pharmacological surgical intervention can reduce neurological deficits after SCI 
by decompressing the swollen, oedematous lesioned spinal cord (Papadopoulos 
et al. 2002).  
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1.8.2 Neurotrophins 
After David and Aguayo (1981) proved that injured axons can regenerate in a 
permissive environment such as peripheral nerve tissues, several regeneration 
obstacles have been identified including inhibitory substances, cavity, scar, and 
lack of neurotrophins. Following SCI, the injured neurons are eventually atrophic 
and may even die in such a non-permissive environment harbouring inhibitors 
such as Nogo-A protein and myelin-assoiated glycoprotein (MAG) produced by 
oligodendroglial cells (described below). Consequently, they are unable to give 
sufficient growth response which is necessary to axonal regeneration. Also the 
scar and cavity provide a mechanical and chemical barrier. Various strategies 
have been investigated to tackle these obstacles in order to enhance axonal 
regeneration. 
The neurotrophin family of growth factors are small molecules including nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophins 3 
and 4 (NT-3/NT-4), fibroblast growth factor (FGF), glia cell line derived 
neurotrophic factor (GDNF) and the leukaemia inhibitory factor (LIF). 
Neurotrophins can stimulate the injured axons to activate the regeneration-
associated genes in order to promote the intrinsic growth capacity of neurons for 
regeneration after SCI (Ramer et al. 2000; Blesch and Tuszynski 2003; Bradbury 
et al. 1999). Moreover, neurotrophins can promote neuron survival and regulate 
neuron-target interactions (Kobayashi et al. 1997; Kwon et al. 2002; Novikova et 
al. 2002). The different density of the corresponding receptors in the injured 
spinal cord may explain the different performance among those neurotrophins.  
However, a few crucial questions still need to be investigated. Firstly, some 
growth factors promote axons that conduct nociceptive information and cause 
increased pain (Pezet and McMahon 2006). Secondly, different neurotrophins 
work at different time points during the repair (Novikova et al. 2002). Thirdly, 
they can not cross the blood-brain barrier. Although a number of growth factors 
show positive effects on axon growth, it still needs to be determined which 
growth factors are suitable, when and by what methods they should be 
administered.  
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1.8.3 Myelin inhibitors 
The normal uninjured spinal cord contains inhibitory substances that regulate 
neurite growth. It is thought that they may play an important role in restricting 
axonal growth once development has occurred. However, this vital function 
becomes a major obstacle to the regeneration of injured axons after SCI. A 
variety of neurite growth inhibitors present in CNS myelin has been well defined 
such as Nogo-A protein (GrandPré et al. 2000; Chen et al. 2000), myelin-
associated glycoprotein (MAG) (McKerracher et al. 1994; Schachner and Bartsch 
2000) and oligodendrocyte-myelin glycoprotein (OMgp) (Wang et al. 2002a).  
1.8.3.1 Nogo 
Nogo-A is possibly the best characterized and has been investigated in closest 
detail among inhibitors in myelin (Schweigreiter and Bandtlow 2006). The Nogo 
gene gives rise to three protein isoforms (Nogo-A, Nogo-B, and Nogo-C) via both 
alternative splicing and promoter usage (Figure 1-6). All three Nogo isoforms 
share a C-terminus of 188 amino acids which contains a short loop of 66 amino 
acids called Nogo-66 and two long hydrophobic domains. This common C-
terminus is called the reticulon-homology domain (RHD). This sequence 
characterizes the Nogo gene as a member of the reticulon protein family 
(GrandPré et al. 2000).  
Nogo-A is a glycosylated transmembrane myelin protein with a high molecular 
weight highly expressed by oligodendrocytes (Schwab 2004). During 
development, Nogo-A is also expressed in subpopulations of neurons and down-
regulated in most of these regions in the adult CNS (Richard et al. 2005). There 
are at least three active sites of Nogo-A that are exposed to the extracellular 
space (Oertle et al. 2003). First, the Nogo-66 domain, which is positioned 
between two hydrophobic stretches (Schweigreiter and Bandtlow 2006). Second, 
a central inhibitory domain termed as NiG which is a large stretch specific to 
Nogo-A. Both of these two sites inhibit neurite growth and induce growth cone 
collapse (GrandPré et al. 2000; Oertle et al. 2003). The third site is found in the 
Nogo-A/B-specific N-terminus. This site inhibits the spreading of cultured 
fibroblast, enhances adhesion of vascular cells and stimulates endothelial cell 
migration (Acevedo et al. 2004; Miao et al. 2006) (Figure 1-6).  
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Figure 1-6 Three Nogo isoforms  
The Nogo gene gives rise to three protein isoforms—Nogo-A, Nogo-B, and Nogo-
C—via alternative splicing and promoter usage. Nogo-A harbors two inhibitory 
domains: Nogo-66 (which is common to all Nogo isoforms) and NiG (which is 
unique to Nogo-A). Nogo-66 is defined by two hydrophobic regions; however, it is 
believed that the first hydrophobic stretch traverses the membrane twice. 
Therefore, both inhibitory domains face the extracellular space when the 
protein is localized to the plasma membrane (taken from Schweigreiter and 
Bandtlow 2006). 
Various lines of Nogo knockout mice lacking one or more Nogo molecules have 
been reported by three different independent laboratories (Simonen et al. 2003; 
Kim et al. 2003; Zheng et al. 2003). Two laboratories (Simonen and Kim) claim 
modest improvement in axonal regeneration and functional recovery. However, 
Zheng reports that no regeneration or sprouting has been observed in both Nogo-
A/B and Nogo-A/B/C mutant mice. The genetic background of different mouse 
lines (Dimou et al. 2006), compensatory up-regulation of other Nogo proteins 
(Simonen et al. 2003) and the lesion paradigms (Cafferty and Strittmatter 2006) 
used may account for this discrepancy. 
A glycosyl-phosphatidylinositol (GPI)-linked cell surface protein is widely 
expressed in many neurons. It has been characterized as a neuronal receptor 
that binds to the Nogo-66 site and termed as NgR (Fournier et al. 2001). Since 
NgR is a cell surface protein which lacks a cytoplasmic domain, co-receptors are 
required to mediate signal transduction across the cell membrane such as p75 
(Wang et al 2002b; Wong et al. 2002), TROY (Park et al. 2005; Shao et al. 2005), 
and LINGO-1 (Mi et al. 2004) (Figure 1-7). A number of groups have also reported 
that another receptor or an additional receptor subunit may mediate Nogo-A-
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specific signalling (Oertle et al. 2003; Song et al. 2004; Zheng et al. 2005). 
Recently, a new functional receptor for myelin inhibitors of axonal regeneration, 
PirB, has been identified (Atwal et al. 2008).     
The binding of Nogo-A to these Nogo-A receptors on the surface of the injured 
neurons leads to inhibition of axon elongation and growth cone collapse 
(Fournier et al. 2001; Yamashita et al. 2005; Atwal et al. 2008). The intracellular 
signalling pathways of Nogo-A involve RhoA and Ca2+. RhoA is a GTPase of the 
Rho family and plays a central role in the signal transduction of axonal guidance 
molecules during development (Figure 1-7). Activation of RhoA may be the major 
intracellular signalling mechanism of Nogo-A (Alabed et al. 2006; Fournier et al. 
2003). Nogo-A also can increase intracellular calcium, and therefore induces 
growth cone collapse (Wong et al. 2002; Bandtlow et al. 1993). This pathway 
may act in parallel or in sequence with RhoA. Targeting these downstream 
effectors of Nogo-A with specific blocking compounds therefore prevents the 
signalling of myelin inhibitors (Figure 1-7). However, the picture of myelin 
inhibitors and their signalling machinery is still far from complete. 
Studies revealed that the failure of axonal regeneration is the main contributor 
to the lack of substantial functional recovery after SCI, and the regeneration is 
limited by neurite growth inhibitors such as Nogo-A (Schwab 2004). Information 
from different experimental animals has shown that inactivation of Nogo-A 
either by function-blocking antibodies or by interfering with Nogo-A receptors or 
signalling pathways results in an increased axonal regeneration below the site of 
injury(Li et al. 2004; Schnell and Schwab 1990; Fouad et al. 2004; Liebscher et 
al. 2005; Freund et al. 2006; 2007).  
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Figure 1-7 Inhibitors and intracellular signalling mechanisms 
The molecular inhibitors of the adult CNS glial environment include chondroitin 
sulphate proteoglycans (CSPGs) associated with reactive astrocytes from the 
glial scar, and myelin-associated inhibitors from intact oligodendrocytes and 
myelin debris, including myelin-associated glycoprotein (MAG), Nogo-A, 
oligodendrocyte myelin glycoprotein (OMgp), ephrin B3 and the transmembrane 
semaphorin 4D. Although the topology of Nogo-A remains unclear, both the 66 
amino acid loop (Nogo-66) and the amino-terminal domain (amino-Nogo) are 
known to be inhibitory to axon outgrowth. The neuronal receptors and 
downstream signalling pathways known to be involved in transducing these 
inhibitory signals are shown. Among the signalling components that are common 
to both CSPG and myelin inhibition are the activation of RhoA and the rise in 
intracellular calcium. Whereas the signals downstream of RhoA that lead to the 
actin cytoskeleton are well characterized (solid arrows), the relationship 
between components upstream of RhoA and the role of calcium influx are still 
ambiguous (dashed arrows). For example, calcium transients might activate 
protein kinase C (PKC), which is required for p75 cleavage by ϒ-secretase, or 
trigger the transactivation of epidermal growth factor receptor (EGFR) (taken 
from Yiu and He 2006). 
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Schnell and Schwab reported that up to 11mm CST regeneration beyond the 
injury site has been observed in anti-Nogo-A antibody group compared to very 
limited regeneration in control animals (Schnell and Schwab 1990). Liebscher 
and colleagues used an intrathecal catheter to deliver highly purified anti-Nogo-
A antibody from an osmotic minipump. Their results also demonstrated that 
neutralization of the Nogo-A leads to enhanced regeneration and reorganization 
of the injured CNS (Liebscher et al. 2005). It is believed that the axons in the 
anti-Nogo-A antibody treated group grow through the denervated spinal cord for 
long distances (more than 1-2mm) and could form extensive terminal arbours in 
the caudal spinal cord. Sprouting collaterals of spared axons above and below 
the lesion site have been also observed. These short (less than 1mm) fibres can 
innervate targets around the lesion (Wang et al. 2006; Li et al. 2005; Simonen et 
al. 2003). Recently, a study shows that Nogo signalling can also be suppressed by 
phosphorylation of the NgR in vitro (Takei 2009). Inactivation of Nogo functions 
by blocking NgR with a blocking peptide or by targeting effectors in signalling 
pathways with blocking compounds also leads to similar CST regeneration 
(Fournier et al. 2003; GrandPré  et al. 2002). However, only a modest 
disinhibitory effect has been seen after blocking the NgR or PirB receptor alone. 
A recent study shows that blocking both PirB and NgR activities leads to near-
complete release from myelin inhibition (Atwal et al. 2008).  
The CST has been chosen for the assessment of regeneration in most studies 
because of the relative ease with which it can be anatomically traced. However, 
other spinal tracts such as raphespinal (serotonergic) axons (GrandPré et al. 
2002), coeruleospinal (noradrenergic) axons (Bregman et al. 1995), and 
cholinergic septohippocampal axons (Cadelli and Schwab 1991) have also been 
reported to show substantial regeneration after inactivation of Nogo function. 
This enhanced regenerative and compensatory fibre growth is commonly 
accompanied by a substantial improvement in the functional recovery after 
injury. Animals treated with anti Nogo-A antibodies scored significantly better 
than control animals in various behavioural tests, in particular in precision tests, 
e.g. crossing a unevenly spaced ladder or climbing a rope (Bregman et al. 1995; 
Liebscher et al. 2005). Similar functional recovery was observed when Nogo-A 
receptors were blocked, or following interference with signalling pathways 
(GrandPré  et al. 2002; Li et al. 2004; 2005). Neutralizing Nogo-A in the lesioned 
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spinal cord enhances sprouting and functional recovery not only in rodents but 
also in primates (Freund et al. 2006; 2007). Interestingly, common malfunctions 
such as pain or spasticity have not been seen in animals treated with reagents 
that block the Nogo-A receptor pathway (Liebscher et al. 2005; Freund et al. 
2006).  
Because functional recovery and axonal regeneration have been seen in the 
same animal, it has been suggested that regenerated axons contribute 
significantly to functional recovery after neutralizing myelin inhibitors. 
However, close anatomical observations reveal that only a small proportion of 
interrupted fibres regenerate beyond the lesion site. It therefore suggests that 
other mechanisms such as collateral sprouting of spared axons may also play an 
important role in the functional recovery (Liebscher et al. 2005; Freund et al. 
2007). In vivo, both axonal regeneration and axon collateral sprouting can be 
enhanced by anti-Nogo-A antibody treatment. A study showed that sprouting of 
damaged axons resulted in new synapse formation between the damaged axons 
and propriospinal neurons, and that these new intrinsic spinal circuits enhanced 
functional recovery after experimental SCI (Bareyre et al. 2004). Another study 
reported that almost complete functional recovery was paralleled by a surprising 
capability of the CST to reorganize anatomically after unilateral pyramidotomy 
and treatment of the animals with the IN-1 antibody (Z’Graggen et al. 1998) 
(Figure 1-8). Reorganization in the spinal cord and restitution of fine motor skill 
were also observed in rats treated with IN-1 (Raineteau et al. 2002). Therefore, 
axonal regeneration, sprouting and plasticity may all contribute to restoring 
function after SCI, rather than each mechanism alone.  
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Figure 1-8 Schematic representation of the corticospinal reorganization 
occurring after pyramidotomy and mAb IN-1 treatment 
Schematic diagram shows the corticospinal reorganization after pyramidotomy 
and mAb IN-1 treatment. a: Unilateral transection of the CST in the brainstem 
above the decussation interrupts axons from the sensorimotor cortex of one 
hemisphere to the spinal cord grey matter on the contralateral side. CST 
projections to mid- and hindbrain nuclei are spared. Hybridoma cells were 
implanted over the contralateral cortex to secrete IN-1 antibody. In response to 
IN-1, CST fibres from the injured side were induced to sprout (red) within nuclei 
of the contralateral side, including the red nucleus. b: In the spinal cord, CST 
fibres from the intact side (green) were induced to sprout collaterals (red), 
which cross the midline to innervate the denervated side (taken from Raineteau 
and Schwab 2001). 
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While the results of animal experiments aimed at neutralizing Nogo-A are quite 
promising, full functional recovery will require a combination of several 
therapeutic strategies. Maier and colleagues (Maier et al. 2009) compared the 
effects of anti-Nogo-A antibody treatment and treadmill training in rats with 
incomplete SCI. Even though functional recovery was observed in both groups, 
axonal regeneration and sprouting of descending systems was seen only in rats 
with antibody treatment. Surprisingly, combinatorial treatment of both 
produced a poorer locomotor performance, compared to individual treatments. 
It is suggested that the mechanisms underlying these changes with each 
treatment are not only different but possibly competitive. Therefore, the 
understanding of the mechanism underlying each individual treatment as well as 
their potential interactions will be crucial to finding the most effective 
combination for future therapies.  
1.8.3.2 MAG and OMgp 
MAG is a type I trans-membrane glycoprotein and was the first identified myelin 
inhibitor of axonal regeneration (McKerracher et al. 1994; Mukhopadhyay et al. 
1994). As a member of the immunoglobulin superfamily, MAG contains five 
extracellular immunoglobulin Ig-like domains. The alternative splicing of MAG 
mRNA in rodents generates two MAG isoforms: large (L) and small (S). These two 
isoforms differ only in their cytoplasmic sequences that may activate different 
signal transduction pathways in myelin-forming cells (Lai et al. 1987; Salzer et 
al. 1987). MAG is also known to be a sialic acid-binding protein and a member of 
the Siglec family of proteins (sialic acid-binding, Ig-like lectins) (Schachner and 
Bartsch 2000).  
MAG is selectively localized in the periaxonal Schwann cell and oligodendroglial 
membranes of myelin sheaths where it functions in glia-axon interactions in both 
the PNS and CNS (Sternberger et al. 1979; Schachner and Bartsch 2000). MAG is 
important for the normal formation and maintenance of myelinated axons. 
Furthermore, it may play a role in signalling in both directions between axons 
and glia, although some of these roles may be different in the CNS and PNS 
(Quarles 2007; Schachner and Bartsch 2000). The higher concentration of MAG in 
the CNS, compared to in the PNS, may reflect the higher need for signalling at 
the oligodendroglial-axon junction than at the Schwann cell-axon junction 
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(Trapp BD 1990). A recent study reports that MAG also promotes axonal stability 
and prevents axonal degeneration both in cell culture and in vivo (Nguyen et al. 
2009). In addition to the protective role, MAG also has the capacity to inhibit 
neurite outgrowth as one of the myelin inhibitors of axonal regeneration 
(McKerracher et al. 1994; Mukhopadhyay et al. 1994). Inactivation of MAG 
function by using anti-MAG antibody has shown neuroprotective effects in brain 
injury models such as stroke (Irving et al. 2005). Improved functional recovery 
was associated with smaller lesion volume and better tissue sparing observed in 
animals receiving anti-MAG antibody (Irving et al. 2005; Thompson et al. 2006). 
Immunization with myelin or recombinant Nogo-66/MAG promotes long distance 
axon regeneration and sprouting in a spinal cord hemisection model (Sicotte et 
al. 2003).  
Oligodendrocyte myelin glycoprotein (OMgp) was first described many years 
before it was identified as the third myelin-associated molecule possessing 
potent growth cone collapsing and neurite growth inhibitory activity (Mikol 
Stefansson 1988; Wang et al. 2002a). OMgp is a glycosyl phosphatidylinositol 
(GPI)-linked protein that contains a leucine-rich repeat (LRR) domain and a C 
terminal domain containing serine/threonine repeats. It is relatively minor 
component in both CNS and PNS myelin, and may be expressed in more 
abundance by other non-myelinating cells (Huang et al. 2005).  
Interestingly, MAG and OMgp also exert their inhibitory effects through binding 
of Nogo-66-receptor (NgR), despite the fact that they have little sequence 
similarity or even domain similarity. Shortly after the NgR was discovered by the 
Strittmatter group, they and Domeniconi’s laboratory simultaneously found that 
MAG was also a ligand for this receptor (Domeniconi et al. 2002; Liu et al. 2002). 
Their studies provide strong evidence that the NgR is necessary for MAG to 
inhibit axonal regeneration. In addition, it was discovered that binding of MAG to 
the NgR is sialic acid-independent. This evidence suggests that the sialic acid-
binding site is distinct and independent of the inhibitory domain. At 
approximately the same time that these experiments were carried out, it was 
independently discovered that the NgR is also a receptor for OMgp and mediates 
its inhibitory actions (Oertle et al. 2003). A transmembrane protein termed as 
p75 is required for NgR-mediated signalling. Therefore, interfering with p75 and 
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its downstream signalling pathways may reduce the inhibitory activities of 
myelin inhibitors, and promote neurite growth in vitro (Wang et al. 2002a) 
(Figure 1-7).  
Interfering with PirB function, a newly discovered functional receptor for myelin 
inhibitors, can partially rescue neurite inhibition and myelin in cultured neurons. 
Blocking both PirB and NgR activities leads to significant release from myelin 
inhibition (Atwal et al. 2008). Since all three myelin inhibitors i.e. Nogo, MAG, 
OMgp, can bind to the same receptors, it seems feasible to antagonize the 
effects of all three myelin inhibitors at once.  
In addition to these three relatively well defined myelin inhibitors, some 
repulsive axon guidance cues with roles in axon pathfinding during development, 
such as ephrin B3 and Semaphorin 4D, continue to be expressed in adult CNS 
myelin. They have been implicated as inhibitors of axonal regeneration. Ephrin 
B3 functions as a midline repellent for growing CST fibres during development, 
but continues to be expressed in myelinating oligodendrocytes during postnatal 
stages and strongly inhibits axonal growth in vivo (Benson et al. 2005). 
Semaphorin 4D, also called CD100, is also present in mature oligodendrocytes, 
inhibits neurite growth and triggers growth cone collapse (Moreau-Fauvarque et 
al. 2003) (Figure 1-7). 
1.8.4 Scar inhibitors 
Scar formation is a natural response to injury but leads to an environment 
hostile for regeneration of injured axons. The glial reaction may have some 
beneficial effects such as isolating the injury site and minimizing the area of 
inflammation and cellular degeneration but inhibitory extracellular matrix 
molecules occur in the glial scar, and it is also a physical barrier for axonal 
regeneration.  
Astrocytes and oligodendrocyte precursor cells, together with invading 
meningeal cells produce chondroitin sulphate proteoglycans (CSPGs) which are 
the major inhibitory species associated with the glial scar, and release them into 
the extracellular space (Morgenstern et al. 2002) (Figure 1-7). CSPGs are a 
relatively big family including NG2, neurocan, aggrecan, versican, phosphacan 
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and brevican (Silver and Miller 2004; Tang et al. 2003). These molecules consist 
of a protein core to which large, highly sulphated glycosaminoglycan (GAG) 
chains are attached (Morgenstern et al. 2002). Following injury, CSPGs are 
secreted rapidly (within 24 hours) at and around the lesion site which forms a 
physical and chemical barrier to axonal growth. CSPG expression quickly reaches 
its peak in the first two weeks, and may persist for many months (Tang et al. 
2003).  
CSPGs have been proved to be strong inhibitors of neurite growth which impede 
sprouting and regenerating axons from crossing the lesion site (Silver J and Miller 
JH 2004). CSPGs inhibit axon growth in vitro and stop axonal regeneration in 
vivo (Davies et al. 1999). The inhibitory effects produced by CSPGs can be 
enzymatically degraded by bacterial chondroitinase ABC (ChABC), an enzyme 
that removes GAG chains from the protein core (Bradbury et al. 2002). 
Therefore, it suggests that the GAG components play a key role for the inhibitory 
activity of CSPGs. Bradbury and colleagues delivered ChABC to rats with dorsal 
column lesions. Their results showed that intrathecal infusion of ChABC 
degraded CSPGs at the injury site, up-regulated a regeneration-associated 
protein in injured neurons, and promoted regeneration of both ascending and 
descending tracts caudal to the lesion site. They also claimed that enhanced 
functional recovery has been observed after this treatment (Bradbury et al. 
2002). However, the functional recovery is probably due to the stimulation of 
plasticity because it is seen as soon as 1 week after injury – too fast to be due to 
axonal regeneration and formation of functional connections. In other studies, 
ChABC has also been proved to stimulate the growth of uninjured systems within 
the CNS, for instance when one corticospinal tract is lesioned the contralateral 
tract can sprout across to the denervated side of the cord, which demonstrate 
the potency with which ChABC can enhance plasticity (Barritt et al. 2006). 
Recently, electrophysiological recordings also confirmed that behavioural 
recovery observed in ChABC treated animals was consequent to reorganization of 
intact primary afferent terminals after SCI (Cafferty et al. 2008). Carter LM 
recently demonstrated that ChABC treatment regulates multiple signalling 
cascades at the injury site and exerts protective effects on injured neurons 
(Carter et al. 2008). A study of the therapeutic time window for the application 
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of ChABC shows that ChABC treatment can be successfully applied starting seven 
days after SCI (García-Alías et al. 2008). 
In addition to CSPGs, several other inhibitory molecules in the glial scar have 
been identified. Semaphorin 3 (SEMA3) is one of these molecules, and has been 
showed to prevent the penetration of regenerating axons past the lesion (De 
Winter et al. 2002). Together with the other inhibitory molecules, such as 
ephrin-B2 and Slit proteins, these additional inhibitors in the glial scar add 
additional levels of complexity to the source of regeneration failure in SCI 
(Bundeson et al. 2003; Brose and Tessier-Lavigne 2000).  
1.8.5 Modulation of the immune system 
Inflammation contributes to the non-permissive environment for neuron survival 
and regeneration after SCI. It has been suggested that immune system activation 
following SCI is both destructive and protective. Consequently, modulating the 
immune system is a potential treatment for SCI (Schwartz and Yoles 2005; 2006; 
Popovich et al. 2002).  
Macrophages play a key role in the inflammatory process (Chang 2007). 
Inadequate macrophage response following injury may be the other contributory 
factor to failure of axon regeneration. Therefore, the successful activation of 
macrophages is the key to efficient phagocytic removal of myelin debris from 
the injured cord (Popovich et al. 2002; Vallieres et al. 2006; Schwartz and Yoles 
2005). By modulating some molecules such as intercellular cell adhesion 
molecule and interleukin, which play key roles in inflammation, it might thereby 
be possible to regulate the inflammatory response in SCI (Mabon et al. 2000; 
Brewer et al. 1999).  
1.8.6 Rho pathway antagonists 
Rho, a small GTPase, plays a key role in many signalling pathways to block 
axonal regeneration and exacerbate posttraumatic neural cell death 
(McKerracher and Higuchi 2006). A few studies reported that inhibition of either 
Rho or Rho-associated kinase (ROCK) can enhance axonal regeneration and 
function recovery in mice (Dergham et al. 2002; Fournier et al. 2003). Based on 
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these persuasive preclinical animal data, a phase Ⅰ /Ⅱ a non-placebo-controlled 
dose-escalation study with Cethrin (a novel Rho inhibitor recombinant protein) 
administered in patients with acute complete SCI is underway in North America 
(Baptiste et al. 2009). 
1.8.7 Cell transplantation 
Typically, a fluid-filled cavity surrounded by a glial scar will develop in the late 
stage of SCI (Figure 1-5). A scaffold thereby will be needed for injured axons to 
regenerate through this gap. Cell transplantation can be the supportive structure 
to fill the gap. It can also theoretically contribute to repair of SCI in the 
following ways. Transplanted cells can reduce further death of neurons and 
supporting glia, replace damaged neural tissue, promote axonal regeneration, 
enhance plasticity, induce remyelination, and limit progressive myelin loss from 
secondary injury. Several different cells have been investigated for cell 
transplantation in the repair of SCI, for example, embryonic stem cells 
(McDonald et al. 1999), adult neural stem cells (Akiyama et al. 2001), foetal 
tissue (Coumans et al. 2001), mesenchymal stem cells (Akiyama et al. 2002), and 
glial cells such as olfactory ensheathing cells (OECs) (Franklin et al. 1996; Li et 
al. 1997; Ramón-Cueto et al. 1998; Riddell et al. 2004; Toft et al. 2007), 
Schwann cells (Duncan et al. 1981; Tuszynski et al. 1998) and oligodendrocyte 
precursor cells (Groves et al. 1993; Bambakidis and Miller 2004). 
1.8.7.1 OEC 
In the past two decades, they have attracted increasing attention from 
neuroscientists as potential therapeutic agents for use in the repair of SCI. The 
olfactory nervous system has ability for regrowth that is uncharacteristic of 
other CNS regions (Figure 1-9). The olfactory system consists of the olfactory 
epithelium, which is the peripheral component, and the olfactory bulb, which 
belongs to the CNS. Olfactory receptor neurons, whose cell bodies are found in 
the olfactory epithelium, send their axons to the olfactory bulb and their axons 
are ensheathed along their length by OECs (Figure 1-9). Throughout life, 
olfactory neurons constantly die and are replaced by neurons from the basal 
stem cell layer of the olfactory epithelium. During normal cell turnover or after 
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injury, axons from new olfactory receptor neurons supported by OECs grow into 
the olfactory bulb and make functional synaptic connections (Doucette 1984; 
1991). Like other glial cells, OECs provide structural, functional and metabolic 
support to neurons.  
 
Figure 1-9 The olfactory nervous system  
Schematic of a sagittal section through the human head, showing the olfactory 
nervous system (right), with a section of the olfactory nervous system depicted 
in greater detail (inset). The olfactory system has PNS and CNS components. The 
olfactory mucosa comprises the olfactory epithelium and lamina propria. The 
olfactory epithelium contains olfactory receptor neurons (which project cilia 
into the nasal cavity), sustentacular cells (non-neuronal supporting cells), 
globose basal cells (putative stem cells for the epithelium), horizontal basal cells 
and Bowman's gland and ducts. The lamina propria consists of loose connective 
tissue and OECs, which ensheath bundles of olfactory receptor axons extending 
from the olfactory epithelium into the CNS via the cribriform plate. Many cell 
types make up connective tissue, including fibroblasts, macrophages, pericytes, 
endothelial cells and smooth muscle cells from the lining of blood vessels, in 
addition to Schwann cells that ensheath the nerves that innervate the blood 
vessels (taken from Thuret et al. 2006). 
OECs operate in both PNS and CNS environments to support the ongoing axonal 
growth, ensheathment, and targeting of olfactory neurons (Farbman and Squinto 
1985; Chuah and Au 1994). OECs can assist axon growth, like Schwann cells, and 
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are able to live within the CNS, like astrocytes (Smale et al. 1996; Li et al. 1997; 
Franklin et al. 1996) throughout adult life, including in humans. This property 
makes OECs a unique glial cell and a promising candidate for SCI repair (Figure 
1-9). 
A number of studies have been undertaken to investigate the ability of OEC 
transplants to repair injured spinal cord in various types of experimental animal 
models including partial transection models, complete transection models, and 
contusion models that typify clinical injuries (see below). Functional recovery, 
axonal regeneration and remyelination have been the main focus of 
investigation. 
Functional recovery after OEC transplantation has commonly been evaluated by 
applying behavioural tests of sensorimotor control in animal models of SCI. The 
evidence for improved functional recovery is mixed. Raisman and colleagues 
(1997) transplanted OECs into rats with a unilateral electrolytic lesion of the 
corticospinal tract at C1. These lesions abolished the ability to reach for food 
pellets using the paw on the affected side. They found that rats partially regain 
this ability after OEC transplantation (Li et al. 1997). They also reported that 
OEC transplantation improves climbing ability and activity in pathways 
controlling breathing in animals with more extensive cervical hemisection 
injuries (Li et al. 2003). Electrophysiological study also showed that substantial 
recovery of the respiratory function can be obtained following OEC 
transplantation (Polentes et al. 2004).  
Promising results have also been reported following transplantation of OECs 
after complete transection injuries of the thoracic spinal cord. Ramón-Cueto and 
colleagues (2000) reported that animals with transplantation recovered 
locomotor functions and sensorimotor reflexes better than animals without. 
They also described dramatic improvements in hindlimb use in an inclined grid 
climbing task, body weight support and recovery of proprioception and tactile 
sensation (Ramón-Cueto et al. 2000). Modest functional recovery has also been 
reported after complete transection injuries (López-Vales et al. 2006) and 
contusion injuries (Plant et al. 2003).  
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However, Ruitenberg and colleagues reported no significant differences in 
functional recovery between experimental groups after unilateral lesions of C4 
dorsal columns interrupting both corticospinal tract and ascending sensory 
pathways (Ruitenberg et al. 2005). Riddell and colleagues (2004) also showed 
that OECs grafts are of little or no advantage in promoting regeneration 
following rhizotomy. Other studies also showed no observable functional 
recovery in both complete transection (Steward et al. 2006) and contusion injury 
models (Takami et al. 2002). 
Reports on the extent of axonal regeneration are also mixed. Axonal 
regeneration was reported to occur not only within a transplant but also beyond 
the transplant in early studies (Ramón-Cueto et al. 2000; Li et al. 1998; Nash et 
al. 2002; Imaizumi et al. 2000). It was therefore suggested that OEC 
transplantation promotes long distance axonal regeneration, and that this might 
be the explanation for the improved functional recovery sometimes observed. 
However, a number of later studies have failed to observe long distance axon 
regeneration across and beyond a lesion (Ruitenberg 2003; 2005; Lu et al. 2006; 
Ramer et al. 2004a, b; Andrews and Stelzner 2004). The discrepancies in results 
do not seem to be related in any consistent way to experimental design. 
Toft and colleagues (2007) used anatomical and electrophysiological techniques 
to investigate the repair promoted by OEC transplants following a dorsal column 
lesion. Although their anatomical results suggest that OEC transplantation did 
not support axon regeneration across the lesion site, electrophysiological results 
showed that the function of circuitry in the region of the lesion site and of 
ascending pathways originating near the injury was improved. Therefore, other 
mechanisms, such as plasticity or a neuroprotective action, were suggested to be 
responsible for the improved functional recovery, rather than axonal 
regeneration.  
Chuah (Chuah et al. 2004) reported that more collateral branches in the minor 
component of the corticospinal tract projecting through ventral white matter 
were seen near OEC transplant in lesioned animals than those without 
transplants. They suggested that this may reflect corticospinal axon sprouting 
induced by OECs. Furthermore, a number of studies suggest that OECs have a 
neuroprotective effect after transplantation by reducing cavity formation at 
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contusion and transection injury sites (Takami et al. 2002; Ramer et al. 2004a), 
by protecting neurons with fibres projecting to an OEC transplanted lesion 
(Sasaki et al. 2006) and preventing loss of cord parenchyma by means of 
neoangiogenesis at transection and photo-chemical lesions (López-Vales 2004). 
Consequently, neuroprotective effects of OEC transplantation might also explain 
some of the improved functional recovery. 
Regenerating axons in SCI must also acquire a myelin sheath to enable efficient 
propagation of action potentials, apart from achieving long regeneration and 
forming functional synaptic connections. Although OECs do not normally form 
myelin in the olfactory system, peripheral-type myelination has been seen when 
OECs encounter axons of an appropriate diameter (Franklin et al. 1996). These 
axons include those regenerating within an OEC transplant (Sasaki et al. 2004). 
However, it is difficult to prove that OECs, rather than Schwann cells, are 
responsible for the peripheral-type myelination. There is no a specific marker 
that reliably discriminates between OECs and Schwann cells which might 
contaminate OEC preparations (Rizek and Kawaja 2006), or Schwann cells from 
the host that might infiltrate the injury site (Takami et al. 2002; Blight and 
Young 1989; Sasaki et al. 2004).  
Some scientists have successfully cultured and harvested human OECs from 
human olfactory tissue (Barnett et al. 2000; Bianco et al. 2004; Féron et al. 
2005; Mackay-Sim et al. 2008). However, it is still difficult to grow pure 
populations of human OECs in the numbers required to fill a typical human SCI 
(Choi et al. 2008). Some studies have proved that two or three biopsies of 
olfactory mucosa can be safely obtained from patients without any detriment to 
their sense of smell (Lanza et al. 1994; Féron et al. 1998). Based on the 
feasibility of isolating OECs from the human olfactory system and the promising 
results observed in experimental animals, several clinical programs of OEC 
transplantation are in progress in China (Guest et al. 2006), Portugal (Lima et al. 
2006) and Australia (Féron et al. 2005; Mackay-Sim et al. 2008) and planned for 
the UK (Ibrahim et al. 2006). These clinical programs hopefully can provide 
important information which can not be obtained from animal experiments due 
to the intrinsic differences between human and animals.        
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1.8.7.2 Stem cells 
Stem cells are not-transformed cells that are self-regenerative, multipotent for 
a tissue type, and highly proliferative. Stem cell therapy is widely accepted to 
treat diseases of modular organs such as the heart and the endocrine pancreas 
nowadays. Stem cells also show great potential for cell transplantation for SCI 
(Tewarie et al. 2009). They can expand to sufficient quantities for use in human 
therapy which is relatively difficult to achieve in many other popular candidates 
for cell transplantation.  
Stem cells may be used to replace the lost neurons after injury, generate new 
supporting cells to stimulate regrowth of damaged nerves and myelinate them, 
and protect the cells at the injury site from further damage by producing 
protective factors. A variety of stem cells or stem cell-derived cells have been 
evaluated for their effects on different animal models of SCI (McDonald et al. 
1999). Many of them indicated that stem cell transplantation plays a beneficial 
role in SCI (Nayak et al. 2006; Barnabé-Heider and Frisén 2008). However, it is 
often difficult to establish the mechanism by which transplanted stem cells may 
promote recovery. Functional benefits can be achieved by creating a permissive 
substrate for axonal growth, supplying trophic support reducing the damage and 
rescuing neurons and oligodendrocytes, providing cells that remyelinate spared 
but demyelinated axons (Parr et al. 2007). A clinical trial of a human embryonic 
stem cell-based therapy is ongoing in an American company Geron (Vogel 2005).  
1.8.7.3 Schwann cells 
Since Santiago Ramon Y Cajal (1928) documented the axonal growth promoting 
abilities of peripheral nerve grafts in the injured CNS, Schwann cells became one 
of most widely studied cell types for repair of the injured spinal cord. These 
cells play a crucial role in endogenous repair of peripheral nerves due to their 
ability to dedifferentiate, migrate, proliferate, express growth promoting 
factors, and promote axonal regeneration (Xu et al. 1997; Tuszynski et al. 1998; 
Weidner et al. 1999) and myelinate regenerating axons (Baron-Van Evercooren et 
al. 1992; Franklin et al. 1997). Schwann cells have many properties that are 
desirable for axonal regeneration in the PNS, such as neurotrophic and cell 
adhesion (Bray et al. 1981). One of the advantages of Schwann cells is that they 
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can be readily harvested from the peripheral nerves and easily purified and 
grown in culture in large numbers from both rat and human tissue. Some studies 
revealed Schwann cells can help remyelinate demyelinated axons and promote 
regeneration (Li and Raisman 1994; Kohama et al. 2001; Tuszynski et al. 1998). 
However, the inhibitory interaction between Schwann cells and astrocytes limits 
their usefulness in CNS repair (Baron-Van Evercooren et al. 1992; Lakatos et al. 
2000; Shields et al. 2000). Clearly, Schwann cells have great potential for repair 
of the injured spinal cord, but they need to be combined with other 
interventions to maximize axonal regeneration and functional recovery. 
1.8.7.4 Foetal Cell 
Foetal cell transplants have been the focus of much interest in animal models of 
human neurodegenerative disorders. The successful use of foetal transplants is 
most evident in Parkinson’s disease (Freed et al. 1992; Spencer et al. 1992).   
Trophic agents released by the transplants appear to facilitate the survival of 
host neurons. Of further importance, regenerating axons appear to readily 
traverse the boundary between the transplants and host tissue, suggesting that 
the continuity of axonal tracts can potentially be re-established (Reier et al. 
1992). Possibly because of the more general plasticity found in the immature 
nervous system, foetal cell transplants appear more effective in neonatal 
recipients than in adults. 
One of the limiting factors in using foetal cell transplants has been the 
availability of foetal tissue as well as the ethical issues surrounding its use in 
clinical settings. However, this may be a general problem in most strategies.  
1.8.7.5 Oligodendrocytes 
Oligodendrocytes were used as a source for remyelination in different animal 
models in some reports (Crang and Blakemore 1991; Tontsch et al. 1994). 
Although the use of oligodendrocytes as remyelinating substrates has been shown 
to be successful in demyelinating animal models, their use in SCI has not been 
extensive. There are some therapeutic limitations to their use, particularly in 
light of recent evidence linking the oligodendrocyte’s potential role in inhibiting 
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axonal regeneration by producing an inhibitory substrate during the acute phase 
of injury (Cadelli et al. 1992). 
1.8.8 Conditioning stimulation 
Conditioning lesions of the peripheral processes of dorsal root ganglia neurones 
has been shown to induce a stronger regenerative response when the central 
processes of these neurones are lesioned in the dorsal columns (Richardson and 
Issa 1984; Neumann et al. 2005). The conditioning stimulation is thought to 
enhance the intrinsic growth capacity and modify the response of axons to 
inhibitory molecules by increasing intracellular levels of cAMP (Qiu et al. 2002). 
A combination of conditioning lesion with OEC transplantation can enhance the 
regeneration (Andrews and Stelzner 2004). 
1.8.9 Impulse propagation 
In all fast conducting nerves, the nerve fibres are surrounded by a myelin 
sheath. Following injury, spared axons probably lose their myelin partially or 
completely (Waxman 1989). The impulse propagation thereby is insecure or even 
totally stopped. Moreover, the electrical impulse propagation could be spread 
between demyelinated axons. Conduction failure happens as a result of 
potassium appearance in the extracellular space released by exposed potassium 
channels on demyelinated axons following SCI.  
Fampridine-SR allows demyelinated axons in injured spinal cord to send signals. 
Fampridine-SR can block the potassium channels and thereby to restore the 
impulse propagation for demyelinated axons (Hayes 2004; Cardenas et al. 2007). 
Fampridine-SR’s effects can range from increases in strength and reduced 
spasticity and pain. Somel clinical trails have reported beneficial effects in SCI 
(Hansebout et al. 1993). 
1.9 Anatomy of rat spinal cord 
The spinal cord in rats is divided into 8 cervical segments, 13 thoracic segments 
and 6 lumbar segments. The grey matter in the centre contains cell bodies of 
neurons and is divided into the dorsal horn, the intermediate grey, the central 
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grey, and the ventral horn. The white matter embraces ascending and 
descending pathways and is divided into dorsal, dorsolateral, ventrolateral, and 
ventral funiculi. Based on cytoarchitectonic characteristics, the grey matter is 
subdivided into 10 laminae from dorsal to ventral (Molander and Grant 1995).  
1.9.1 Corticospinal tract 
The corticospinal tract (CST) is one of the main descending pathways and is 
found only in the mammalian CNS. It is an important descending pathway best 
developed in primates and particularly associated with fine control of the hand 
in human beings (Afifi and Bergman 2005). 
1.9.1.1 The origin and course of the CST in the rat 
Corticospinal neurons are found in the sensorimotor cortex. Their distribution in 
rats is similar with the organization of corticospinal system in higher animals. 
Considerable overlap between somatosensory and motor cortex exists in the rat 
cerebral cortex (Miller 1987; Dum and Strick 1991). Corticospinal fibres have 
been shown to send collaterals to various brain stem nuclei including the red 
nucleus, pontine nuclei, inferior olivary nuclei and dorsal column nuclei (O’Leary 
and Terashima 1988). 
The CST can be divided into a crossed and uncrossed component (Figure 1-10). 
The majority of the axons cross to the contralateral side in the medulla 
oblongata level (pyramidal decussation) to descend through the dorsal column of 
the spinal cord. The main (90% of fibres) crossed component is located in the 
ventromedial aspect of the dorsal funiculus (Rouiller et al. 1991; Hicks and 
D’Amato 1975; Miller 1987). However, minor components have been described to 
exist in the ipsilateral dorsal, contralateral lateral and ipsilateral ventral funiculi 
(Casale et al. 1988; Rouiller et al. 1991; Brosamle and Schwab 1997; Liang et al. 
1991). Earlier studies did not reveal ventral, uncrossed fibres below thoracic 
levels (Vahlsing and Feringa 1980; Joosten et al. 1992). But tracing with BDA, 
Brosamle and Schwab (1997) showed that the ipsilateral, ventral CST projections 
extend to low spinal levels (Figure 1-10). 
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Figure 1-10 Schematic representation of the organization of CST.  
Schematic diagram shows cross section at midthoracic level. Biotin Dextran-
amine (BDA) tracing of the adult rat corticospinal tract from the right 
hemicortex reveals several components of the corticospinal tract (CST). Camera 
lucida drawing with the areas of the different components photographed (A-D) 
and marked in the drawing as boxes. A: The main CST component and the 
ipsilateral dorsomedial funiculus (arrowheads) B: The contralateral component. 
C: Ipsilateral ventromedial funiculus. D: Ipsilateral lateral white matter. The 
dashed line delineates the border between grey matter and white matter. Scale 
bar 5 250 um (taken from Brosamle and Schwab 1997). 
The dorsal column component of the rat CST descends to reach the cervical, 
thoracic, lumbar and even sacral levels (Hicks and D’Amato 1977; Casale et al. 
1988; Raineteau et al. 2002), although the number of fibres reaching more 
caudal levels probably progressively decreases. A number of electron microscope 
studies have revealed that unmyelinated fibres outnumber myelinated fibres at 
the medullary level (Leenen et al. 1982; Harding and Towe 1985). Although 
there are some unmyelinated fibres at the spinal cord level, the number 
decreases substantially (Leenen et al.1985). 
Studies of the terminal pattern of CST fibres showed that the CST terminates 
mainly within a region corresponding approximately to laminae III-V in the 
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contralateral grey matter of the spinal cord at cervical and lumbar levels, and 
within lamina VI in the enlargements. However, terminations have also been 
found within other laminae including ipsilateral laminae III-X, with an emphasis 
in laminae VII, VIII and X, contralateral laminae VI-X, and sparse projections to 
the more superficial laminae I and II (Casale et al. 1988). 
The existence of monosynaptic corticomotoneuronal connections is believed to 
be responsible for the ability to conduct independent digit movements in 
primates and man. In the rat, however, evidence of direct CST connections onto 
motoneurones is controversial (Liang et al. 1991; Alstermark et al. 2004; Yang 
and Lemon 2003). Previous electrophysiological studies suggested the existence 
of a monosynaptic corticomotoneuronal projection (Babalian et al. 1993; Liang 
et al. 1991). However, a recent electrophysiological study suggested that these 
were probably reversed corticospinal field potentials which has been mistaken as 
excitatory postsynaptic potentials, and therefore claimed that no monosynaptic 
corticomotoneuronal excitatory postsynaptic potentials can be evoked in the rat 
(Alstermark et al. 2004). One study showed anatomical evidence for close 
appositions between corticospinal boutons and motoneurons by using light 
microscopic technique (Liang et al. 1991). Yang and Lemon also observed close 
appositions at light microscopic level. However, they did not find any positive 
ultrastructural evidence for corticomotoneuronal monosynaptic connections at 
electron microscopic level (Yang and Lemon 2003).  
1.9.1.2 Functions of the CST 
The CST is one of the most important descending motor tracts and plays an 
important role in motor function. For example, the forelimb reaching task 
especially involves the type of fine, voluntary movement that is thought to be 
controlled by the CST (Anderson et al. 2005). Some studies proved that a dorsal 
CST injury or damage to the motor cortex resulted in deficits in fine digital 
control in the rat (McKenna and Whishaw 1999; Schrimsher and Reier 1993). 
Furthermore, Kennedy (1990) proposed that the CST can compensate for damage 
to the rubrospinal tract via activation of the rubro-olivary projection. 
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1.9.2 Ascending pathways in the dorsal columns of the spinal 
cord 
Ascending pathways in the spinal cord conduct information from sensory 
receptors in the trunk and limbs to the brain. There are two main groups of 
ascending fibres in the dorsal columns of the spinal cord, a direct dorsal column 
pathway and a postsynaptic dorsal column pathway (Tracey and Waite 1995). In 
addition, approximately 25% of the fibres in the dorsal funiculus are 
propriospinal (Chung et al. 1987). 
The direct dorsal column pathway is made up of the ascending branches of 
primary afferents of sensory neurons. The cell bodies of sensory neurons within 
the dorsal root ganglia give rise to axons which bifurcate (Figure 1-11). One 
branch innervates receptors in the skin, muscle and viscera. The other branch 
enters the spinal cord through the dorsal roots. These central branches then 
bifurcate into descending (caudally) and ascending (rostrally) projecting fibres 
(Willis and Coggeshall 2004). In general, the descending fibres maintained a less 
organised topographic distribution, and typically only a small amount of fibres 
descend two segments from their site of entry (Smith and Bennett 1987). Only a 
fraction of the ascending branches of primary afferents actually reach the dorsal 
column nuclei. Other fibres end in the grey matter at some level of the spinal 
cord. A much larger proportion of dorsal root ganglion cells in the cervical 
enlargement projected to the dorsal column nuclei, compared to lumbar dorsal 
root ganglion cells (Smith and Bennett 1987; Giuffrida and Rustioni 1992). Axons 
travelling within the dorsal column may give rise to collateral branches which 
terminate in various regions of the grey matter, including the dorsal horn, 
intermediate region, and ventral horn (Willis and Coggeshall 2004) (Figure 1-11). 
The ascending branches of primary afferents have a somatotopic organization in 
the dorsal column, i.e. fibres from the tail project close to the midline, whereas 
fibres from the hind limb, trunk, and forelimb are added to the lateral border of 
the column at progressively more rostral levels (Willis and Coggeshall 2004; 
Smith and Bennett 1987). 
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Figure 1-11 Schematic representation of the organization of ascending 
pathways.  
Schematic diagram show the organization of ascending pathways. The soma of 
sensory neurons within the dorsal root ganglia give rise to axons which bifurcate. 
One branch innervates receptors in the peripheral system. The other branch 
enters the spinal cord through dorsal root. These central branches then bifurcate 
into ascending and descending branches. Axons travelling within the dorsal 
column may give rise to collateral branches which terminate in various regions of 
the grey matter (adapted from Brown et al. 1981). 
A study shows that about 25% of primary afferents in the dorsal columns are 
unmyelinated in the rat (Chung et al. 1987). Many of these unmyelinated fibres 
contain calcitonin gene-related peptide. It is suggested that unmyelinated 
afferents in the dorsal columns might carry information from nociceptors or 
visceral receptors to the dorsal column nuclei (McNeill et al. 1988; Tamatani et 
al. 1989; Patterson et al. 1990). 
The postsynaptic dorsal column pathway is formed by the axons of the spinal 
neurons originating in the spinal cord and projecting to the dorsal column nuclei 
(Giesler et al. 1984). The cells are in the nucleus proprius just ventral to the 
substantia gelatinosa. The axons of postsynaptic dorsal column neurons 
terminate at all rostrocaudal levels of the gracile and cuneate nuclei and also 
terminate in the external cuneate nucleus (de Pommery et al. 1984); they make 
apparent synaptic contacts with lemniscal neurons projecting to the ventrobasal 
thalamus (Cliffer and Giesler 1989). The postsynaptic dorsal column pathway 
projects in a somatotopic fashion to the dorsal column nuclei, since the nucleus 
cuneatus receives an input from cells in the cervical enlargement and the 
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nucleus gracilis from the lumbar enlargement (Giesler et al. 1984; de Pommery 
et al. 1984).  
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Response of sensorimotor pathways 
to injury -spontaneous plasticity 
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2.1 Introduction 
Following SCI, the disruption of both descending and ascending axonal pathways 
leads to loss of motor, sensory and autonomic function. Significant spontaneous 
functional recovery, that is recovery without any intervention or treatment, has 
been observed in both experimental animals and humans over a period of days, 
weeks or months following injury (Weidner et al. 2001; Gulino et al. 2007; 
Ballermann and Fouad 2006; Burns et al. 1997). The mechanisms behind this 
spontaneous functional recovery have been investigated mainly using anatomical 
and behavioural approaches but remain unclear.   
Although adult CNS neurons have the intrinsic capacity for regrowth over long 
distances (David and Aguayo 1981), anatomical studies described earlier show 
that regrowth is inhibited by an inhospitable environment after SCI and axonal 
regeneration is unlikely to contribute importantly to spontaneous recovery. For 
this reason, interest has focused on other mechanisms including remyelination 
and plasticity. 
It is believed that several types of so-called ‘injury-induced plasticity’ or 
rearrangements of the nervous system may occur in response to SCI, and could 
play a role in generating functional recovery. The existence of synaptic and 
anatomical (sprouting) plasticity in the injured and remaining uninjured axons 
has been observed by molecular and anatomical approaches in animals in which 
spontaneous functional recovery has been seen. Shortly after an injury, inactive 
synapses or pathways may be transformed to be functional (Merzenich et al. 
1984). Later on, the target of a partially lesioned projection may produce a 
greater number of receptors to bind a reduced number of available 
neurotransmitter molecules (Gulino et al. 2007). The spared axons may also 
sprout to form new functional synapses (Brus-Ramer et al. 2007; Bareyre et al. 
2004; Weidner et al. 2001).  
So far, evidence for plasticity following injury has been based mainly on 
anatomical observation and evidence for improved function on behavioural 
observation. However, direct functional investigations of injured and uninjured 
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pathways following SCI which are needed to prove changes in these systems are 
relatively rare.  
The main aims of the experiment described in this chapter were therefore: 1) to 
determine whether an electrophysiological approach can be used to detect 
changes in spinal cord function in response to injury; 2) if so, to determine in 
which locations of the cord the plasticity happens; 3) to determine the degree of 
the plasticity that occurs; 4) to determine the time course over which the 
plasticity develops.    
To assess functional changes in ascending and descending pathways of the spinal 
cord, cord dorsum potentials (CDP) evoked by pyramidal or radial nerve 
stimulation were recorded rostral and caudal of a dorsal column lesion. These 
potentials were compared in normal animals, acutely lesioned animals, and in 
dorsal column lesioned animals at 1 week and 3 months after lesioning.  
Electrophysiological assessment is a potentially powerful means to directly 
evaluate changes of pathways of interest in response to spinal cord injury and 
experimental treatments designed to improve function. However, it is crucial 
that the stimulation and recording conditions are properly understood and 
appropriately controlled so that valid quantifiable results are obtained in order 
to compare among different groups. Ideally, the electrical stimulation used to 
activate the pathway of interest should be applied at a location and at an 
intensity which will fully activate the whole of that pathway but do so 
selectively. It is relatively easy to achieve this when stimulating peripheral nerve 
to activate sensory pathways because peripheral nerves can be isolated from 
surrounding tissues. However, the problem is much greater when activating the 
descending corticospinal tract because the target pyramid is surrounded by the 
reticular formation and close to the contralateral pyramid. The first aim of this 
part of the study was therefore to establish a reliable approach to fully activate 
the CST by stimulating within the pyramid on one side without activating fibres 
in the contralateral pyramid or reticular formation. 
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2.2 Methods 
2.2.1 Animals 
All experiments were approved by the Ethical Review Process Applications Panel 
of the University of Glasgow and performed in accordance with the UK Animals 
(Scientific Procedures) Act 1986.  
The observations reported in this chapter are based on investigation of 61 male 
Fischer 344 rats (Harlan, Loughborough, UK). Twenty-four rats were naïve non-
lesioned animals from which normal data was obtained in an acute 
electrophysiological experiment. Subsequently, 7 of them were subjected to 
acute bilateral dorsal column lesions and further electrophysiological 
assessment. The remaining 37 rats were subjected to dorsal column lesions and 
were allowed to recover. Of these, 19 animals were investigated 
electrophysiologically after 1 week survival and 18 were investigated after 3 
months survival. Rats used for the naïve group weighed 310 –385g at the time of 
electrophysiology to approximately match the weight of animals which had been 
lesioned and allowed to survive for 3 months. At the time of surgery, rats used 
for the lesioned group weighed 246-290g (1 week survival) and 203 - 255g (3 
months survival). 
2.2.2 Lesioning 
All the dorsal column lesions in this study were carried out by Dr. John Riddell. 
2.2.2.1 Drugs 
Lesioned animals routinely received the following peri-operative medication as 
required: 
Buprenorphine (Vetergesic): 0.05mg/kg subcutaneous route, one dose at the 
time of induction and a further dose the following morning.  
Carprofen (Rimadyl): 5mg/kg subcutaneous route, one dose at the time of 
induction and as required. 
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Saline: 0.2-0.4ml/100gm body weight (subcutaneous route), two or three times 
daily for up to three days and as required. 
Enrofloxacin (Baytril): 5mg/kg subcutaneous route, twice daily from day of 
surgery for 7 days. 
Amfipen (antibiotic): 22.5mg/kg, pre-op subcutaneously. 
An ophthalmic ointment was applied to the eyes to prevent drying. 
2.2.2.2 Dorsal column lesion procedure 
The dorsal columns were lesioned bilaterally at the C4/C5 junction. This location 
was chosen because it is accessible surgically and allows electrophysiological 
assessment of corticospinal and sensory input originating from the forelimb. The 
lesion of the dorsal columns interrupts the main component of the corticospinal 
tract which runs in the ventral aspect of the dorsal columns and the ascending 
dorsal column pathway more dorsally. Surgical materials and instruments were 
sterilised and precautions were taken to minimise the risk of infection. 
Animals were anaesthetised with 5% halothane and oxygen at the time of 
induction, 1.5% halothane and oxygen during the surgery. The cervical spinal 
cord was exposed by laminectomy between C3 and C5. The dorsal columns were 
lesioned close to the C4/5 segmental border using a wire knife (David Kopf 
Instruments, Tujunga, USA; Figure 2-1). The wire knife, made of a 100µm 
diameter tungsten wire ensheathed within a Teflon cannula, is such that when 
the wire is protruded from the cannula, it coils to form an arc. The knife was 
mounted on a stereotactic device fitted with a stepper motor. The C4/5 
segmental border was identified by locating the C2 Processus spinosus and dorsal 
roots. The sheathed knife was inserted through a slit in the dura over the left 
dorsal root entry zone, approximately 700 µm left from the midline of the spinal 
cord lowered to a depth of 950 µm and then protruded to form an arc 
(approximately 1.8 mm diameter) encompassing the dorsal columns. This was 
then raised against a glass rod placed on the surface of the cord, cleanly 
transecting the dorsal columns without damage to the surface vessels. To ensure 
transection of the most superficial fibres while preserving the integrity of the 
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dorsal vein, a pointed cotton bud was pressed into the arc created by the wire 
knife for approximately 20 seconds. The advantage of this method is that it is 
accurate and reproducible and this provides greater consistency across and 
within groups of animals.  
A suture was placed in the dura over the lesion so that the location could be 
identified at the later electrophysiological experiment and the segmental level 
confirmed at the end of the experiment. The wound was closed and analgesia, 
antibiotics and s.c. saline routinely administered as mentioned before. Animals 
were recuperated in a warm environment in which easy access to food and water 
was provided. Animals were allowed to survive up to 3 months. 
2.2.3 Eelectrophysiological experiment 
2.2.3.1 Anaesthesia 
Anaesthesia was induced with 5% halothane in oxygen, maintained with 1.5-2% 
halothane in oxygen during the initial surgical procedures, and subsequently with 
frequent doses of sodium pentobarbital (10 mg/kg i.v.), given as required. The 
depth of anaesthesia was assessed during the dissection by monitoring 
withdrawal reflexes, the corneal reflex, arterial blood pressure and an 
electrocardiogram. Additional doses of anaesthetic were given if a withdrawal 
reflex was seen on pinching or if blood pressure increased on pinching or was 
abnormally high. During the recording phase of the experiment, when the animal 
was paralysed and artificially ventilated (see below), administration of 
anaesthetics was continued at a rate commensurate with that required before 
paralysis. The adequacy of this regime was checked by continuously monitoring 
the arterial blood pressure and its response to noxious stimuli. 
2.2.3.2 Preparatory surgery 
The animal was placed in the supine position on an operating table and secured 
with adhesive tapes attached to each of the limbs. The animal’s core 
temperature was continuously measured by a rectal probe and maintained by a 
heating blanket and radiant heat close to 38oC. The electrocardiogram was 
monitored during dissection through needle electrodes which were inserted 
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through skin of the left and right forelimb and the right hind-limb (when a 
surgical level of anaesthesia had been obtained heart rate was typically between 
360-400 beats/minute). Before starting the surgery, dexamethasone sodium 
phosphate (2-3 mg/kg i.m., Faulding Pharmaceutics Plc, UK) was injected to 
prevent the swelling of the brain and spinal cord. Atropine sulphate (Martindale 
Pharmaceuticals, UK) at a dose of 0.05 mg/kg was also injected intraperitoneally 
to reduce bronchial constriction and salivary secretions. Before making skin 
incisions, fur was removed from the relevant areas using an animal fur clipper. 
Fine surgery including cannulation, nerve dissection and laminectomy were 
performed with the aid of a dissecting microscope (Zeiss S5, Germany). A 
cautery (Eschmann equipment, TDB 50, UK) or soldering iron was used to prevent 
bleeding from blood vessels. 
2.2.3.3 Cannulation 
A carotid artery, jugular vein and the trachea were cannulated. A midline 
incision was made through the skin overlying the trachea, the skin was retracted 
and the superficial muscles covering the trachea were separated. A carotid 
artery (usually right side) was carefully exposed by blunt dissection and about 2 
cm of the artery freed from surrounding connective tissue, avoiding damage to 
the vagus nerve. The artery was ligated distally and a cannula inserted 
proximally (i.e. towards the heart) to permit continual monitoring of arterial 
blood pressure which was maintained above 80mm Hg (usually at 100-120mm Hg) 
during the experiment. The arterial cannula was filled with heparinised saline 
(1% heparin in sterile saline) to help prevent blood clot formation and maintain 
patency for chronic blood pressure measurement. A jugular vein was cannulated 
to allow intravenous administration of anaesthetics and other drugs. The skin 
and muscles overlying the trachea were retracted and a small length of the 
trachea was separated from the surrounding tissues. The trachea was opened 
and a cannula with appropriate diameter inserted and tied in position. From 
time to time excessive secretions in the trachea were removed by suction. All 
cannulae were secured to the skin by threads in order to prevent them being 
accidentally dislodged and skin incisions were closed with Michel clips.  
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2.2.3.4 Radial nerve dissection 
To dissect superficial branches of the left radial nerve, the animal was placed in 
the pronate position and an incision was made on the dorsal aspect of the left 
forelimb from the shoulder proximally to about the elbow distally. The tensor of 
triceps brachii muscle was cut to expose the superficial branches of the radial 
nerve. The branches were dissected free (approximately 2 cm) and sectioned 
distally. A suture loop was tied to the end of the radial nerve in order to lift it 
without damage. The exposed nerve was covered with cotton soaked with saline 
to prevent the nerve from drying (Figure 2-2). 
2.2.3.5 Laminectomy 
A laminectomy was performed to expose the cervical (C1-T1) segments of the 
spinal cord. A mid-line skin incision was made from skull to upper thoracic 
region. The skin was retracted and the cervicoauricular muscles and trapezius 
muscles were separated (partially removed if necessary) from the vertebral 
column. Afterwards, the posterior arch was cautiously removed by using small 
bone rongeurs and bone cutting instruments to expose the cervical spinal cord. 
In lesioned animals, the lesion location was identified from a 10/0 marking 
suture left in the dura at the end of the lesion operation and by its darker 
appearance compared to the surrounding cord. Bone wax and plasticine were 
used to prevent the seeping of blood from the cut edge of vertebrae and gel 
foam was also used to prevent bleeding. Care was taken to avoid damage to the 
cord which is vital. 
2.2.3.6 Transferring to recording frame 
After completing the surgery, the animal was transferred to the recording 
frame. The animal’s head was secured by an incisor bar and ear bars. The 
vertebral column was fixed rigidly by the incisor bar, ear bars and a clamp which 
gripped the spinal processes of lower-thoracic vertebrae. 
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2.2.3.7 Paraffin pools 
Paraffin pools were formed around the posterior side of the left forelimb and the 
laminectomy region by attaching threads passed through the edge of the skin 
incision to part of the frame. The pools were filled with liquid paraffin at about 
37oC so as to cover all exposed tissues. This insulation prevented current spread 
to other tissue on electrical stimulation of peripheral nerves. In addition, heat 
loss and drying of tissue were also avoided. The lesion site and/or the C4/5 
border were identified and a strip of paper with mm markings placed along side 
the cord to provide a reference for the positioning of recording electrodes. The 
dura was carefully opened. The C2, C3 and C4 left dorsal roots were cut to avoid 
any input to the spinal cord above the lesion from afferents travelling in these 
roots. Care was taken to avoid damage to the cord.  
2.2.3.8 Artificial ventilation 
Before beginning recording, it was necessary to paralyse and artificially ventilate 
the animal in order to prevent movements while stimulating in the pyramids. 
The trachea was cleared of excessive secretions by suction and the animal was 
paralysed with Pancuronium Bromide (Sigma, induce with 0.3 mg/kg i.v. and 
top-up with doses of 0.04mg every 30 minutes or as required). The animal was 
artificially ventilated with air by connecting the tracheal cannula to a 
respiratory pump (6025 ventilator, UGO basile, Italy). The level of carbon 
dioxide was monitored (Micro-Capnometer, Columbus Instrument, USA) and was 
kept about 4% throughout the experiment by adjusting the ventilation rate. 
2.2.3.9 Craniotomy 
A small craniotomy was performed on the interparietal bone by using a fine dental 
drill. Care was taken to prevent continuous bleeding. The appropriate location 
(between lambda and the ridge on the back of the skull) was chosen to allow access 
for the stimulating electrode to be sited in the pyramids (see below).  
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2.2.3.10 Stimulation of the corticospinal tract 
The corticospinal tract was activated by stimulation within the pyramids by a 
dorsal approach (Stone 1972) (Figure 2-3B). A bipolar electrode was used in 
order to maximise the current density close to the tip and reduce stimulus 
spread (SNE-100X, shaft diameter 0.25mm, shaft length 50mm, Kopf 
instruments, Tujunga, CA, USA). The electrode was checked before each 
experiment for impedance and for the integrity of the insulation. The electrode 
was mounted in a Kopf electrode holder at an angle of 20 degrees with the tip 
pointing rostrally. The electrode holder was mounted on the Kopf U-frame (head 
holder), the tip was then calibrated to ear bar zero by alignment with an ear bar 
set in the frame. The electrode and its carrier were then removed and replaced 
once the animal was in the frame and the craniotomy was completed. After 
examining a stereotaxic atlas of the rat brain (Paxinos and Watson 1998), the 
following stereotaxic co-ordinates were chosen with the aim of targeting the 
middle of the right pyramidal tract at a point in the brainstem where it is 
discrete and compact (Medio-lateral: 0.7mm to the right; Anterior-posterior: 
slightly rostral to the intra-aural line, depth: approximately 1mm below intra-
aural line).  
After adjusting the medio-lateral positioning of the electrode carriage 
appropriately for the above co-ordinates, the electrode was lowered through the 
dura and into the brain. Once in the brain it was lowered to a position 
approximately 1mm above the intra-aural line. 
Electrical stimuli (0.2ms duration square waves, up to 5mA in amplitude) were 
then applied and the final positioning of the electrode was completed while 
monitoring the cord-dorsum potential evoked on the surface of the cervical 
spinal cord (for details of recordings, see below). Recordings were routinely 
made at a position 5 mm rostral to the C4/5 border which was used as a 
reference point in non-lesioned animals and is above the dorsal column lesion in 
the lesioned groups of animals. The electrode was advanced in 0.1 or 0.2mm 
steps while observing the size of the CDP and determining the threshold intensity 
for its appearance.  
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Sometimes the base of the skull was reached without the optimum conditions for 
eliciting pyramidal-evoked CDPs from being found. In this case, the electrode 
was raised to the surface again and, after moving medially or laterally by 
0.5mm, lowered once more to find the optimum location. Sometimes stimuli 
were also applied within the left pyramids to activate the contralateral tracts. 
Once the optimum position was located, a stimulus-recruitment curve for the 
pyramidal-evoked CDP at this location was collected. Recordings of the CDP 
(averages of 25 or 50 sweeps) were made at the same location while increasing 
the intensity of the stimuli applied within the pyramids in graduated steps from 
threshold to values that were supramaximal. The stimulus intensity producing a 
maximal CDP response was determined from this procedure and a supramaximal 
value for use in the experiment was then chosen (see Results). 
2.2.3.11 Stimulation of the radial nerve    
The radial nerve was mounted on bipolar silver wire electrodes immersed in the 
paraffin pool made from the skin flaps of the forelimb surgical site (Figure 2-2C). 
Care was taken to avoid any contact of the nerve with surrounding tissues and 
the electrode was firmly secured in position once adjusted. The nerve was 
stimulated electrically using single square wave stimulus pulses of 0.2ms 
duration and up to 500µA. The maximal intensity for evoking activity in the 
myelinated group I and group II fibres in the nerve was determined by recording 
at a position 5 mm below the C4/5 border which is where a large radial-evoked 
CDP is normally produced and is below the level of the dorsal column lesion in 
the lesioned group of animals (Figure 2-3A). The stimulus intensity was then set 
at a value that was supramaximal for the radial-evoked CDP (typically 100-
200µA). 
2.2.3.12 Recordings of cord dorsum potentials  
To assess spinal cord function in the region of the lesion, CDPs evoked by 
electrical stimulation of the radial nerve and/or corticospinal tract were 
recorded. Recordings were made using a silver ball electrode placed on the 
dorsal surface of the cord, with the indifferent electrode placed on nearby back 
muscles. Recordings were made at 1mm intervals for 8 mm above and below the 
C4/5 reference level (position of the dorsal column lesions in the lesioned 
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animal group; see Figure 2-4A). The positioning of the electrode was guided with 
reference to mm graduated paper placed alongside the exposed spinal cord. At 
each rostro-caudal position the electrode was placed over the dorsal columns 
next to the dorsal root entry zone usually on the left side of the cord (though 
sometimes recordings were also made from the opposite side). 
Recordings of CDPs were made while stimulating either the radial nerve or 
within the pyramids at supramaximal stimulus intensity (Figure 2-4B). The 
stimulus repetition rate was approximately 2Hz and recordings of 25 sweeps 
were typically collected and averaged at each recording position for radial nerve 
stimulation while 50 sweeps were averaged for the smaller potentials produced 
by pyramidal stimulation. 
Throughout the recording of CDPs, great care was taken to remove fluid from 
the surface of the cord. The accumulation of cerebrospinal fluid tends to short 
circuit the recording electrodes and therefore results in smaller potentials than 
when precautions are taken to remove the fluid. This is an important potential 
source of inaccuracy and fluid was therefore removed before moving the cord 
dorsum recording electrode to each new recording position and also during 
recording if a decline in the amplitude of the CDPs was observed while collecting 
records from the same location. 
All recordings of electrical potentials were digitised (Cambridge Electronic 
Design 1401+ interface, Cambridge, UK) and stored on a computer at a sampling 
rate of 20 kHz, without filtering. Averaging and measurements of the amplitudes 
and latencies of electrical potentials were performed using Signal software 
(Cambridge Electronic Design, Cambridge, UK). 
2.2.3.13 Conditioning of radial CDPs with pyramidal stimulation  
As an additional way of assessing the function of the corticospinal projection 
below the level of a lesion we applied conditioning stimuli in the pyramids and 
looked at their effect on CDPs evoked by radial-nerve afferents below the level 
of the lesion (Figure 2-5). 
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Test potentials were evoked by electrical stimulation of the radial nerve (single 
shock, 0.2ms duration, supraximal intensity). Responses to test stimuli were 
conditioned by prior application of stimuli within the pyramids (5 shocks at 300 
Hz, 0.2ms duration, supramaximal intensity). The tests were carried out using 
intervals between the first conditioning stimulus and the test stimulus 
(conditioning-test interval) of 20ms, 25ms and 30ms. In case the conditioning 
stimulus evoked potentials that interfered with the test potential, recordings 
were also made of the conditioning stimulus-evoked potentials on their own. 
Stimuli were applied in an alternating fashion in order to avoid changes over 
time (i.e. drift of the recording conditions over time due to e.g. build up of 
fluid) that could affect the results if sequential averaging of responses to test 
stimuli were collected, followed by collection of responses to conditioning plus 
test stimuli and then conditioning stimuli alone. For each test, the pattern of 
stimulation was therefore in an alternating cycle consisting of 1) test stimulus 
alone, 2) conditioning stimulus followed by test stimulus, 3) conditioning 
stimulus alone. To avoid possible interaction (e.g. inhibition) between each 
application of the condition-test paradigm, the repetition rate between each 
stimulus was 1 second. A total of 75 sweeps were collected, 25 sweeps for each 
of the stimulus conditions. This procedure was repeated for recordings made at 
3mm, 4mm, 5mm and 6mm below the C4/5 reference position. Each of the 
conditioning-test intervals (20ms, 25ms, and 30ms) was tested at each position 
(see result). 
For normal animals it was sometimes necessary to subtract records obtained 
during application of conditioning stimuli alone from those obtained with both 
conditioning and test stimuli. The resulting record of the conditioned potential 
was then compared to that obtained with the test stimulus alone. After dorsal 
column lesions, the pyramidal-evoked potentials below the lesion were much 
smaller so that this was not necessary. Measurements of the peak amplitude of 
test and conditioned potentials were made off-line and the conditioned 
amplitude expressed as a percentage of the test amplitude. 
2.2.3.14 Perfusion 
Most of the animals were transcardically perfused with mammalian Ringer’s 
solution followed by paraformadehyde fixative at the end of the 
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electrophysiological experiment for histology. Animals were perfused through 
the left ventricle with mammalian Ringer’s solution containing 0.1% lidocaine (to 
help dilate the blood vessels) followed by 500 ml 4% paraformaldehyde in 
0.1MPB, pH 7.4. Brain stem and cervical spinal cord were then carefully removed 
without damaging the marking electrode if present. Post fixation of the cord was 
achieved by placing the cord in the same fixative solution overnight in which 30% 
sucrose was added for the purpose of cryoprotection. 
2.2.4 Histological processing 
2.2.4.1 Histological processing of brainstem for stimulation sites 
After washing in 0.1MPB, the electrode tracks in the brainstem were identified. 
Blocks containing the electrode tracks were carefully prepared. Blocks were 
notched at the ventral aspect of the spinal cord on the left side (usually 
electrode tracks were on right side) and sectioned transversely at 70µm using a 
freezing microtome (Ernst Leitz wetzlar, Germany). Sections with electrode 
tracks were mounted on plain glass slides in Vectashield mounting medium 
(Vector Laboratories, UK) and then coverslipped and the edges of the coverslip 
sealed with nail varnish. Slides were stored at -20°C.  
2.2.4.2 Histological processing of spinal cord for lesions 
After washing in 0.1MPB, lesion sites were identified. Blocks containing the 
whole lesion were prepared. Dorsal and ventral roots were removed without 
damaging the lesion site. A notch was made at the ventral aspect of the cord on 
the right side. 70µm sections were transversely (occasionally parasagitally) cut 
on a freezing microtome (Ernst Leitz Wetzlar, Germany). Sometimes, where the 
lesion was extensive, it was difficult to cut whole sections or sections fell apart 
after cutting. A note was made of any sections which were lost in the cutting 
process so that they could be taken into account when quantifying the lesion 
size. Sections were washed in phosphate buffered saline 0.3M (PBS double salt), 
and then incubated for 30 min in 50% ethanol. After washing 3 times 10 minutes 
each in PBS sections were treated with fluorescence histochemistry techniques. 
72h incubation of sections with anti-NF200 (1:1000 Sigma) and anti-GFAP 
(1:1000) primary antibodies at 4°C which label respectively the axons and the 
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astrocytes (lesion boundaries) was followed by appropriate species secondary 
antibodies conjugated to fluorophores (Alexa 488 1:500,  Rhodamine 1:100) (2 
hours at room temperature or overnight at 4°C). After washing 3 times for 10 
minutes in PBS, sections were mounted on plain glass slides in anti-fade medium 
(Vectashield; Vector Laboratories, UK), and coverslipped and the edges of the 
coverslip sealed with nail varnish and then stored at –20°C. 
2.2.5 Microscopy 
2.2.5.1 Reconstruction of stimulation sites in the Pyramids 
Sections containing stimulating electrode tracks were reviewed under 
microscopy (Zeiss Axioplan 2 Imaging). The stimulating electrode tracks were 
reconstructed by using Camera lucida drawings.  
2.2.5.2 Verification of dorsal column lesion  
Sections containing the lesion cavity were observed using phase contrast light 
microscopy to determine the perimeter of the cavity and the relationship to the 
boundaries between grey and white matter. The same sections were sometimes 
viewed using epifluorescence microscopy to observe neurofilament 
immunolabelling and/or GFAP immunolabelling in the section.  
2.2.5.3 Quantification of lesion size  
Because we have previously found that the lesion elongates rostro-caudally but 
does not increase significantly in cross sectional area over time, we have 
measured the length of cavity to indicate the lesion volume. For parasagital 
sections, length of cavity for the section with the longest cavity from each 
animal was measured using a camera lucida attachment with a calibrated 
setting. For transverse sections, length of cavity = (the number of sections with 
lesion + any sections lost during cutting) X 70µm (section thickness). 
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2.2.6 Off-line analysis of electrophysiology 
2.2.6.1 Off-line analysis of CDPs 
Average records were inspected offline using Signal software. The amplitudes of 
CDPs recorded at each location were measured by using Signal software. The 
data was noted in excel spreadsheets then imported to Prism 4 software 
(GraphPad Software Inc, USA) to create potential plots. 
2.2.6.2 Off-line analysis of CDP conditioning 
Average records were inspected offline using Signal software. The amplitudes of 
radial-evoked CDPs at different test intervals (i.e. 20ms, 25ms, and 30ms) at 
each recording location were measured by using Signal software. The amplitudes 
of radial-evoked CDPs after subtracting pyramidal conditioning were also 
measured for each recording. The data were entered on excel spreadsheets. 
Conditioned CDPs were expressed as a percentage of control CDPs. Average 
percentages of each recording location at different conditioning-test intervals in 
each group were calculated.  
2.2.7 Statistical analysis   
The following statistical tests were carried out on the electrophysiological data 
(GraphPad Software Inc, USA). Analysis of variance (ANOVA), The Dunnett Post-
hoc test, and Student’s t-test were used to reveal the differences among 
different groups.
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2.3 Results 
2.3.1 Spinal cord function assessed by electrophysiology 
In this study, cord dorsum potentials (CDPs) evoked by stimulating the 
corticospinal tract and/or radial nerve were used to assess function in the 
cervical spinal cord.  
Recordings were made from normal animals (n=24) and animals with dorsal 
column (DC) lesions (n=37). Animals with dorsal column lesions were investigated 
at three time points: immediately after the lesion (n=7), one week following the 
lesion (n=19), and three months following the lesion (n=18). 
2.3.1.1 Components of surface potentials evoked by pyramidal stimulation 
When the stimulating electrode was lowered into the brain stem using the 
appropriate stereotaxic co-ordinates (see methods), a potential could be 
detected with an electrode on the surface of the spinal cord. The potentials 
were recorded with a silver ball electrode positioned on the dorsal columns at 
1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border 
(Figure 2-4). Examples of pyramidal-evoked CDPs are shown in Figure 2-6. The 
surface recordings consist of a stimulus artefact which indicates the onset of 
stimulation. This is followed after a brief interval by a short duration wave 
called an afferent volley which represents the action potentials travelling along 
fibres in the CST. Immediately following this is a longer duration wave called a 
CDP. This represents the synaptic activity generated by connections between the 
collaterals of the CST fibres and spinal cord neurons in the grey matter and 
provides a measure of the strength of these connections. The recordings in 
Figure 2-6 were made at different rostro-caudal locations. The afferent volley is 
clearest and largest at locations close to the stimulation site, becomes dispersed 
further from the stimulation site and eventually merges with the CDP at more 
caudal locations. 
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2.3.1.2 Conduction velocity of corticospinal fibres  
To obtain a value for the conduction velocity of the corticospinal fibres, the 
latency between the onset of the stimulating pulse and the onset of the afferent 
volley (as is indicated for the recording in Figure 2-6) was measured in two 
normal animals. The latencies were measured for all recordings from 8mm 
rostral to 8mm caudal of the C4/5 border. The latencies were then plotted 
against recording locations as shown in Figure 2-7. The plots were fitted with 
lines using linear regression. The slopes of these lines give the conduction 
velocity of the fastest conducting corticospinal fibres which are as indicated on 
the plots in Figure 2-7. 
In each case the plots were best fitted by two separate lines of different slopes 
indicating a change in conduction velocity. The fibres appeared to conduct more 
rapidly (20.3ms-1 and 21.2ms-1) in the upper cervical segments and to slow within 
the C4-7 segments (10.3ms-1 and 14.5ms-1). This slowing presumably reflects the 
more extensive branching of the fibres within these segments and the resultant 
thinning of the parent branches. The conduction velocities of the CST measured 
between +3 and -8mm are similar to those reported by others (Alstermark et al. 
2004; Mediratta and Nicoll, 1983). 
2.3.1.3 Technical problems associated pyramidal stimulation 
In order to obtain a quantitative measure of the strength of actions of the 
corticospinal pathway which can be compared between animals, it is necessary 
to be able to activate the corticospinal pathway consistently, i.e. to the same 
extent, from animal to animal. Using a supra-maximal stimulus intensity is a 
convenient way of achieving this. The pyramids consist of compact bundles of 
corticospinal fibres and therefore provide an anatomically convenient location at 
which to activate the whole of the corticospinal tract. In principle, with an 
electrode placed in the middle of a pyramid, it should be possible to increase 
the stimulating current intensity until it is sufficient throughout the pyramids to 
activate the whole of the tract. In practice there are several potential problems. 
1) The stimulus intensity has to be raised sufficiently to achieve a current 
density that activates fibres at the outer edge of the pyramids; 2) At the same 
time, there should not be current spread beyond the outer edge of the pyramids 
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that would activate reticulospinal fibres in the adjacent reticular formation; 3) 
the stimulus current should also activate fibres at the edge of the pyramids 
before reaching a density close to the electrode tip that would produce anodal 
block of fibres at the centre (Ranck 1981); 4) The pyramids are bilateral 
structures which lie very close to one another at the midline. If the electrode is 
not optimally placed in the target pyramid (e.g. too close to the midline), then 
there is the possibility that partial activation of the opposite pyramid may occur 
before activation of the target pyramid is fully achieved. This could be a 
problem depending on the type of recordings being made. 
2.3.1.4 Method for supramaximal activation of the corticospinal tract 
unilaterally 
To determine whether it was possible to fully activate the pyramidal tract on 
one side only, careful stereotaxic placement of the electrode was combined with 
investigation of the stimulus-recruitment curve and subsequent histological 
determination of the position of the electrode tip. Figure 2-8 illustrates this 
process. First the electrode was lowered to the position where the threshold for 
evoking a CDP at the +5 mm position was lowest and a careful note made of this 
threshold intensity. In Figure 2-8A, a CDP was just evident at an intensity of 8µA. 
Recordings were then made while the stimulus intensity was increased 
incrementally (as shown by in Figure 2-8A) and a note was made of the point at 
which the CDP was maximal. Measurements of the CDP amplitude at different 
stimulus intensities were later plotted as shown in Figure 2-8B. This procedure 
was followed in all experiments in which pyramidal stimulation was used to 
determine an appropriate supramaximal stimulus intensity for use in the 
experiment. After the experiment, the electrode track was identified in 
histology of the brain stem (Figure 2-8C) and its position reconstructed (Figure 2-
8D). 
In order to determine the conditions under which stimulation within the 
pyramids could safely be considered to have maximally activated the target 
pyramid without stimulus spread to the opposite pyramid, a systematic 
comparison was made of the stimulus-recruitment curves and electrode position 
for all animals where this was obtained. For this exercise, data from 
experiments reported in this chapter has been pooled with that from 
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experiments described in Chapter 3. Table 2-1 shows the different experimental 
groups from which these animals were drawn. The comparison is based on 40 
F344 animals for which histological reconstruction of one or more stimulating 
electrode sites was performed. 
The animals were divided into four groups based on the position of the 
stimulating electrode determined histologically: a “Middle” group where the 
electrode was located in the middle third of the target pyramid, a “Lateral” 
group where the electrode was located in the lateral third of the target 
pyramid, a “Medial” group where the electrode was within the medial third of 
the target pyramid, and a “Midline” group where the electrode was at the 
extreme medial end of the target pyramid and/or very close to the midline. 
Note that animals in this later group were excluded from further study but are 
reported here for the purpose of validating the pyramidal stimulation conditions. 
The numbers of animals and stimulation sites in each of these groups is shown in 
Table 2-2. 
2.3.1.5 Comparison of stimulus-recruitment curves and electrode position 
Threshold stimulus intensity  
Table 2-2 shows data for the threshold stimulus intensities for animals in each of 
these groups. As can be seen, when the electrode was placed in the middle or 
lateral third of the target pyramid the mean threshold was around 10µA and 
when in the medial third less then 20µA. However, when the electrode was off 
target and lay close to the midline, the mean threshold was just above 30µA, 
three times higher than at the centre (bottom line of Table 2-2). When each of 
the animal groups is considered as a whole, irrespective of the electrode 
position (but excluding animals where the electrode was off target i.e. midline), 
the mean threshold values are quite similar, being between 8 and 17µA. In 
particular, there is no difference between the normal animal group and the 
three month survival dorsal column lesioned animals. This suggests that the 
dorsal column lesion has little effect on the excitability of the corticospinal 
fibres being investigated. 
Pattern of recruitment  
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The pattern of recruitment of corticospinal fibres as stimulus intensity was 
raised above threshold was evaluated in three ways. 1) by visually inspecting the 
shape (steepness and position of plateau) of the stimulus-recruitment curves; 2) 
by determining the stimulus intensity evoking a CDP 95% of maximum amplitude 
and 3) by noting the maximal amplitudes of CDPs at a fixed recording location.  
Examples of stimulus-recruitment curves obtained with the stimulating electrode 
positioned in the middle third of the target pyramid are shown in Figure 2-9. The 
stimulus-recruitment curves obtained from this group were generally very steep 
and plateaued abruptly. The mean stimulus intensity at which CDPs in this group 
were 95% of maximal was 226µA (Figure 2-13) and the mean amplitudes of 
maximal CDPs were 0.3mV (see Table 2-3). Once the stimulus-recruitment curve 
had reached a plateau there was minimal change in amplitude as the stimulus 
intensity was increased several fold above maximal. Not only was there rarely 
much of an increase in the amplitude of CDPs but usually there was little or no 
decrease in amplitude as might be expected if anodal block was a problem. 
Examples of stimulus recruitment curves obtained with the stimulating electrode 
positioned in the lateral third of the pyramids are shown in Figure 2-10. The 
stimulus recruitment curves obtained from this group were quite similar to the 
“middle third” group being steeply rising and arriving abruptly at a plateau. The 
mean stimulus intensity at which CDPs in this group were 95% of maximal was 
136µA (see Figure 2-13) and the mean amplitudes of the maximal CDPs were 
0.42mV (see Table 2-3). Minimal change in amplitude occurred even when the 
stimulus intensity was increased several fold above maximal.  
Examples of stimulus recruitment curves obtained with the stimulating electrode 
positioned in the medial third of the pyramids are shown in Figure 2-11. The 
picture was broadly similar to the previous two groups except that some of the 
stimulus recruitment curves were less steep and approached a plateau level less 
abruptly. Consistent with this the mean stimulus intensity at which CDPs in this 
group were 95% of maximal was a little higher at 310µA (see Figure 2-13). 
However, the mean amplitudes of the maximal CDPs was similar at 0.34mV (see 
Table 2-3). Again, once the stimulus response curve had reached a plateau, 
there was minimal change in amplitude as the stimulus intensity was increased 
several fold beyond maximal.  
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Examples of stimulus recruitment curves obtained with the stimulating electrode 
positioned close to the midline are shown in Figure 2-12. The picture here was 
quite different from when the stimulating electrode more accurately targeted a 
pyramid. In this case, the stimulus-recruitment curves were always more gently 
sloping and more gradual in their approach to a plateau level. This was reflected 
in the mean stimulus intensity at which the CDPs evoked from these locations 
were 95% maximal which was much higher than at the other locations at 497µA 
(see Figure 2-13). Furthermore the maximal amplitudes of CDPs evoked by 
stimuli near the midline were considerably greater than at all the other 
locations, in some cases up to twice as large (mean 0.58mV, see Table 2-3).  
The results show that stimulation within the middle and lateral thirds of the 
pyramids produces steep stimulus recruitment curves which reach a maximum 
and do not grow further when the stimulus intensity is raised to several 
multiples of maximal. Stimulation within the medial third can also result in 
complete activation of the target pyramidal tract without significant stimulus 
spread provided that the electrode tip is not too close to the midline. 
Stimulation throughout these sites results in CDPs of broadly similar amplitudes. 
However, when the stimulation site is too close to the midline, it appears that 
stimulus can spread to activate fibres in both pyramids resulting in larger CDPs 
at the spinal level. 
Histological verification of the position of the stimulating electrode relative to 
the pyramids was obtained only for a proportion of the animals (40 out of 112; 
36%). It was therefore necessary to have a method of filtering out those animals 
where the pyramidal electrode was too medially placed but the electrode 
position not determined histologically. This was done by inspecting the stimulus 
recruitment curve for the following features: 1) a relatively high threshold 
stimulus intensity (i.e. 20 µA or more); 2) a gradual and rounded slope; 3) a 
relatively high maximal stimulus intensity 4) a relatively high maximal CDP 
amplitude. Where these features were seen the animals were omitted from the 
study.  
Although for purposes of comparison we have divided animals into “medial” and 
“midline “ groups, in practice there must be a continuum in the distribution of 
stimulating positions moving progressively more medially to approach the 
  92 
midline. To check how effective the use of the above electrophysiological 
exclusion criteria were in the selection of animals, we compared the amplitudes 
of maximal CDPs recorded from animals for which histological verification of the 
stimulation site was obtained with that for the population of animals as a whole. 
As can be seen in Table 2-4 these proved to be closely similar so validating the 
approach. 
The ideal placement for the electrode is in the middle third of the pyramids 
though the results show that placement within the medial or lateral third of the 
pyramids can also be compatible with selective and full activation of the target 
pyramid. The histological reconstructions of electrode tracks showed that in 43% 
of animals the electrode tip lay within the middle third and in a further 45% 
within the lateral or medial third of the pyramids. In only 12% of animals was the 
electrode tip close to the midline and therefore unsuitable for obtaining valid 
results. Furthermore, in some of these cases, it was possible to re-position the 
electrode to obtain valid results. This shows that the method can be used with a 
fairly high success rate. 
2.3.1.6 Cord dorsum potentials generated unilaterally can be recorded 
bilaterally 
Recording from the surface of the spinal cord is a convenient way of recording 
population synaptic activity generated at synapses between spinal cord neurones 
and the afferent pathways terminating on them. However, synaptic activity 
generated by activity on one side of the cord can be detected at varying 
positions on the cord surface including on the contralateral side. For recordings 
of CDPs evoked by peripheral nerve stimulation there is usually some attenuation 
of the contralateral potential. However, for CDPs evoked by stimulation in the 
pyramids, even under conditions where we were confident the stimulation was 
unilateral, CDPs recorded from the two sides of the cord were often closely 
similar in amplitude. Figure 2-14 shows examples of CDPs recorded from both 
sides of the cord in 3 different animals where the stimulating electrode was 
located close to the middle of the target pyramid. Figure 2-15 shows stimulus 
recruitment curves recorded contralateraly and ipsilaterally to the stimulated 
side when the electrode was placed in the lateral half of the target pyramid. 
The close similarity of the curves indicates that they are generated by activation 
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of the same population of fibres. It is evident from this that being sure that 
pyramidal stimulation results in the activation of the pyramids on one side only 
is important to the validity of using cord dorsum potentials as a measure of the 
effectiveness of the corticospinal tract. 
2.3.1.7 Assessment of pyramidal-evoked CDPs 
Pyramidal-evoked CDP recordings were made from normal animals (n=18), 
acutely lesioned animals (n=7), one week survival lesioned animals (n=14), and 
three month survival lesioned animals (n=15). 
Normal animal group 
CDPs evoked by pyramidal tract stimulation were investigated in 18 normal 
animals. Examples of CDPs recorded from three representative animals of this 
group are shown in Figure 2-16. The recordings show that clear surface 
potentials are evoked by pyramidal stimulation at all of the recording locations 
examined. This is from 8mm rostral to 8mm caudal to the C4/5 border of the 
cervical segments. Cervical segments are about 3mm long in the rat so that this 
corresponds to approximately C2 to C7. The recordings show clear afferent 
volleys rostrally which become more dispersed and show a longer latency at 
progressively more caudal recording locations due to the longer conduction 
distance. The amplitudes of the CDPs were often quite similar at all of the 
recording locations as shown in Figure 2-16. However, sometimes the amplitudes 
of the CDPs were smaller at particular locations perhaps because of blood 
vessels. The mean CDP amplitude for all animals in this group at each recording 
location is shown in Figure 2-17. This plot confirms that in normal animals, 
pyramidal-evoked CDPs are on average of similar amplitude at all recording sites 
from 8mm rostral to 8mm caudal of the C4/5 segmental border. The average 
amplitudes are around 0.25-0.3 mV, though as the error bars indicate, there was 
some variation from animal to animal.  
Repeatability of CDP recordings 
To test the repeatability of CDP recordings, multiple mappings of pyramidal-
evoked CDPs were performed in two animals while the stimulating electrode 
remained at exactly the same location in the right pyramid. Other conditions 
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such as the stimulus intensity also remained the same. The mapping was 
performed from 8mm above to 8mm below the C4/5 segmental border and each 
mapping was performed sequentially. Recordings at each location were 
separated by between 15 to 20 minutes since this is the time it takes to 
complete one mapping. An example of the recordings made from one of these 
animals is shown in Figure 2-18. As can be seen, the amplitudes of the CDPs 
recorded in each mapping are closely similar showing that the recording method 
is quite consistent and the CDPs quite stable over time.  
Acute lesion group 
The effect of acutely lesioning the dorsal columns on CDPs evoked by pyramidal 
stimulation were investigated in 7 animals. Recordings were made both before 
and after lesioning the dorsal columns and the first recordings began between 10 
and 25 minutes after making the lesion. Examples of CDPs recorded from two 
representative animals of this group are shown in Figure 2-19. As expected, CDPs 
recorded below the level of the lesion were virtually abolished due to the 
axotomy of the main component of the corticospinal tract on which these 
potentials largely depend. CDPs remained, however, above the lesion site. The 
rostro-caudal distribution of CDPs for this group is shown in Figure 2-20, which 
shows the mean CDP amplitude for all animals in this group at each recording 
location. This confirms that CDPs below the lesion are almost undetectable but 
also shows that the lesion did not change the amplitudes of CDPs above the 
lesion (from +3 to +8mm).   
One week survival DC lesioned group 
CDPs evoked by stimulation in the pyramidal tract were investigated in 14 
animals one week after a dorsal column lesion. Examples of CDPs recorded from 
two representative animals of this group are shown in Figure 2-21. The rostro-
caudal distribution of CDPs for this group is shown in Figure 2-22. As in the 
acutely lesioned group, CDPs below the lesion were almost abolished. At some 
positions close to the lesion, the CDPs appeared to be slightly larger than 
following acute lesions but this was not significant (Table 2-5). Above the lesion, 
the CDPs persisted and in fact tended to be of larger amplitude (by 20-40%) than 
those recorded from normal animals and acutely lesioned animals. This tendency 
was significant at most locations when compared to normal animals but did not 
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reach significance for acutely lesioned animals because of the small number of 
animals investigated (Table 2-5).  
Three months survival DC lesioned group 
CDPs evoked by stimulation in the pyramidal tract were investigated in 15 
animals three months after a dorsal column lesion. Examples of CDPs recorded 
from two representative animals of this group are shown in Figure 2-23. The 
rostro-caudal distribution of CDPs for this group is shown in Figure 2-24. 
Although CDPs below the lesion were much smaller than those recorded in 
normal animals, they were two to five times larger at all recording locations 
than those recorded in animals one week after a dorsal column lesion. This 
difference was significant at all recording sites (-2 to -8mm) except those closest 
to the lesion (Table 2-5). Above the level of the lesion, CDPs were significantly 
larger than in normal animals (Table 2-5) and virtually the same as those 
recorded in animals one week after a dorsal column lesion.  
2.3.1.8 Cord dorsum potentials evoked by radial nerve stimulation 
Recordings were made from normal animals (n=22), acutely lesioned animals 
(n=7), one week survival lesioned animals (n=17), and three month survival 
lesioned animals (n=18). 
Potentials evoked by radial nerve stimulation were recorded with a silver ball 
electrode positioned on the dorsal columns at 1mm intervals from 8mm rostral 
to 8mm caudal to the C4/5 segmental border as for pyramidal-evoked potentials 
(Figure 2-4). Examples of radial nerve-evoked CDPs are shown in Figure 2-25. 
Electrical stimulation of the radial nerve typically produces an afferent volley 
followed by a distinct negative CDP from the dorsal surface of the spinal cord. 
The recordings in Figure 2-25 were made at different rostro-caudal locations. 
The afferent volley is clearest and largest at locations close to the segment of 
entry of the stimulated root, becomes dispersed at more rostral and caudal 
locations. The CDPs represent the synaptic activity generated by connections 
between the collaterals of the primary afferent fibres and spinal cord neurons 
and provide a measure of the strength of these connections.  
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To test the contribution of each spinal dorsal root to the amplitude of radial 
nerve-evoked CDPs, dorsal roots were sequentially sectioned following a 
different order in two animals, while recording the CDPs at a fixed position. The 
amplitudes of CDPs following dorsal root sectioning were expressed as 
percentages of the CDPs before lesioning. The percentages are shown in Table 2-
6. In the first animal, CDPs were recorded from the middle of C6 (about 4mm 
below the C4/5 segmental border). The amplitude of this CDP was substantially 
reduced to 35.2% after C6 dorsal root sectioned and almost abolished after 
sectioning both C6 and C7 dorsal roots. Similar results were obtained from the 
second animal. CDPs were recorded from the middle of C7 (about 7mm below 
the C4/5 segmental border). When the C7 dorsal root was sectioned, the 
amplitude of the CDP was reduced to 63.9%. Sectioning both C7 and C6 almost 
abolished the CDP. Therefore, C6 and C7 dorsal roots contribute most to the 
CDPs.  
Normal animal group 
CDPs evoked by radial nerve stimulation were investigated in 22 normal animals. 
Examples of CDPs recorded from three representative animals of this group are 
shown in Figure 2-26. The recordings show that clear surface potentials are 
evoked by radial nerve stimulation at all of the recording locations examined. 
Afferent volleys are seen especially close the entry of the radial afferent which 
was 3 to 4 mm below C4/5 segmental border.  
The rostro-caudal distribution of CDPs for this group as a whole is shown in 
Figure 2-27, which shows the mean CDP amplitude for all animals in this group at 
each recording location. In normal animals, the biggest radial-evoked CDPs were 
recorded at around 3 to 4mm below the C4/5 segmental border. The amplitudes 
of the biggest CDPs were around 0.7mV. CDPs of gradually declining amplitude 
could be recorded for several segments above and below the C4/5 segmental 
border. Small CDPs were still detected at 8mm above the C4/5 segmental 
border. 
Acute lesion group 
CDPs evoked by radial nerve stimulation were investigated in 7 acutely lesioned 
animals. Examples of CDPs recorded from two representative animals of this 
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group are shown in Figure 2-28. As anticipated, CDPs were virtually absent above 
the lesion due to axotomy of the ascending branches of primary afferent fibres 
on which these potentials largely depend. CDPs remained, however, below the 
lesion site. The rostro-caudal distribution of CDPs for this group is shown in 
Figure 2-29. Surprisingly, CDPs recorded below the lesion tended to be smaller 
following the acute lesion compared to those recorded in normal animals but 
this was not significant (Table 2-7).   
One week survival DC lesioned group 
CDPs evoked by radial nerve stimulation were investigated in 17 animals one 
week after a dorsal column lesion. Examples of CDPs recorded from two 
representative animals of this group are shown in Figure 2-30. The rostro-caudal 
distribution of CDPs for this group as a whole is shown in Figure 2-31. CDPs 
tended to be larger than those recorded in acutely lesioned animals at every 
recording location. However, this was only significant for certain sites below the 
lesion probably because of the small number of animals in the acute lesion group 
(Table 2-7). Interestingly, CDPs recorded below the lesion tended to be larger 
than those recorded in the normal animals group between -3 and -8 and the 
difference was significant at some locations (Table 2-7). 
Three months survival DC lesioned group 
CDPs evoked by radial nerve stimulation were investigated in 18 animals three 
months after a dorsal column lesion. Examples of CDPs recorded from two 
representative animals of this group are shown in Figure 2-32 and the rostro-
caudal distribution of CDPs for this group as a whole is shown in Figure 2-33. In 
three month survival animals, CDPs recorded above the lesion were very similar 
in amplitude to those recorded in one week lesioned animals. Below the lesion, 
CDPs recorded from three month survival animals were significantly larger at all 
locations than those recorded for the acute lesion group except -2mm (Table 2-
7). CDPs differed in a more complex way from those recorded at one week. 
Close to the lesion (0 to -2mm) the CDPs in three month animals tended to be 
smaller than those recorded in one week animals and this difference was 
significant (Table 2-7). Farther away from the lesion, however, CDPs in three 
month animals were the same or larger than those recorded at one week after 
lesioning though the difference was only significant at -6mm. 
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2.3.1.9 Conditioning 
Activity in the corticospinal tract leads to inhibition of transmission at the 
terminals of sensory afferents in the spinal cord and this can be detected using a 
conditioning-test paradigm where stimulation in the pyramids precedes 
stimulation of sensory afferents (see methods, Figure 2-5). 
In order to test whether the significantly larger amplitude pyramidal-evoked 
CDPs seen at the caudal locations in the three month dorsal column lesioned 
animals compared to the one week animals also leads to a change in the strength 
of the inhibition, conditioning was performed while recording at -3, -4, -5, and -
6mm using conditioning-test intervals of 20ms, 25ms, and 30ms. Conditioning 
was performed in 7 normal animals, 8 one week dorsal column lesioned animals 
and 9 three month survival animals.  
An example of conditioning in a normal animal is shown in Figure 2-34. Here a 
radial nerve-evoked CDP recorded at -3 is conditioned by applying stimuli in the 
pyramids at a conditioning-test interval of 20ms. A train of 4 shocks within the 
pyramid was applied as this has previously been found to evoke maximal 
inhibition. The effects of the inhibition were clear in a normal animal (Figure 2-
34B). The percentages of inhibition produced at different conditioning-test 
intervals at different position are shown in Figure 2-35. In normal animals, the 
radial-evoked CDPs were inhibited by between 13% and 17%. The inhibition was 
similar at different conditioning-test intervals i.e. 20ms, 25ms, and 30ms and 
tended to be slightly stronger more rostrally. 
An example of conditioning in a lesioned animal is shown in Figure 2-36 and the 
results from all animals in the lesioned animal groups are summarized in Figure 
2-35. The percentages of inhibition detected in each of the lesion groups 
(between 6%-12%) was much lower than in normal animals as expected following 
axotomy of the main component of the corticospinal tract. The remaining 
conditioning effect may be due either to the minor corticospinal component 
travelling in the lateral funiculus or propriospinal actions. However, there was 
little difference between any of the lesioned animal groups. In particular, the 
inhibition seen in three month survival animals did not differ significantly from 
the one week survival animals.  
  99 
2.3.2 Lesion 
The appropriate locations of the dorsal column lesions (C4/5 segmental border) 
were confirmed in all the lesioned animals included in this study. The lesions 
made by the wire knife were accurate and consistent across and within groups of 
animals. 
Examples of sections containing lesion cavities from different animal groups are 
presented in Figure 2-37. In the acute lesion group, the lesion was contained 
within only a few sections. The wire knife lesion interrupted the full width of 
the dorsal columns, while the dorsal horn of the grey matter was almost intact. 
The one week survival dorsal column lesioned animals developed a cavity and 
some parts of the dorsal horns were evidently damaged together with the dorsal 
columns. The lesion cavities were typically observed in about 20-30 sections 
since the cavity developed mainly rostro-caudally. The lesion site of the three 
months survival animals appeared similar to that of one week survival animals. 
The cavities occupied the dorsal columns and varying amounts of the grey 
matter but were more extensive rostro-caudally than those in the one week 
survival animal group.       
A quantitative comparison of the lengths of the lesion cavities which developed 
following a dorsal column lesion in the one week and three month survival 
animal groups is shown in Table 2-8. The lengths of the lesion cavities in the one 
week survival group ranged from 1330-2100µm with a mean length of 1788µm. 
The cavities in the three month survival group were more variable with a range 
of 1260-3920µm, and the mean of length of the cavity was 2511µm which is 
significantly larger than in the one week animal group (P=0.0081) (Table 2-8). 
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2.4 Discussion 
Methodological considerations 
In this thesis an electrophysiological approach has been used to investigate 
plasticity in the spinal cord following injury and following potential treatments. 
The main approach has been to maximally activate the pathways of interest and 
then to record the massed activity produced at connections within the spinal 
cord in order to quantify the efficacy of the pathways. The reliability of the 
results reported depend on the consistency with which the sensory and 
corticospinal pathways are activated and the accuracy with which the recordings 
made reflect their connectivity. The stimulation and recording protocols used 
are therefore crucial to the validity of the quantitative comparisons between 
different animal groups. 
Maximal activation of afferent systems 
Electrical stimulation of peripheral nerves or sites within the brain is a standard 
electrophysiological technique which has been widely used for several decades 
to investigate the connectivity of neuronal pathways in the CNS in vivo. In 
studies designed to demonstrate connections it is not essential to achieve 
maximal activation of a given afferent pathway since activation of a significant 
proportion is usually sufficient. Furthermore, submaximal stimulation is usually 
preferred in order to avoid the problem of stimulus spread to nearby neurones or 
fibres of passage which if activated could be misidentified as connections form 
the intended target of the stimulation. Stimulating an afferent system in a 
manner that leads to activation of all of the neurones or fibres comprising the 
system, whilst at the same time avoiding any “contamination” of the recordings 
by inadvertent activation of other afferent systems, is a technically more 
challenging requirement especially for systems originating within the brain.  
Maximal activation of sensory afferents 
Throughout this thesis, electrical stimulation of the superficial radial nerve has 
been used to activate sensory afferents. The superficial radial nerve was chosen 
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in part because sensory fibres from the nerve were found to terminate and 
therefore produce CDPs in a convenient location within the cervical segments. In 
addition the radial nerve is one of the few forelimb nerves for which it is 
possible to form a paraffin pool which is the optimum method for fully 
controlling stimulation (Ranck 1981; Swett and Bourassa, 1981). Although it is 
possible to stimulate forelimb afferents by inserting needle electrodes 
percutaneously, it is difficult to control their location relative to the nerves or 
precisely target individual nerve branches. It is not therefore a suitable method 
of achieving maximal stimulation of a selected nerve branch that is reproducible 
from one experiment to another. Placing the nerve in a cuff electrode (Swett 
and Bourassa, 1981) would be an alternative approach but cuffs are prone to 
problems of fluid collection or pressure block of the nerve. Mounting the cut end 
of the nerve on electrodes in a paraffin pool allows maximum control over the 
stimulation conditions because the nerve is insulated from surrounding tissues. 
This means that all of the stimulus current applied flows through the nerve and 
the stimulus intensity can be raised to very high values without any stimulus 
spread. 
The superficial radial nerve innervates predominantly skin. In addition, group I 
muscle afferents do not produce CDPs on the dorsal surface of the rat spinal 
cord and group II muscle afferents produce only small CDPs at specific locations 
(Riddell and Hadian, 1998). Most of the sensory primary afferent fibres 
contributing to the CDPs recorded following radial nerve stimulation are 
therefore of cutaneous origin. There are however, several populations of 
cutaneous sensory fibres; large/medium diameter myelinated (A-beta) fibres 
which innervate mainly low threshold mechanoreceptors in skin,  small diameter 
myelinated (A-delta) fibres which are mainly nociceptive or thermoreceptive and 
unmyelinated C-fibres (Willis and Coggeshall, 2004). These populations of fibres 
differ with respect to their conduction velocity, electrical excitability and 
terminations within the spinal cord. In this study the aim was to maximally 
activate the A-beta fibres in order to detect any changes in their central actions 
following spinal cord injury and following potential treatments. This is 
comparatively easy because the A-beta fibres, being the largest diameter fibres 
are the most easily excited by electrical stimulation. Furthermore, although a 
few A-delta fibres may be activated when the stimulus intensity is raised 
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sufficiently to activate the whole population of A-beta fibres in the nerve, the 
population of A-delta fibres as a whole require much greater stimulus 
intensities. The small overlap that occurs in electrical threshold between A-beta 
and A-delta fibres is not a problem because A-delta fibres conduct more slowly 
than A-beta fibres and produce much smaller CDPs even when maximally 
activated. The CDPs produced by the small number of A-delta fibres activated by 
stimuli that are maximal for A-beta fibres therefore make no difference to the 
peak amplitude of the A-beta evoked CDP. Maximal activation of A-beta sensory 
afferents and selective detection of their synaptic actions is therefore a 
relatively straight forward procedure.  
Maximal activation of the corticospinal tract  
Maximal activation of the corticospinal projection represents a greater problem. 
Although corticospinal neurones can be activated by stimulation within the 
sensorimotor cortex (Donoghue and Wise, 1982; Hummelsheim and 
Wiesendanger, 1985; Adamson et al. 1989; Neafsey et al. 1986), it is difficult to 
activate all corticospinal fibres this way because the corticospinal neurones are 
spread over a large area. A more commonly used method for activating the 
corticospinal tract is to take advantage of the compact projection of 
corticospinal fibres as they course through the brain stem forming the ventral 
midline structure called the pyramids. Placement of stimulating electrodes 
within the pyramids can be achieved using a dorsal approach and stereotaxic 
techniques and this has been widely used to investigate the functional 
connectivity of the corticospinal tract in monkeys (Porter and Lemon, 1993) and 
rats (Alstermark et al. 2004). There are, however, several potential difficulties 
in achieving maximal selective activation of this projection suitable for 
quantitative comparisons. Firstly, the pyramids are bilateral structures and 
although smaller than the cortex, would be difficult to activate bilaterally. 
Furthermore, even when activation of the corticospinal tract is limited to one 
side only, CDPs can be detected anywhere over the dorsal surface of the spinal 
cord, not just on the side to which the corticospinal fibres project. This means 
that it is necessary to develop an approach that allows the corticospinal tract on 
one side to be fully activated but without activation of any of the cortiospinal 
tract on the opposite side. The anatomical proximity of the left and right 
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corticospinal projections at the midline makes this a challenge. Secondly, the 
pyramids are surrounded dorsally and laterally by the reticular formation and 
reticulospinal projections originate from the nucleus reticularis gigantocellularis 
in particular (Hermann et al. 2003). Activation of these projections by spread of 
stimulus from the pyramidal electrode is a further potential complication. 
Thirdly, when the stimulating current density reaches a certain multiple of 
threshold anodal block occurs. Current density is greatest near the electrode tip 
and falls off with distance (Ranck 1981). There is therefore the possibility that 
fibres near the electrode tip would be subject to anodal block before fibres at 
the periphery of the tract had become activated. 
To minimise these problems, in this study we used a concentric bipolar 
stimulating electrode which concentrates the current density at the tip of the 
electrode and so minimises current spread. Use of these electrodes was 
combined with careful stereotaxic placement within the pyramids, the accuracy 
of which could be assessed during the experiment from the very low threshold 
for evoking CDPs and from the stimulus-recruitment curve. Histological 
determination of the actual position of the stimulating electrode relative to the 
pyramids showed that they could be targeted quite reliably. Comparison of 
stimulus-recruitment curves in animals where the position of the stimulating 
electrode was known allowed interpretation of the curves. It was concluded that 
stimuli applied within the lateral and middle thirds of the pyramid could fully 
activate the target pyramid without spread to the opposite pyramid. However, 
when the electrode was very medially located, the maximal amplitudes of 
evoked CDPs were usually considerably larger suggesting bilateral activation of 
corticospinal fibres. Instances where this occurred could also be recognised by 
high thresholds and gentler, more rounded stimulus-recruitment curves. These 
characteristics enabled animals with non-optimally placed pyramidal electrodes 
to be omitted from the study, even where the electrode position was not 
histologically confirmed. 
Although the stimulus intensities used in the study are relatively low and did not 
lead to activation of the contralateral pyramidal tract, we cannot rule out the 
possibility of stimulus spread sufficient to activate reticulospinal axons. 
Reticulospinal axons are faster conducting than corticospinal fibres in the rat 
(Shapovalov and Gurevitch, 1970) and will therefore also be more readily 
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excitable by electrical stimuli. It is therefore likely, particularly where the 
electrode was located in the lateral third of the pyramids, that some activation 
of reticulospinal fibres will occur when using stimuli which are sufficient to 
activate the thinner corticospinal fibres on the farthest perimeter of the 
pyramids. However, field potential recordings made in the ventral horn while 
stimulating in the pyramids (described in the next chapter) show that any such 
activation of the reticulospinal projection is quite minimal because field 
potentials were small and infrequent within the ventral horn where the 
reticulospinal projection terminates. Furthermore, because of the predominantly 
ventral termination of reticulospinal fibres, like muscle afferents, they do not 
produce CDPs (Riddell, Enriquez-Denton and Toft unpublished). This is evident 
from the results obtained in animals with acute lesions of the dorsal columns 
where stimulation in the pyramids resulted in a virtual abolition of CDPs below 
the lesion, even though the reticulospinal projection through the lateral and 
ventral white matter is unaffected by the lesion.  
Anodal surround block is a potential issue when applying electrical stimuli in the 
brain if the stimulus intensity used is well above threshold for activating fibres. 
For example, when stimulating primary afferent fibres in the dorsal columns, 
anodal block occurs when the stimulus intensity is raised to approximately 20 
times threshold. If corticospinal fibres have a similar blocking factor then, since 
thresholds for pyramidal evoked CDPs were mostly of the order of 10 – 20 µA, 
anodal block might be expected to begin to occur at between 200 and 400µA. If 
anodal block had occurred at these and higher stimulus intensities then it would 
be expected that once the maximal stimulus intensity was reached, further 
increases in stimulus intensity would result in a reduction in the amplitude of 
the CDP as fibres near to the tip of the electrode became blocked rather than 
excited. Several of the stimulus-recruitment plots do in fact show a reduction in 
amplitude at higher stimulus intensities, however, these reductions are very 
modest (see Figures 2-9 to 2-12). Anodal block does not therefore appear to be a 
problem. In theory it is possible that fibres near the electrode tip could be 
blocked while fibres at the most distant perimeter of the pyramid were still 
being recruited so masking the anodal block. However, this seems unlikely to 
have occured since this would be expected to create a rounded stimulus 
recruitment curve while for the most part they are quite steep and show a sharp 
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deflection when reaching a plateau. We therefore conclude that anodal block 
occurs only infrequently and where it might have occurred does not greatly 
affect the amplitude of the recorded CDP. We therefore considered it safe to 
stimulate at a supramaximal intensity which should avoid any problems of drift 
of threshold due to changes in stimulation conditions over time. 
We are therefore confident that the pyramidal stimulation protocol we have 
used is valid for quantitative analysis of corticospinal actions because: 1) it 
maximally activates the corticospinal tract on one side, 2) it can achieve this 
without activation of the contralateral corticospinal projection but where this 
does occur it can be recognised and excluded from the study 3) activation of 
reticulospinal projections does not complicate interpretation of the results.  
Does axotomy affect the excitability of corticospinal fibres in the 
pyramids? 
For a valid comparison of CDPs in injured and non injured animals, the 
effectiveness of the protocol for maximally activating the corticospinal 
projection should not be affected by the lesioning. Injury to a neurone or its 
axon is known to trigger many changes, including changes that affect the 
electrical properties of the neurone. For example, after section of a peripheral 
nerve, the surviving proximal length of the axon becomes gradually thinner and 
its myelin sheath also thins. This means that the fibres conduct more slowly but 
also that they become less excitable to electrical stimulation so that greater 
stimulus intensities are required to activate them (Cragg and Thomas, 1961). 
The effects of axotomy on central axons are less well documented but it is well 
established that axotomy can cause hypertrophy of surviving neurones including 
of pyramidal neurones within the sensorimotor cortex following a dorsal column 
lesion (Giehl and Tetzlaff, 1996; Carter et al. 2008).  
In the present study, electrical stimulation in the pyramids activates the whole 
population of fibres in the pyramid but different populations of fibres will be 
differently affected by the lesion. 1) Those corticospinal fibres projecting 
caudally to the lumbar and thoracic segments are likely to be completely 
disconnected from their target neurons. These might be expected to undergo the 
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greatest atrophy. 2) Most corticospinal fibres projecting to the cervical 
enlargement are likely to retain some connections with neurones above the level 
of the lesion, though they may be partly disconnected if they projected in part 
to neurones in segments below the lesion level. Since this group of pyramidal 
neurones retain some or all of their connections, they are likely to be less 
affected by the axotomy 3) the corticospinal fibres forming the minor 
components projecting in the contralateral lateral funiculus and ipsilateral 
ventral funiculus will not be axotomised at all and their excitability should not 
be changed. In our investigations we examined normal animals and animals with 
lesions of the main corticospinal projection at midcervical level. However, 
thresholds for evoking CDPs above the lesion level using stimulation in the 
pyramids were very similar in both groups of animals. This suggests that axotomy 
has little effect at least on the corticospinal fibres responsible for CDPs recorded 
above the dorsal column lesion.  
Validity of using CDPs as a measure of the strength of synaptic 
connections in spinal pathways 
Cord dorsum potentials provide a reflection of the current flow generated at 
active synapses between afferent pathways and spinal cord neurones. They can 
be considered analogous to population post-synaptic potentials although in part 
they also reflect the firing of spinal cord neurones. CDPs therefore provide a 
convenient means of measuring the strength of connections between a given set 
of afferent connections and spinal cord neurones. One of their advantages is that 
they are relatively quick to record and the electrode can be moved progressively 
along the cord so allowing assessment over a relatively long section of the cord 
in the same experiment. They can also be used to assess spinal cord function 
several times in the same experiment; before and after a dorsal column lesion 
for example. Cord dorsum potentials are biased towards revealing connections 
that occur more dorsally within the grey matter. This makes them particularly 
suitable for measuring the synaptic actions of cutaneous sensory fibres and 
corticospinal fibres both of which terminate predominantly in the dorsal horn 
(Willis and Coggeshall 2004; Casale et al. 1988). In the case of pyramidal evoked 
CDPs it also helps ensure the selectivity of the measurements since even if 
reticulospinal fibres are inadvertently activated by pyramidal stimuli, their 
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connections are too ventrally located to produce detectable CDPs. 
Measurements of maximal CDPs also appear to be repeatable and stable over 
time provided the animal is maintained in a healthy state. They are not affected 
by topping up anaesthetic. However, they are very sensitive to accumulation of 
CSF on the surface of the cord which short circuits the recording and reduces the 
amplitude of the recorded potential. Frequent checking and removal of this fluid 
is crucial to the accuracy of the recordings.  
The use of CDPs as a recording method does have limitations. The spatial 
resolution of CDPs is poor. CDPs generated on one side of the cord can be 
detected on the opposite side of the cord so that it is crucial that when stimuli 
are applied in the pyramids, for example, care is taken to ensure activation of 
corticospinal fibres is limited to one side. The poor spatial resolution also means 
that no information can be obtained about the distribution of synapses in the 
grey matter, so that changes in the strength or number of connections in a given 
area or the appearance of connections in new areas of the grey matter cannot 
be determined by this approach. Field potential recording is a potential 
alternative to the recording of CDPs but is a much more time consuming process 
and can therefore only be carried out at a limited number of sites. It provides 
greater spatial resolution and can provide information on the distribution of 
potentials in different areas of the grey matter of the spinal cord. Neither CDPs 
nor field potentials are suitable methods for determining the specificity of 
connections. Intracellular recording is required for this but is technically 
difficult, limited to the largest neurones and involves very small samples at best.  
Evidence for spontaneous plasticity of the corticospinal tract 
after dorsal column lesions 
In normal animals, CDPs evoked by stimulation in the pyramids could be 
recorded at all segmental levels of the cervical spinal cord as has been reported 
previously (Alstermark et al. 2004). Pyramidal-evoked CDPs showed more 
variability than sensory CDPs. This may be a technical issue. CDPs evoked by 
pyramidal stimulation are relatively small (at least half the amplitude of radial 
nerve CDPs) so that they are more susceptible to any factors (e.g. fluid 
accumulation) that affect the amplitude of the recordings. However, it is also 
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possible that much of the variation is biological as there is considerable evidence 
for activity-dependent plasticity in the spinal cord (Wolpaw and Tennissen, 
2001) 
Corticospinal tract plasticity above a dorsal column lesion 
When CDPs evoked by the corticospinal tract were investigated, acute lesions of 
the dorsal columns were found to have minimal effect on CDP amplitudes except 
at those sites closest to the lesion. Axotomy of corticospinal fibres at the C4/5 
level does not therefore lead to any immediate change in function at their more 
rostral connections within the spinal cord. However, when examined one week 
after a dorsal column lesion, CDPs evoked at sites above the lesion were 
significantly larger than those seen in normal animals indicating a potentiation 
of corticospinal actions in this region. There was little difference between 1 
week and 3 month survival animals showing that the plasticity is close to 
maximal within 7 days but also that it persists for at least 3 months following 
injury. 
This enhancement of corticospinal actions was not an acute effect triggered by 
axotomy or due to release from tonic inhibitory influences as a result of the 
dorsal column lesion because the CDPs were not changed following an acute 
lesion. The mechanisms could involve sprouting of fibres so that they form more 
connections within the grey matter after lesioning, or an increase in the efficacy 
of the same compliment of connections that existed before the lesion. The 
relatively rapid time course of the enhancement (less than 7 days following 
axotomy) might be considered to support synaptic plasticity since it is less likely 
that a process involving anatomical plasticity would be complete within this 
time. 
As discussed above, stimulation in the pyramids activates corticospinal fibres 
projecting from the forelimb area to the cervical segments, from the hindlimb 
area to the lumbar enlargement and a trunk area projecting to the thoracic 
segments. We cannot therefore determine from our results which of these 
populations are involved in the plasticity. However, corticospinal fibres with a 
hindlimb projection form few if any connections with neurones in the cervical 
segments so that if these contribute to the enhanced CDPs then anatomical 
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plasticity is certainly involved. This issue could be resolved either by further 
electrophysiological experiments in which microstimulation in the forelimb and 
hindlimb areas was compared or by tracing the corticospinal tract. 
Sprouting of the corticospinal tract above a dorsal column lesion has been 
reported previously (Fouad et al. 2001). In this case the dorsal columns were 
lesioned at a midthoracic (T8) level and microstimulation in the cortex centred 
on the forelimb and hindlimb area carried out while observing muscle twitches 
under very light anaesthesia. The threshold stimulus required to elicit responses 
in forelimb and hindlimb muscles before lesioning was compared before and 4 
weeks after lesioning. A shift in the motor map was reported such that 
stimulation in the hindlimb area, which did not evoke responses before 
lesioning, began to produce twitches in the forelimbs after lesioning. 
Anterograde labelling from the hindlimb area revealed more collaterals entering 
the cervical segments following lesioning suggesting that sprouting of the 
hindlimb corticospinal projection was the mechanism responsible for the 
responses in forelimb muscles on stimulation of the former hindlimb area.  
Corticospinal tract plasticity below a dorsal column lesion 
CDPs recorded below the level of the lesion, were very much reduced in 
amplitude in all lesioned animals. This is to be expected since the great majority 
of fibres (90%) forming the corticospinal tract travel in the dorsal columns and 
will have been severed by the lesion (Rouiller et al. 1991; Hicks and D’Amato 
1975; Miller 1987). After acute lesions of the dorsal columns, CDPs below the 
lesion were barely detectable. At seven days after lesioning there was little 
change, but 3 months following the lesion, the potentials at most positions 
below the lesion, though still very small compared to normal, were significantly 
larger than at the 1 week time point. Corticospinal fibres do not regenerate and 
grow around a dorsal column lesion in the absence of any intervention in rats (Lu 
et al. 2006), although there is a report that they may do so in mice (Steward et 
al. 2008). Similarly, remyelination of axons (Yang et al. 2006) is not an 
explanation because transaction models do not result in demyelinated fibres to 
any significant extent (Siegenthaler et al. 2007). 
  110 
There are two potential explanations for plasticity below the lesion. One 
involves plasticity in the spared minor components of the CST which course in 
the lateral and ventral funiculi and are unaffected by the dorsal column lesion. 
The other involves a strengthening of propriospinal connections originating 
above the lesion and terminating below. 
The longer time course for the expression of the plasticity below the lesion 
compared to that seen above the lesion tends to suggest an entirely different 
process from that operating above the lesion, although it is conceivable that 
sprouting of non-axotomised fibres proceeds on a much slower time scale than 
for axotomised fibres. Weidner et al. (2001) reported that sprouting of ventral 
corticospinal fibres into medial motoneurone columns could be seen 6 weeks 
following a cervical dorsal column lesion in rats. However, if sprouting is the 
explanation for the enhanced CDPs we have observed, then it is more likely they 
are due to the minor lateral component as the ventral component projects 
ipsilaterally and sprouting into motonuclei is unlikely to be detected with 
dorsally sited recording electrodes. It should be possible to confirm this 
mechanism using tract tracing techniques. 
There are known to be numerous priopriospinal interneurones at various levels 
within the cervical spinal cord. Some of these have descending axons within 
white matter other than the dorsal columns (Jankowska et al. 1974; Giovanelli 
Barilari and Kuypers, 1969). Strengthening of connections between corticospinal 
fibres and existing propriospinal interneurones above the lesion cannot be the 
whole explanation because plasticity above the lesion is seen at 1 week while 
that below the lesion is not evident at this time point. It has been suggested that 
following cervical level hemisection lesions the corticospinal fibres sprout onto 
propriospinal neurones above the lesion and that these in turn form new 
connections in the motonuclei below the lesion (Bareyre et al. 2004). It is 
unlikely that this is responsible for the enhanced CDPs below the lesion because 
again, this involves connections in the motonuclei. However, it is possible that a 
similar strengthening of propriospinal connections from neurones contacted by 
corticospinal fibres above the dorsal column lesion but terminating on more 
dorsally located targets below the lesion can occur.   
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Spontaneous plasticity in sensory circuits below the level of a 
dorsal column lesion 
Spontaneous plasticity in sensory systems is much less well investigated than 
that in the corticospinal tract. In this study, evidence of plasticity of the 
connections formed by large diameter sensory fibres in the radial nerve was seen 
following dorsal column lesions. CDPs evoked by radial nerve stimulation 1 week 
after a dorsal column lesion were significantly larger below the level of the 
lesion than those recorded from normal animals at the same location. This effect 
was similar if not greater at the 3 month survival period. This is the first time 
that spontaneous changes of transmission at the central terminal of primary 
afferent fibres have been demonstrated. As for the corticospinal tract, the 
underlying mechanism may involve either synaptic plasticity or sprouting. 
Injection of a tract tracer into the radial nerve and quantification of the central 
terminals of afferent fibres before and after a dorsal column lesion would be one 
way of investigating this question. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2-1 Summary of the number of animals of each group for which 
histological verification of the pyramidal electrode position was 
obtained  
For some animals stimulation in the pyramid was performed at more than one position 
so that the number of stimulating electrode tracks is also given. Note that the ‘OEC 
above’ and ‘Medium’ animal groups are fully described in chapter 3. 
Animal group Number of animals Number of stimulation sites 
Normal 7 8 
1 week 4 6 
3 month 9 11 
OEC above 14 15 
Medium 6 9 
Total 40 49 
 
 
 
 
 
 
 
 
 
Table 2-2 Threshold stimulus intensities for evoking CDPs on 
stimulation in the pyramids 
The table shows the mean thresholds (µA) for each group of animals arranged 
according to the position of the stimulating electrode relative to the target pyramid: 
middle = middle third, medial = medial third, lateral = lateral third. Midline = 
between the left and right pyramids. The mean threshold for each of these sites 
considering all animals is shown in the bottom row. The mean threshold for animals 
in each of the treatment groups, omitting animals where the electrode was off target 
(midline), is shown in the right hand column. Note that the ‘OEC above’ and 
‘Medium’ animal groups are fully described in chapter 3.  
 
 
 
 
Electrode location 
Middle (1) Medial (2) Lateral (3) Midline (4) 
Mean of 
(1+2+3) Animal group 
n mean n mean n mean n mean n mean 
Normal 4 6.8 2 27.5 1 6.0 1 50.0 7 12.6 
1 week 1 5.0 2 27.5 1 6.0 2 25.0 4 16.5 
3 month 2 10.0 6 14.2 3 9.3 0 0 11 12.1 
OEC above 10 9.6 4 20.0 0 0 1 40.0 14 12.6 
Medium 4 7.0 2 11.0 1 5.0 2 25.0 7 7.86 
Mean of each 
column 21 10.4 16 18.2 6 11.4 6 31.7  
 
 
 
 
 
 
Table 2-3 Amplitudes of maximal corticospinally-evoked CDPs following 
stimulation at different locations 
The table shows the numbers of animals of different groups for which the position of 
the stimulating electrode aimed at the pyramids was histologically verified. The 
animals are grouped according to stimulating electrode location relative to the target 
pyramid: middle third, medial third, lateral third, or midline. The mean maximal 
amplitude (mV) of CDPs evoked by stimulation in each animal group and each 
location is shown. Means for all animals stimulated at a given location are shown in 
the bottom row and means for maximal CDPs recorded from all animals of the group 
at all stimulation locations within the target pyramid (middle, medial, and lateral) are 
shown in the far right column. 
 
 
 
 
 
 
Middle (1) Medial (2) Lateral (3) Midline (4) Mean of (1+2+3) Animal group n mean n Mean n mean n mean n mean 
Normal 4 0.33 2 0.22 1 0.45 1 0.50 7 0.31 
1 week 1 0.42 2 0.38 1 0.68 2 0.63 4 0.47 
3 month 2 0.27 6  0.34 3 0.29   11 0.31 
OEC 
above 10 0.25 4 0.37 0 0 1 0.53 14 0.29 
Medium 
above 4 0.39 2 0.31 1 0.54 2 0.60 7 0.40 
Mean of 
each 
column 
21 0.30 16 0.34 6 0.42 6 0.58  
 
 
 
 
 
 
 
 
 
Table 2-4 Summary of mean maximal amplitudes of CDPs evoked by 
pyramidal stimulation and recorded at +5mm  
The data is presented for each animal group and is given separately for those animals 
for which histological verification of the electrode position was performed and for all 
animals in each group. Note that there is a close correspondence between the CDP 
amplitudes of the histologically verified animals and the group as a whole. Note that 
the ‘OEC above’ and ‘Medium’ animal groups are fully described in chapter 3. 
Mean of maximal CDP amplitudes (mV) Animal group Histology animals All animals 
Normal 0.31 0.32 
1 week 0.47 0.43 
3 month 0.31 0.32 
OEC above 0.29 0.31 
Medium 0.40 0.40 
All 0.36 0.35 
 
 
  
 
 
Table 2-5 Statistical analysis of the differences between pyramidal-evoked 
CDPs recorded in different animal groups at each recording location 
ANOVA with post-hoc Dunnett’s test was first applied and where a significant difference 
was found the P value threshold is given. Where no significance was detected with 
ANOVA, Student’s t-test was used and where a significant difference was detected the P-
value is given. Comparisons where no significance was detected with either test are 
indicated by NS.  
  
 
 
 
Normal 
Acute 
Normal 
1 week 
Normal 
3 month 
Acute 
1 week 
Acute 
3 month 
1 week 
3 month 
+8 NS P=0.0192 P=0.0017 NS P=0.0173 NS 
+7 NS P=0.0082 P=0.0066 NS NS NS 
+6 NS P=0.0006 P=0.0045 NS NS NS 
+5 NS P=0.0036 P=0.023 NS NS NS 
+4 NS P=0.0061 P=0.0307 NS NS NS 
+3 NS NS P<0.05 NS P<0.05 NS 
+2 NS NS NS NS P=0.0135 NS 
+1 P<0.01 P<0.01 P<0.01 NS P=0.0285 NS 
0 P<0.01 P<0.01 P<0.01 NS P=0.0376 NS 
-1 P<0.01 P<0.01 P<0.01 NS P=0.0126 NS 
-2 P<0.01 P<0.01 P<0.01 NS P=0.0027 P=0.0113 
-3 P<0.01 P<0.01 P<0.01 NS P<0.05 P=0.0097 
-4 P<0.01 P<0.01 P<0.01 NS P=0.0133 P<0.05 
-5 P<0.01 P<0.01 P<0.01 NS P=0.0371 P=0.0021 
-6 P<0.01 P<0.01 P<0.01 NS P=0.0362 P=0.0093 
-7 P<0.01 P<0.01 P<0.01 NS P=0.0313 P=0.0055 
-8 P<0.01 P<0.01 P<0.01 NS P=0.011 P<0.05 
 
 
 
 
 
 
Table 2-6 Contribution of spinal dorsal roots to CDPs 
To test the contribution of each spinal dorsal root to the amplitude of CDPs, dorsal 
roots were sequentially sectioned following different orders in two animals, and CDPs 
were recorded immediately. The amplitudes of CDPs following roots sectioning were 
expressed as percentages of the previous amplitudes of CDPs. The percentage was 
100% with CDP recorded when all the roots were intact. In the first animal (A), the 
amplitude of CDP was substantially reduced to only 35.2% after C6 dorsal root 
sectioned. After sectioning both C6 and C7 dorsal roots, only a small percent of CDP 
was left. Similar result has also been observed in the second animal (B). C7 dorsal 
root was firstly sectioned. The amplitude of CDP was reduced to 63.9%. After 
sectioning both C7 and C6, CDP was almost abolished. Therefore, C6 and C7 dorsal 
roots contribute to most of CDPs.  
 
 
 
A                                                                             B       
Roots sectioned Percentage of amplitudes (%) 
Intact 100 
C6 35.2 
C6+C7 10.7 
C6+C7+C5 8.4 
C6+C7+C5+C8 0.3 
Roots sectioned Percentage of amplitudes (%) 
Intact 100 
C7 63.9 
C7+C6 4.5 
C7+C6+C5 0.3 
 
 
 
 
 
Table 2-7 Statistical analysis of the differences between radial nerve-evoked 
CDPs recorded in different animal groups at each recording location 
ANOVA with post-hoc Dunnett’s test was first applied and where a significant difference 
was found the P value threshold is given. Where no significance was detected with 
ANOVA, Student’s t-test was used and where a significant difference was detected the P-
value is given. Comparisons where no significance was detected with either test are 
indicated by NS.  
 
 
 
 
 
Normal 
Acute 
Normal 
1 week 
Normal 
3 month 
Acute 
1 week 
Acute 
3 month 
1 week 
3 month 
+8 P<0.01 P<0.01 P<0.01 NS NS NS 
+7 P<0.01 P<0.01 P<0.01 NS NS NS 
+6 P<0.01 P<0.01 P<0.01 NS NS NS 
+5 P<0.01 P<0.01 P<0.01 NS NS NS 
+4 P<0.01 P<0.01 P<0.01 NS NS NS 
+3 P<0.01 P<0.01 P<0.01 NS NS NS 
+2 P<0.01 P<0.01 P<0.01 NS P=0.026 NS 
+1 P<0.01 P<0.01 P<0.01 P<0.01 P=0.0004 NS 
0 P<0.01 P<0.01 P<0.01 P<0.05 NS P=0.0163 
-1 P<0.01 P<0.01 P<0.01 NS P=0.0455 P<0.01 
-2 NS NS P<0.01 NS NS P=0.0167 
-3 NS NS NS NS P=0.0379 NS 
-4 NS P=0.0316 P=0.0019 P<0.01 P<0.01 NS 
-5 NS NS P<0.05 P<0.05 P<0.01 NS 
-6 NS NS P<0.01 NS P<0.01 P=0.039 
-7 NS NS P<0.01 P<0.05 P<0.01 NS 
-8 NS P=0.017 P<0.05 NS P<0.05 
 
NS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2-8 Quantification of lesion cavity size in the one week survival and 
three month survival groups 
The lengths of the cavities in both one week and three month survival groups were 
assessed and compared (see methods) using Students’ t-test which showed a significant 
difference in mean cavity length (P=0.0081). The cavities in the three month survival 
group were more variable compared to those in the one week survival group.   
 
 
 
 1 week group (n=14) 3 month group (n=15) 
Length of cavity (Range) 1330-2100 µm 1260-3920 µm 
Length of cavity (Mean) 1788 µm 2511 µm 
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Figure 2-1 Procedure for making dorsal column lesions using wire knife  
A, the relevant segment of the spinal cord is exposed by laminectomy and the guide 
cannula containing the wire knife lowered into the spinal cord at an appropriate position 
and to an appropriate depth. B, the wire knife is then extruded and a glass rod lowered to 
the surface of the cord. The wire knife is then raised against the glass rod in order to cut 
through the dorsal columns. C, The glass rod is raised, the wire knife retracted and the 
guide cannula removed. The lesion can be seen through the intact dura. Note that the 
blood vessels remain undamaged.
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Figure 2-2  Radial nerve dissection and stimulation 
A, the superficial branches of the radial nerve are exposed and identified.  B, the branches 
of the radial nerve are dissected free and sectioned distally, a suture loop is tied to the end 
of the branches in order to lift it without damage. C, the branches of the radial nerve are 
placed on bipolar silver wire electrodes immersed in the paraffin pool.
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Figure 2-3 Schematic diagram of preparation of electrophysiological experiments for 
assessing CDPs
Schematic diagrams show location of lesion and of stimulating and recording electrodes 
for assessing radial nerve-evoked (A) and corticospinally-evoked (B) CDPs. The dorsal 
columns were lesioned bilaterally at the C4/C5 junction interrupting the main component 
of the corticospinal tract which runs in the ventral aspect of the dorsal columns and the 
ascending dorsal column pathway more dorsally.
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Figure 2-4 Schematic diagram showing recording locations for CDPs and examples 
of CDPs
Cord dorsum potentials (CDPs) evoked by electrical stimulation of the radial nerve and/or 
corticospinal tract were recorded to assess spinal cord function in the region of the lesion. 
Recordings were made at 1mm intervals for 8 mm above and below the C4/5 reference 
level (the lesion site in the lesioned animal group) (A). Typical radial nerve-evoked and 
corticospinally-evoked CDPs were showen in B.
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Figure 2-5 Conditioning of radial CDPs with pyramidal stimulation 
Schematic diagram shows the experimental arrangement. The effects of conditioning 
stimuli in the pyramids on CDPs evoked by radial nerve afferents below the level of the 
lesion were investigated to assess the function of the corticospinal projection. The 
recordings were made at  3mm, 4mm, 5mm and 6mm below the C4/5 reference position at 
different conditioning test intervals (20ms, 25ms, and 30ms). Another recording electrode 
was placed at 5mm above the C4/5 reference position to monitor the efficacy of 
appropriate pyramidal stimulation.
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Figure 2-6 Examples of CDPs evoked by pyramidal stimulation 
Examples of surface recordings made at different locations on the cervical spinal cord in a 
normal animal. All recordings are averages of 50 sweeps. The numbered arrows point to 
different components of the surface recordings: (1) stimulus artefact, which indicates the 
timing of the stimulation; (2) afferent volley, which represents the action potentials 
travelling along CST fibres; (3) CDP, which represents the synaptic activity generated by 
connections between the collaterals of the CST fibres and spinal cord neurons and provides 
a measure of the strength of these connections; (4) the peak amplitude of these CDPs was 
measured at each recording location using Signal software. The afferent volley is clearest 
and largest at locations close to the stimulation site (top trace), becomes dispersed further 
from the stimulation site and eventually merges with CDP recordings at more caudal 
locations (bottom trace).  
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Figure 2-7 Determination of CST conduction velocity in two normal animals 
The latencies of volleys recorded from 8mm rostral to 8mm caudal were measured and 
plotted against recording locations. Lines were fitted using linear regression and the slopes 
of the plots represent the conduction velocity of the CST. In these two animals, the 
-1 -
conduction velocity is faster in the rostral cervical segments (C2-3); (20.3ms  and 21.2ms
1 -1 -1
 respectively) than more caudally (C4-7); (10.3ms  and 14.5ms ).  
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Figure 2-8 Electrical stimulation of the pyramids 
A, CDPs evoked by stimuli of graded intensity applied to the pyramids using the 
electrode which made the track shown in C and D; B, stimulus-response curve obtained 
using the records illustrated in A. C, histological verification of the correct positioning of 
a stimulating electrode in the right pyramid. Scale bar=0.7mm; D, schematic diagram of 
the outline of the section and stimulating electrode track was reconstructed by using 
Camera lucida drawings. Scale bar=0.7mm; 
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Figure 2-9 Stimulus-recruitment curves for animals of the ‘Middle’ electrode 
placement group
The diagrams to the left show reconstructions of the stimulating electrode tracks. The 
plots to the right show corresponding stimulus-recruitment curves, one for stimulation up 
to 1mA and another up to 5mA. The animal group is indicated above each histological 
reconstruction. Note that this figure includes two pages. 
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Figure 2-10 Stimulus-recruitment curves for animals of the ‘Lateral’ electrode 
placement group
The diagrams to the left show reconstructions of the stimulating electrode tracks. The 
plots to the right show corresponding stimulus-recruitment curves, one for stimulation up 
to 1mA and another up to 5mA. The animal group is indicated above each histological 
reconstruction. 
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Figure 2-11 Stimulus-recruitment curves for animals of the ‘Medial’ electrode 
placement group
The diagrams to the left show reconstructions of the stimulating electrode tracks. The 
plots to the right show corresponding stimulus-recruitment curves, one for stimulation up 
to 1mA and another up to 5mA. The animal group is indicated above each histological 
reconstruction. Note that this figure includes two pages. 
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Figure 2-12 Stimulus-recruitment curves for animals of the ‘Midline’ electrode 
placement group
The diagrams to the left show reconstructions of the stimulating electrode tracks. The 
plots to the right show corresponding stimulus-recruitment curves, one for stimulation up 
to 1mA and another up to 5mA. The animal group is indicated above each histological 
reconstruction. 
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Figure 2-13 Stimulus intensities required to evoke CDPs 95% of maximal at different 
stimulus locations
The bar chart shows the average stimulus intensities required to evoke CDPs 95% of 
maximal amplitude for each of the groups of animals that were organized according to the 
location of the stimulating electrode. The error bars show +/- SD. ANOVA and Dunnett 
post-hoc test were used to compare the different stimulus intensities. There was no 
statistically significant difference between the ‘Middle’, ‘Medial’, or ‘Lateral’ groups but 
the ‘Midline’ group required a significantly higher stimulus intensity than each of the 
other groups (P value is labelled on the top of the relevant column).   
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Figure 2-14 Pyramidal-evoked CDPs recorded from the left and right sides of the 
spinal cord
A, reconstructions of the stimulating electrode tracks for three animals where the 
electrode targetted the middle of a pyramid on one side. Scale bar=0.7mm; B, pyramidal-
evoked CDPs recorded at 4mm above the C4/5 segmental border from both sides of the 
spinal cord. Note that CDPs can be detected from both sides of the spinal cord while 
stimulating unilaterally. The relative amplitudes of CDPs recorded on the two sides vary 
and may be closely similar or larger on the side contralateral to the stimulating electrode. 
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Figure 2-15 Stimulus-recruitment curves for CDPs recorded from the left and right 
sides of the spinal cord while stimulating the pyramids on one side are similar
A, shows a reconstruction of the stimulating electrode positioned in the middle of the right 
pyramid. Scale bar=0.7mm; B, shows the stimulus-recruitment curve recorded from the 
left (contralateral) and right (ipsilateral) sides of the spinal cord while stimulating at the 
position shown in A. 
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Figure 2-16 Examples of CDPs evoked by pyramidal stimulation in normal animals 
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated to the left of each trace. Some traces (recorded at +7, +5, -5, -7mm) are omitted. 
The traces represent averages of 50 sweeps and the calibrations apply to all traces. The 
arrows indicate stimulus artifacts.
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Figure 2-17 Amplitudes of pyramidal-evoked CDPs recorded in normal animals
Each data point is the mean CDP amplitude for all animals (n=18) in this group. The error 
bars show +/- SEM. The recordings were made over the cervical spinal cord and are 
shown relative to the C4/5 border (0 mm) where dorsal column lesions were made in the 
lesioned groups. In normal animals, pyramidal-evoked CDPs were on average of similar 
amplitudes at all recording sites from 8mm rostral to 8mm caudal of the C4/5 segmental 
border. 
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Figure 2-18 Plots showing the repeatability of CDP recordings
Plots of CDPs recorded from 8mm above to 8mm below the C4/5 segmental border. Each 
individual plot represents a separate mapping of the CDPs. The order in which the 
mapping was performed is shown in the key. Note that the three plots were made 
sequentially from the same animal while the stimulating electrode remained at the same 
location. Recordings at each location were separated by 15 to 20 minutes since this is the 
time it takes to complete one mapping. Note that the amplitudes of the CDPs in each of 
the plots is very similar.
Figure 2-19 Examples of CDPs evoked by pyramidal stimulation in acutely lesioned 
animals 
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. Note that CDPs are virtually absent caudal to the lesion but remain above the 
lesion.
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Figure 2-20 Amplitudes of pyramidal-evoked CDPs recorded in acutely lesioned 
animals
The plot shows the amplitudes of CDPs recorded from the acutely lesioned animal group 
(n=7) as a whole. The amplitude of CDPs recorded from these same 7 animals before 
making the lesion is indicated by the dashed line. The previous plot for normal animals is 
also shown for comparison. Each data point is the mean CDP amplitude for all animals 
from each group. The error bars show +/- SEM. The recordings were made over the 
cervical spinal cord and are shown relative to the C4/5 border (0 mm) where dorsal 
column lesions were made in lesioned animals. In acutely lesioned animals, pyramidal-
evoked CDPs below the lesion (from -1 to -8mm) were virtually absent, while CDPs 
above the lesion (from +3 to +8mm) were not affected.
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Figure 2-21 Examples of CDPs evoked by pyramidal stimulation in one week 
survival DC lesioned animals 
Each column of traces shows recordings made from one animal. The recordings were 
made at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate 
stimulus artifacts. Note that tiny CDPs were observed at some caudal locations, especially 
close to the lesion site. 
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Figure 2-22 Amplitude of pyramidal-evoked CDPs recorded in one week survival DC 
lesioned animals
The plot shows the amplitudes of CDPs recorded from the one week survival lesioned 
animal (n=14) group as a whole. The previous plots for the normal group and for the 
acutely lesioned animal group are also shown for comparison. Each data point is the mean 
CDP amplitude for all animals from each group. The error bars show +/- SEM. The 
recordings were made over the cervical spinal cord. Recording positions are shown 
relative to the C4/5 border (0 mm) where dorsal column lesions were made in lesioned 
animals. In one week survival animals, CDPs below the lesion (from -8mm to -2mm) were 
almost abolished as in the acutely lesioned group. At some positions close to the lesion, 
CDPs were larger than those in acutely lesioned animals, but not significantly different. 
Above the lesion, the CDPs remained and in fact tended to be of larger amplitudes than 
those recorded from normal animals and acutely lesioned animals. This difference was 
significant only in comparison to the normal group.
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Figure 2-23 Examples of CDPs evoked by pyramidal stimulation in three months 
survival DC lesioned animals
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. Note that small but obvious CDPs were observed at the caudal locations of the 
lesion site.
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Figure 2-24 Amplitudes of pyramidal-evoked CDPs recorded in three month survival 
DC lesioned animals
The plot shows the amplitudes of CDPs recorded from three month survival lesioned 
animals (n=15). The previous plots for the normal group and for the one week survival 
group are also shown for comparison. Each data point is the mean CDP amplitude for all 
animals from each group. The error bars show +/- SEM. The recordings were made over 
the cervival spinal cord. Recording positions are shown relative to the C4/5 border (0 mm) 
where dorsal column lesions were made in lesioned animals. In the three months group, 
CDPs below the lesion were larger at all recording locations than those recorded in animals 
one week after a dorsal column lesion. This difference was significant at all recording sites 
(-2 to -8mm) except those closest to the lesion. Above the level of the lesion, CDPs were 
significantly larger than in normal animals and virtually the same as those recorded in 
animals one week after a dorsal column lesion.
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Figure 2-25 Examples of CDPs evoked by radial nerve stimulation 
Examples of surface recordings made at different locations on the cervical spinal cord in a 
normal animal (R4207). All recordings are averages of 25 sweeps. The numbered arrows 
point to different components of the surface recordings: (1) stimulus artefact, which 
indicates the timing of the stimulation; (2) afferent volley, which represents the action 
potentials travelling along the afferent fibres; (3) CDP, which represents the synaptic 
activity generated by connections between the collaterals of the primary afferent fibres and 
spinal cord neurons and provides a measure of the strength of these connections; (4) the 
peak amplitude for CDPs, which was measured at each recording location using Signal 
software. The afferent volley is clearest and largest at locations close to the segment of 
entry of the stimulated root (middle trace), becomes dispersed at more rostral and caudal 
locations.   
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Figure 2-26 Examples of CDPs evoked by radial nerve stimulation in normal animals 
Each column of traces shows recordings made from one animal. The recordings were 
made at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate 
stimulus artifacts. Note that the largest CDPs were recorded at -3/-4mm.
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Figure 2-27 Amplitudes of radial nerve-evoked CDPs recorded in normal animals 
The plot shows the amplitudes of CDPs recorded from the normal animal group as a 
whole (n=22). Each data point is the mean CDP amplitude for all animals in the group. 
The error bars show +/- SEM. The recordings were made over the cervical spinal cord. 
Recording positions are shown relative to the C4/5 border (0 mm) where dorsal column 
lesions were made in the lesioned groups. In normal animals, the biggest radial-evoked 
CDPs were recorded around 3 to 4mm below C4/5 border. The amplitudes of the biggest 
CDPs were around 0.7mV. CDPs decreased in amplitude more rostrally and caudally. 
Small CDPs were still detected at 8mm above the C4/5 border. 
Figure 2-28 Examples of CDPs evoked by radial nerve stimulation in acutely lesioned 
animals  
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. Note that CDPs were virtually absent rostral to the lesion.
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Figure 2-29 Amplitude of radial nerve-evoked CDPs recorded in acutely lesioned 
animals
The plot shows the amplitudes of CDPs recorded from acutely lesioned animals (n=7). The 
plot for normal animals is also shown for comparison as is the plot for CDPs recorded from 
the seven animals prior to lesioning. Each data point is the mean CDP amplitude for all 
animals from each group. The error bars show +/- SEM. The recordings were made over 
the cervical spinal cord. Recording positions are shown relative to the C4/5 border (0 mm) 
where dorsal column lesions were made in lesioned animals. After lesioning, CDPs above 
the lesion site (from 1 to 8mm) were virtually absent, while CDPs below the lesion (from -
2mm to -8) were also smaller compared to those recorded in normal animals but not 
significantly.
Before lesioning
Figure 2-30 Examples of CDPs evoked by radial nerve stimulation in one week 
survival DC lesioned animals 
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. Note that small CDPs were observed at locations rostral to the lesion site.
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Figure 2-31 Amplitude of radial nerve-evoked CDPs recorded in one week survival DC 
lesioned animals
The plot shows the amplitudes of CDPs recorded from the one week survival lesioned 
animal group (n=17). The previous plots for normal animals and acutlely lesioned animals 
are also shown for comparison. Each data point is the mean CDP amplitude for all animals 
from each group. The error bars show +/- SEM. The recordings were made over the cervical 
spinal cord. Recording positions are shown relative to the C4/5 border (0 mm) where dorsal 
column lesions were made in lesioned animals. In the one week group, radial-evoked CDPs 
were bigger at all recording locations than those recorded in the acutely lesioned group. 
CDPs at some caudal locations (-4mm and -8mm) were even significantly larger than those 
recorded in normal animals.
Normal animal group
Figure 2-32 Examples of CDPs evoked by radial nerve stimulation in three month 
survival animals 
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. Note that small CDPs were obeserved at locations rostral of the lesion site.
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Figure 2-33 Amplitudes of radial nerve-evoked CDPs recorded in three month 
survival DC lesioned animals
The plot shows the amplitudes of CDPs recorded from the 3 month survival group (n=18). 
The previous plots for normal animals and one week survival lesioned animals are also 
shown for comparison. Each data point is the mean CDP amplitude for all animals from 
each group. The error bars show +/- SEM. The recordings were made over the cervical 
spinal cord. Recording positions are shown relative to the C4/5 border (0 mm) where 
dorsal column lesions were made in lesioned groups. CDPs above the lesion were very 
similar in amplitude to those in 1 week lesioned animals. Below the lesion, CDPs differed 
in a more complex way from those recorded at 1 week. Close to the lesion (0 to -2mm) the 
CDPs in 3 month animals tended to be smaller than in 1 week animals and this difference 
was significant. Farther away from the lesion, however, CDPs were the same or larger than 
those recorded at 1 week after lesioning though the difference was only significant at -
6mm. 
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Figure 2-34 Inhibitory control of sensory transmission by the corticospinal tract from 
a normal animal  
A, CDP recordings evoked by radial nerve afferents with conditioning stimuli in the 
pyramid were recorded at 3mm below the C4/5 reference location in a normal animal 
(9308). The top trace (test) shows a cord dorsum potential evoked by radial nerve 
stimulation. The second trace (cond + test) shows the effect of preceding the stimulus to 
the peripheral nerve with a train of 4 shocks within the pyramid. Note the strong inhibition 
(reduction in amplitude) of the cord dorsum potential. The next trace (cond) shows the 
effect of stimulation in the pyramids alone and the bottom trace (diff) shows cond + test 
minus cond. B, the radial nerve-evoked potential from the top trace (test) and the bottom 
trace (diff) are shown superimposed in order to illustrate the degree of inhibition 
(reduction in amplitude) produced by the corticospinal tract. The interval between the first 
conditioning stimulus and the test stimulus (C-T interval) is 20ms. C and D show an 
example recorded at 4mm below the C4/5 border with a conditioning-test interval of 30ms. 
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Figure 2-35 Inhibitory control of sensory transmission by the corticospinal tract in 
different groups
Inhition was tested in normal animals (n=7) and lesioned animals (acute n=4; 1 week n=8; 
3 months n=9). The data are presented as groups. The recording locations are shown on the 
top of each column. Conditioning intervals are shown at the bottom. The percentages of 
inhibition were leballed in the columns as white numbers. As expected, the inhibition in 
normal animals were stronggest compared to lesioned animals. There is a tendency that 
more inhition was presented in three month survival animals compared to those in one 
week lesioned animals. However, it was not significantly different. Note that the data were 
collected from small number of animals.  
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Figure 2-36 Inhibitory control of sensory transmission by the corticospinal tract from 
a lesioned animal 
A, surface recordings from the cervical spinal cord close to where radial CDPs are largest 
(-4mm) in a lesioned animal (R8008). The top trace shows a cord dorsum potential evoked 
by radial nerve stimulation (test). The second trace shows the effect of preceding the 
stimulus to the peripheral nerve with a train of 4 shocks within the pyramid (cond + test). 
Note the small inhibition (reduction in amplitude) of the cord dorsum potential. The third 
trace shows the effect of stimulation in the pyramids alone (cond). The bottom trace shows 
cond + test minus cond (diff). B, the radial nerve-evoked potential from the top trace (test) 
and the bottom trace (diff) are shown superimposed in order to illustrate the degree of 
inhibition (reduction in amplitude) produced by the corticospinal tract. The interval 
between the first conditioning stimulus and the test stimulus (C-T interval) is 20ms. C and 
D show an example with C-T interval of 30ms.
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Figure 2-37 Lesion morphology
Light microscope images taken with a dark field condenser from transvers sections of the 
C4/5 spinal cord of different animal groups. A section from a normal animal is shown top 
left. The lesion interrupted the whole dorsal columns in acutely lesioned  animals (bottom 
left). Lesion cavities were observed in 1 week and 3 month survival lesioned animals 
(middle and right columns respectively). Varying amounts of the dorsal horn grey matter 
were also affected by the lesion. Scale bar 1mm applies to all images.
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Effects of OEC transplants on 
sensorimotor pathways following injury 
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3.1 Introduction 
OECs, which are glia from the olfactory system, have become a promising 
candidate for transplant-mediated repair after SCI on the basis that they operate 
in both PNS and CNS environments to support the ongoing axonal growth, 
ensheathment, and targeting of olfactory neurons throughout life. Although 
unique in function, they share many properties with Schwann cells, including 
antigenic and morphologic profiles, growth factor response, and transcription 
factor expression during myelination. However, OECs evoke a less-severe 
astrocytosis after transplantation (Santos-Sliva et al. 2007).  
Evidence for improved functional recovery after OEC transplants is mixed and is 
derived from the use of various behavioural tests of sensorimotor function. For 
example, OEC transplants have been reported to improve performance in a 
reaching task following lesions of the corticospinal tract (Li et al. 1997) and to 
improve ladder climbing and other motor tasks following complete transection 
(Ramon-Cueto et al. 2000; Lu et al. 2001; Lopez-Vales et al. 2006). On the other 
hand, Steward et al. (2006) failed to see improved recovery following complete 
transection and following contusion injuries recovery has variously been reported 
to be absent (Takami et al. 2002) or modest (Plant et al. 2003). It therefore 
seems that OEC transplants may bring about some functional benefits following 
spinal cord injury in rodent models under appropriate conditions and/or with 
appropriate tests. 
The mechanisms responsible for the functional improvements reported are 
equally contentious. There are numerous reports that OEC transplants support 
axonal regeneration. However, while it is evident that axonal regeneration is 
supported within the transplanted lesion itself, reports on the extent of axonal 
regeneration beyond the lesion are mixed. Some report long-distance 
regeneration across the injury (Li et al. 1998; Ramon-Cueto et al. 2000; Lu et al. 
2001) while others report that regeneration is restricted to the transplant site 
(Andrews and Stelzner, 2004; Ruitenberg et al. 2003, 2005; Ramer et al. 2004a, 
b; Lu et al. 2006). In our own lab, regeneration of the ascending dorsal column 
pathway has been studied after OEC transplantation and although a small 
numbers of fibres have been seen growing for very short distances beyond the 
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lesion we have concluded that OEC transplants alone promote very limited long 
distance axonal regeneration (Toft et al. 2007).   
Apart from promoting axonal regeneration, transplants of OECs could contribute 
to improved function following injury by several other mechanisms. These 
include reducing cavitation (Takami et al. 2002; Ramer et al. 2004a, b), 
improving vascularisation (Lopez-Vales et al. 2004; Ramer et al. 2004a, b), 
remyelinating axons with a damaged myelin sheath (Franklin et al. 1996; Sasaki 
et al. 2004), neuroprotection of long projection neurones (Sasaki et al. 2006) or 
the promotion of sprouting (Chuah et al. 2004) or other forms of plasticity.  
In a recent study from our lab an electrophysiological approach was used to 
investigate the effect of OECs transplanted into dorsal column lesions on the 
function of sensory pathways in spinal cord segments adjacent to the lesion (Toft 
et al. 2007). The actions of sensory afferents on spinal cord neurones in the 
vicinity of the lesion were found to be better in OEC transplanted animals than 
in lesioned controls without the cells. Furthermore, this improved function at 
the spinal level appeared to translate into improved transmission of sensory 
information to the sensorimotor cortex. Two potential mechanisms were 
suggested to explain the improved function in transplanted animals, these were 
neuroprotection and plasticity. It was recognised that both of these mechanisms 
might operate together but it was not possible to distinguish between their 
respective contributions. The aim of the work described in this chapter was to 
determine whether OEC transplants induce plasticity following a spinal cord 
lesion. This requires a situation where any potential plasticity inducing actions 
are not complicated by the neuroprotective actions of OECs. When OEC 
transplants fill a lesion cavity they have been shown to prevent expansion of the 
lesion with time and to have neuroprotective actions. To test whether sprouting 
is also induced by OEC transplants therefore requires that the cells are 
distributed within the spinal cord above and/or below the lesion but not within 
the lesion itself. Fortuitously, we had previously found when transplanting OECs 
into a cervical level dorsal column lesion, that very few cells remained within 
the lesion cavity, but numerous cells became distributed within the spinal cord 
below the level of the lesion. We therefore made use of this situation, together 
with injection of OECs directly into the spinal cord above the lesion, to test 
whether plasticity was induced in regions containing OECs. The method of 
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assessment was the same as that described in the previous chapter. Lesions of 
the dorsal columns were made at the C4-C5 level and electrophysiological 
assessment of the actions of the corticospinal pathway and sensory afferents 
from the radial nerve were performed to determine whether transmission in 
these pathways was enhanced by the presence of OECs. 
3.2 Methods 
3.2.1 Animals 
The observations reported in this chapter are based on investigation of 51 male 
Fischer 344 rats (Harlan, Loughborough, UK, 200-250g). Fischer 344 rat was 
chosen because this inbred strain can avoid the problem of immunological 
rejection after cell transplantation. Forty two rats were subjected to dorsal 
column lesions and were allowed to recover for 3 months. Of these, olfactory 
ensheathing cells (OECs) were transplanted into the lesion site in 16 animals 
(OEC below group) and into the cord above the lesion in 14 animals (OEC above 
group). A further group of 12 animals was injected with similar volumes of 
medium as a control (medium above group). The remaining 9 animals were used 
to check cell distribution at different time points after transplantation. Of the 9 
animals, OECs were transplanted into the lesion site in 3 animals and into the 
cord above the lesion in 6 animals after lesioning. 
Results obtained using field potential recording include fields recorded from 
some normal animals described in the previous chapter. 
3.2.2 Cell culture 
3.2.2.1 Preparation of olfactory ensheathing cells 
All cell culture was carried out by Mr. Thomas Sardella in Professor Sue Barnett’s 
laboratory in the Beatson Institute, University of Glasgow. 
OECs for transplantation were prepared from the olfactory bulb. The olfactory 
bulb consists of a mixture of cell types including oligodendrocytes, astrocytes, 
OECs, and neurons. To purify OECs from this mixture, fluorescence activated cell 
sorting (FACS) and appropriate antibodies were used. The FACS machine applies 
an electromagnetic field to deviate the cell trajectory and redirect the selected 
cells to a specific collecting tube, while excluding all other cells, dead cells, 
debris and auto-fluorescent material. 
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Franceschini and Barnett have shown that OECs express the O4 antibody in vivo 
(Franceschini and Barnett 1996). However, the O4 antibody is also expressed by 
oligodendrocytes (Sommer et al. 1981). Galactocerebroside is the major 
galactosphingolipid in myelin; and it has been shown that anti-
galactocerebroside antibody is expressed by oligodendrocytes but not by OECs 
(Ranscht et al. 1982). Therefore it is possible to discriminate and purify OECs 
from the other cell types present in the olfactory bulbs by using FACS coupled 
with the O4 antibody and monoclonal antibodies to GalC (Barnett et al. 1993). 
The protocol followed to purify the OECs was a modification of that designed by 
Barnett and colleagues (1993) and is described below. 
Dissection 
OECs were purified from the olfactory bulbs of post natal day 7 Fisher 344 rats. 
Rats were sacrificed with an overdose of Euthatal (sodium pentobarbital, 200 
mg/ml, Vericore Ltd, UK) in accordance with UK Animals Scientific Procedures 
Act of 1986 under the restrictions and regulations of the schedule 1 killing 
method. Rats were placed on ice to maintain cell viability. The dissection was 
carried out on a polystyrene box top covered with tin foil. Using forceps and 
scissors the olfactory bulbs were exposed, excised and placed in a 7ml bijou 
tube containing 1-2ml of L15 and 25µg/ml gentamicin. Samples were then 
transported from the animal house to the tissue culture facility in the Beatson. 
From this step onwards all procedures were carried out in a vertical laminar flow 
bench with the use of sterile material. 
Dissociation 
The sample containing the olfactory bulbs was maintained on ice as much as 
possible throughout the purification procedure in order to promote cell viability. 
Within 2 hours from dissection the olfactory bulbs were transferred to a 90mm 
Petri dish and all media removed with a Pasteur pipette. The tissue was 
dissociated by chopping it into small pieces using a scalpel, followed by 
enzymatic dissociation by placing the sample in a 7ml bijou tube containing 
0.5ml of a 1.33% collagenase solution for 30 min at 37oC. Subsequently 0.5ml of 
a mix (SD) of soya been trypsin inhibitor (0.52mg/ml) and DNAse1 (0.04mg/ml) 
were added mainly to prevent cell clumping from the DNA released from dead 
cells. 
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The sample was finally fully dissociated into a cell suspension using a syringe 
attached to needles of decreasing diameter: starting with a needle sized 18 
gauge, switching to a needle sized 23 gauge and ending with a needle sized 26 
gauge. It was vital during this second step of mechanical dissociation to be 
gentle and not to pull or push the syringe plunger too hard as this would have 
produced strong negative or positive pressures that would have had a 
detrimental effect on cell viability. 
Subsequently the sample was transferred into a 15ml falcon centrifuge tube and 
washed in 4ml of Dulbecco’s modified eagle medium (DMEM, Gibco, 21885) 
containing sorting media and centrifuged at 306m/sec2, discarding the 
supernatant and leaving the pellet in a small volume of liquid. This allowed the 
pellet to be easily resuspended in the remaining solution by flicking the tip of 
the tube. 
Cell purification step 
The sample contained in the tube was gently resuspended in filtered primary 
antibodies and left 30 minutes on ice: the solution of primary antibodies was a 
mixture comprised of the O4 antibody (mouse monoclonal IgM, 1:4) and anti-
galactocerebroside (mouse monoclonal IgG3, 1:2) antibodies, diluted in sorting 
media to a final volume of 2ml. 
The excess of primary antibodies was removed by two washes and the sample 
was resuspended and incubated with a mix of secondary antibodies for 15 
minutes on ice: goat anti-mouse IgM Phycoerythrin (1:100, Southern Biotech) and 
goat anti mouse IgG3 Fluorescein (1:100, Southern Biotech) or the inverse, 
diluted in sorting media to a final volume of 2ml. The excess of secondary 
antibodies was removed with 2 washes. The resulting cell sample was finally 
resuspended in 1ml of sorting media, filtered through a 40µm sieve and 
transferred to a FACS machine purification tube. The filtration process was 
necessary in order to remove cell clumps which would block the nozzle of the 
FACS machine. 
A negative control to set up and standardise the FACS machine was a small 
aliquot of cells taken from the sample before incubation with the secondary 
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antibodies. Once the FACS machine settings were optimized the cells were 
separated as O4 positive and Galc negative cell population and collected in a 
new tube. The cells were centrifuged, the supernatant discarded and the sample 
centrifuged again for 1 second at 306m/sec2 to get rid of the thin film of sorting 
media present on the tube inner side surface (as this can occasionally cause 
bacterial or fungal contamination). A Gilson pipette was inserted in the tube and 
the sample was transferred to a 12.5 cm2 poly –L-lysine (PLL, 13μg/ml) coated 
flask. The flask was placed into a 37oC incubator in a humidified atmosphere of 
7% CO2 and 93% air. After 10 minutes, the time required for viable cells to 
adhere to the flask surface, the flask was topped up with cell culture media. 
The FACS machine was fully operated by Thomas Gilbey and occasionally by 
Margaret O'Prey, two specialized technicians in the Beatson Institute. 
All centrifuging steps in the 15ml falcon tubes involving OECs were carried out at 
g-force of 306m/sec2 for a time that was determined by multiplying the sample 
volume (ml) by 30sec/ml. 
GFP lentiviral transduction 
One or two days after OEC purification, if cell numbers and viability looked good 
the cells would be transduced with a lentiviral vector expressing a gene that 
encodes the enhanced green fluorescent protein (EGFP, virus kindly donated by 
Dr George Smith, University of Kentucky, USA); which will be referred to as GFP 
for simplicity). The procedure was carried out in a category 2 hood and involved 
adding concentrated GFP lentivirus to the cultured cells and leaving for 1-2 days. 
This time allowed the GFP gene to become integrated into the nuclear DNA of a 
high proportion of cells. Media was then changed and the transduction efficacy 
was confirmed by placing the flask under an inverted UV microscope (Olympus, 
CKX41) with the appropriate filter set and counting the number of GFP 
expressing cells. 
OEC propagation 
After the GFP lentiviral transduction procedure, cells were passaged every 2-3 
days once they reached confluency. To passage OECs the culture media was 
removed from the tissue culture flasks and washed with PBS. This step was 
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repeated once more and a PBS solution containing 0.025% trypsin was added, the 
flask placed in the incubator at 37oC and monitored under the phase microscope 
to confirm cell detachment. To stop the trypsin reaction a solution containing 
foetal bovine serum (DMEM-10% FBS) was added and the cells transferred to a 
centrifuge tube and placed on ice. At this point cells were often counted with a 
haemocytometer (Weber Scientific). Then the sample was centrifuged and the 
supernatant discarded; and the cells resuspended in cell culture media and 
diluted (1:2 or 1:3) into a new flask. The amount of media used to plate cells in 
the 12.5 cm2 flasks, 25 cm2 flasks and 75 cm2 flasks was approximately 
0.12ml/cm2 of flasks surface area (3ml, 5ml, and 12ml respectively). 
The daily growth rate of OECs calculated on 19 populations of OECs, each 
deriving from different animals and different purification dates, equalled 0.85 
(StErr=0.06). This means that the number of OECs doubled on average every 57 
hours. 
The number of OECs per cultured surface area were calculated when the cells 
were fully confluent on cell populations from 19 independent olfactory bulb 
purifications: OEC density was of 21080 cells/cm2 (StErr=1347 cells/cm2).  
Long-term freezing of OECs in the liquid nitrogen 
During cell culture unpredictable and uncontrollable events could affect the 
growth of OECs: e.g. 7 day old rats were not necessarily available at the 
appropriate time, the cells plated after an olfactory bulb sort were not always 
viable, fungal or bacterial infections were unexpected and unwanted guests. 
These unpredictable events were incompatible with planning in advance for the 
surgical procedures in the knowledge that a source of cells could be available at 
any time. It proved to be more convenient and certainly more controllable to 
make the timing of cell purification independent from the timing of cell 
transplantation; this was possible by freezing a stock of purified GFP positive 
cells. After purification and GFP infection of OECs, once cells had reached a 
sufficient number, cells were frozen in liquid nitrogen to be retrieved and 
cultured when needed. It has been reported that no obvious differences in 
morphology or antigenic phenotype were found in cultured mouse OECs before 
and after storage in liquid nitrogen (Ramer et al. 2004a). Furthermore, 
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transplanted cryopreserved OECs from canine olfactory bulb were shown to 
retain their ability to myelinate demyelination axons in vivo (Smith et al. 2002).  
Cell freezing 
Cells were detached from the culture flasks with trypsin, DMEM-10% FBS was 
then added to inactivate trypsin and a cell count was made with a 
haemocytometer. Following centrifugation, the supernatant was discarded and 
cells were resuspended in freezing media that contained Dimethyl sulfoxide 
(DMSO) and aliquoted in cryotubes (this was completed as quickly as possible 
because DMSO is toxic to cells). Cryotubes were covered with cotton wool and 
placed in the -80oC freezer for a few hours or up to a few days prior to storage in 
the liquid nitrogen freezer for an indefinite amount of time. 
Cell thawing 
Cells were normally thawed about a week before they were required for 
transplantation. A cryotube was collected from the liquid nitrogen and placed  in 
a 37oC water bath to thaw the cells quickly prior to centrifugation in a falcon 
centrifuge tube containing DMEM-10% FBS to dilute residue DMSO. Following 
centrifugation the supernatant was discarded and the cells were resuspended in 
culture medium and plated at the required confluency. 
3.2.2.2 Cell preparation for transplantation 
The phase contrast microscope was used to assess the general appearance and 
confluency of the cells and to check lack of bacterial or fungal infection. The 
FBS present in the media was removed from the flasks and a PBS solution 
containing trypsin added. The flasks were placed in the 37oC incubator and 
monitored until cell detachment took place. The trypsin reaction was stopped by 
incubation in DMEM-10% FBS also containing approximately 2µg/ml DNAse: DNAse 
prevented the cells from forming clumps that would block the injection cannula 
during the transplantation process. The content of the flasks was transferred 
into a 15ml falcon centrifuge tube and placed on ice. After counting the cells 
with a haemocytometer the tubes were centrifuged and the supernatant 
discarded. A second but brief centrifugation was necessary to get rid of any 
medium present on the inner surface of the falcon tube and to avoid 
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contamination when inserting the Gilson to transfer the concentrated cells to a 
0.2ml PCR sterile tube. The tube was placed inside a larger tube in ice, 
transported from the Beatson institute to the University main campus animal 
house. Before starting the transplantation, the tube containing the cells was 
centrifuged on a bench centrifuge to remove excess medium. The average 
density of the OECs at the time of transplantation was of 229322 cells/µl 
(StErr=10544 cells/µl). OECs were cultured for an average time of 29 days and 
passaged on average 8 times before being transplanted.  
3.2.2.3 Cell purity and GFP labelling 
Cultured OECs possess a characteristic morphology when viewed under the phase 
contrast microscope giving an indication of cell type. However to check for 
purity we used the marker P75NTR that characterises OECs. OECs were seeded on 
PLL-coated cover slips for 2-3 days and then immunolabelled with antibody to 
P75 neurotrophin receptor (P75NTR, hybridoma supernatant, 1:2, IgG1). 
Coverslips were incubated with the primary antibody diluted in DMEM for 15min 
at room temperature, rinsed in PBS and then incubated in the goat secondary 
class specific antibody diluted 1:100 (Southern Biotechnologies) for 15min at 
room temperature. Coverslips were rinsed in PBS and mounted in anti-fade 
containing DAPI (Vectashield, Vector Laboratories, Peterborough, UK) to identify 
nuclei. On a few occasions OECs were incubated with Thy1.1 to quantify 
fibroblast contamination. P75NTR expression was always detected on more than 
98% of the cells in OECs cultures (Figure 3-1).  
The presence of GFP expressing cells was determined on all cell populations 
before transplant by placing the tissue culture flask under a UV inverted 
microscope (Olympus, CKX41) and switching between the UV and the plain light 
source to confirm the expression of GFP in a reasonable proportion of cells. A 
more precise quantification was achieved on all cell populations that were 
transplanted by labelling the cells with a rabbit anti-GFP antibody (1:1000 
AbCam). Cells were plated on PLL coated coverslips and fixed 2-3 days later with 
a solution of 4% paraformaldeyde; membranes were then permeabilised in a PBS 
0.5% triton (Sigma) solution and non-specific antibody binding sites blocked with 
a PBS 0.2% porcine skin gelatine (Sigma) solution for 30 minutes. The GFP 
antibody was incubated with the cells for 30 minutes followed by donkey anti 
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rabbit or anti goat Alexa 488 secondary antibody incubation for 10 minutes 
(Molecular Probes). Primary and secondary antibodies were incubated in a PBS 
solution 0.1% Triton X-100 and 0.2% gelatine. Coverslips were mounted with DAPI 
containing Vectashield (Vector laboratories, Peterborough, UK) to visualize the 
nuclei. GFP expression varied between individual OEC cultures and was generally 
between 20% and 80%. 
Images for both cell surface and intracellular staining were taken by 
fluorescence microscopy (Zeiss Axioplan2) coupled with ISIS software 
(MetaSystems). Colour levels were adjusted with Photoshop (Adobe) and cell 
counting was performed with the Cell Counter plug-in on ImageJ (NIH, USA). 
3.2.2.4 Cell culture materials 
All cell culture formulations were filtered to reduce microbial contamination. 
Regular mycoplasma screening was performed to reduce the possibility 
mycoplasma infections.  
OECs  Media 
OECs media is made up by adding to DMEM (see below): 5% FBS, 48% DMEM-BS 
media, 25 ng/ml fibroblast growth factor (PeproTech, 100-18b), 25ng/ml 
Heregulin (R&D systems, 396-HB) and 2.1μg/ml Forskolin (Sigma, F-6886). 
Bottenstein-Sato’s Media (DMEM-BS) 
This media was composed of DMEM, 5ng/ml insulin (bovine pancreas, Sigma), 
50ng/ml transferrin (Sigma), 0.022% SATO mix (see below) and 100mM glutamine 
(GIBCO, 25030) and was stored at 4oC. 
DMEM-10% FBS 
Made up of 90% DMEM and 10% foetal bovine serum (FBS). 
Sorting Media 
Made up of 99% DMEM and 1% FBS. 
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DMEM 
Once Dulbecco's Modified Eagle Medium (Gibco, 21885) was opened 25μg/ml 
gentamicin (Gibco, 15750) was added to reduce risk of bacterial infections and 
stored at 4oC. 
Leibovitz's L-15 Medium (L15) 
Once Leibovitz's L-15 Medium (Gibco, 11415) was opened, 25ug/ml gentamicyn 
(Gibco, 15750) was added and stored at 4oC. 
Collagenase  
Collagenase was made up of L15 and 13.3mg/ml collagenase (MP Biomedicals, 
195109) and stored at -20oC. 
Soya been trypsin inhibitor and DNAse (SD) 
Made up of L15, 3.0mg/ml bovine serum albumin (BSA) (Sigma A2153), 
0.52mg/ml Soya been trypsin inhibitor (Sigma T-9003), 0.04mg/ml bovine 
pancreas DNAse (Sigma D-4263); storage at -20oC. 
Polylisine (PLL) coated flasks and coverslips  
PLL (Sigma, MW>80,000) was dissolved  to a final concentration of 13.3μg/ml. 4 
ml, 1 ml and 1 ml of this PLL solution were added to a 75 cm2, a 25 cm2 and a 
12.5 cm2 flask respectively, while 0.5ml was added to each well containing a 
13mm diameter coverslip in a 24 multi-well plate. These were agitated to get 
PLL all over the surface. After incubation at 37oC for 30 min PLL was removed 
and washed away (as free PLL is toxic for cells) with sterile water. It is not 
necessary to completely dry the flasks or coverslips before plating the cells. 
Freezing media 
Made up of 50% FBS, 40% DMEM and 10% DMSO (Fisher Chemicals, D/4121/PB08) 
and stored at 4o C. 
O4, GalC and p75NTR hybridoma cell lines 
O4 and GalC monoclonal antibodies were produced from the O4 and the 
Galactocerebroside cell lines which were kindly donated by Professor Mark 
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Noble, University of Rochester. Hybridomas for the O4 antibody and 
Galactocerebroside and P75NTR antibodies were maintained in liquid nitrogen in 
1ml cryotubes.  Cryotubes were rapidly thawed in a 37oC water bath and 
transferred to a 15ml falcon centrifuge tube. 10ml of Optimem-50% FBS was 
added and the sample was centrifuged. The supernatant was discarded and the 
cells were resuspended in 5ml of Optimem-50% FBS and counted with a 
haemocytometer. Cells were plated in non-poly-lysine coated flasks at 30% of 
full confluency (full confluency is approximately 2x105 cells/cm2) in a final 
volume of approximately 0.25ml/cm2 of Optimem-50% FBS. Two or three days 
later cells would be confluent and others formed floating clumps. The flasks 
were tapped strongly and any cell clumps dissociated using a pipette and then 
passaged. The cells in each flask were then transferred to new flasks and the 
volume of media adjusted to approximately 0.25ml/cm2 of Optimem-10% FBS in 
order to gradually reduce the FBS concentration from 50% to 10%. 
Antibody production 
Following 2-3 more days in culture, cells were dissociated and transferred to a 
centrifuge tube. Following the centrifugation step the supernatant was 
discarded and cells were resuspended in Optimem-10% FBS and plated in new 
flasks. Three days later cells were dissociated and centrifuged. The supernatant 
was filtered, aliquoted and placed in the -20oC freezer for long storage. The 
titre of the hybridoma supernatant was tested on unpurified cultured olfactory 
bulb cells or on other CNS derived cultured cells. 
An aliquot of the hybridoma was re-frozen for future use into cryotubes. Each 
cryotube, containing approximately 2.5x106 hybridoma cells, was wrapped in 
cotton wool and placed in the -80oC freezer for a few hours or up to a few days 
and finally placed in liquid nitrogen for storage. 
Optimem-50% FBS 
Made up of 50% Optimem (Gibco 11415) with 25μg/ml gentamicin and 50% foetal 
bovine serum; stored at 4o C. 
Optimem-10% FBS 
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Made up of 90% Optimem (Gibco 11415) with 25μg/ml gentamicin and 10% foetal 
bovine serum; stored at 4o C.  
SATO mix 
Made up of: 200 ml PBS + 5.72 ml BSA path-o-cyte 5 (Bovine albumin path-o-
cyte, MP biomedicals 810111) mixed with 200 ml dH20 + 322 mg Putrescine 
(Sigma P7505), and with 20 ml ethanol + 8.0 mg thyroxine T4 (Sigma T-2501), 
and with 20 ml ethanol + 6.74 mg Tri-Iodo-Thyronine T3 (Sigma T-2752). Once 
the above solutions were combined, 2 ml of each of the following were added: 
20 ml ethanol + 12.46 mg Progesterone (Sigma P-0130) and then 20 ml dH20 + 
7.74 mg Selenium (Sigma S-1382). The resulting solution was filtered and stored 
at -20º C. 
Hybridoma freezing medium 
Made up of 90% FBS and 10% DMSO; stored at 4o C. 
3.2.2.5 Pipettes for cell injection 
To prepare pipettes with appropriate diameter tips for cell transplantation, glass 
capillary tubes (GC 100T-10, Harvard Apparatus Ltd, UK) were pulled using a 
vertical puller (Narishige PE-2, Narishige, Japan). The tip of pipette was cut by 
blunt micro-scissors to approximately 60-70μm internal diameter. After 
measuring the internal diameter under a microscope, the tip of the pipette was 
sharpened by using a beveller for approximately 5 minutes. And then, the tip 
was cleaned by blowing on it and by stroking it gently. The final internal and 
external diameters of the tip were measured and noted down. A permanent 
marker was used to mark gradations at 1.65mm apart from the neck of the 
pipette tip along the length of the pipette. These gradations approximated to a 
volume of 1μl and were used to keep tack of the volume of cells injected. 
Pipettes were securely stored in labelled glass containers and autoclaved before 
using.  
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3.2.2.6 Cell preparation for transplantation 
A phase contrast microscope was used to assess the general appearance and 
confluency of the cells and to exclude bacterial or fungal infection which would 
have unpredictable effects on the transplant outcome. The FBS present in the 
media was washed away from the flasks and a PBS solution containing trypsin 
was added. The flasks were placed in the 37oC incubator and monitored until 
cell detachment took place. The trypsin reaction was blocked with a solution of 
10%FBS also containing approximately 2µg/ml DNAse. The content of the flasks 
was transferred into 15ml falcon centrifuge tubes and placed on ice. After 
counting the cells with a haemocytometer the tubes were centrifuged and the 
supernatant discarded. A second but brief centrifugation was necessary to get 
rid of any medium present on the inner surface of the falcon tube and to avoid 
contamination when inserting the Gilson pipette tip to transfer the concentrated 
cells to a sterile PCR tube. The PCR tube was placed inside a larger tube in ice, 
transported from the Beatson institute to the main campus animal house and 
centrifuged again briefly on a bench centrifuge to get rid of any excess medium. 
The cell suspension was then carefully drawn into the pipette as required. Care 
was taken to avoid producing any air bubbles and/or damaging the tip of the 
pipette. 
3.2.3 Lesioning 
All the dorsal column lesions and cell transplantations in this study were carried 
out by Dr. John Riddell. 
The dorsal columns were lesioned bilaterally at the C4/C5 junction. The 
lesioning procedure used was the same as described in the methods section of 
chapter 2. Animals routinely received the peri-operative medication described 
previously in Chapter 2. OECs were transplanted into the animals immediately 
after lesioning. 
3.2.4 Acute cell transplantation 
In order to test whether OECs are able to induce plasticity in sensorimotor 
pathways we aimed to transplant cells so that they were distributed within the 
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spinal cord above and below the lesion but not within the lesion site itself. 
Fortuitously, we found that following injection into a cervical dorsal column 
lesion, OECs spread caudally for more than 6mm along the dorsal columns but 
did not remain within the lesion cavity. Animals transplanted with cells in this 
way were therefore used to investigate the effect of OECs on the function of 
sensory afferents terminating in this region. Since the cells did not spread 
rostrally in significant numbers, to investigate the effect of OECs on the function 
of corticospinal fibres terminating in this region, OECs were injected rostral 
(above) of the lesion site.   
3.2.4.1 Transplantation of OECs into the lesion 
A pipette with appropriate diameters loaded with cells, was mounted on a 
stereotactic manipulator, and then inserted into the lesion at an angle of 28o on 
each side through a slit in the dura with the tip pointing to the lesion centre and 
was lowered to a depth of approximately 1000µm. Cells were then injected until 
they overflowed out of the lesion, which required injection of up to 10µl of cell 
suspension into each lesion. The injection was performed by applying brief 
(40ms) pressure pulses (Picoinjector, WPI, Sarasota FL, USA) over the course of 
several minutes, during which the pipette was gradually raised to the surface. 
Three animals with OECs transplanted into the lesion were sacrificed at 3 weeks, 
4 weeks, and 6 weeks to investigate the distribution of the transplanted cells at 
different time points.  
3.2.4.2 Transplantation of OECs above the lesion 
A pipette loaded with cells was mounted on a stereotactic manipulator, and 
then vertically inserted into the cord approximately 250µm to the left of the 
midline through a slit in the dura and was lowered to a depth of approximately 
1100µm. Approximately 1µl cells were then injected by applying brief (40ms) 
pressure pulses (Picoinjector, WPI, Sarasota FL, USA) over the course of several 
minutes, during which the pipette was gradually raised to a depth of 
approximately 750µm. The pipette was then slowly removed from the cord. OECs 
were injected into the cord between the lesion site and 4mm rostral of the 
lesion at a depth corresponding to the main component of the corticospinal 
tracts. Cells were injected at between 4 and 5 sites in order to produce a 
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relatively even distribution. Six animals with OECs transplanted above the lesion 
were sacrificed at different time points (1 day, 2 days, 1 week, 2 weeks, 3 
weeks, and 4 weeks) to investigate the distribution of the transplanted cells. 
3.2.4.3 Medium injected above the lesion 
As a control for the animals in which cells were injected above the lesion, a 
further group of animals were injected with the same medium as was used to 
suspend the cells. Injections were made of similar volumes and with a similar 
distribution as for the OECs.  
A suture was placed in the dura over the lesion at a known location so that it 
could be identified at the later electrophysiological experiment and the 
segmental level could be confirmed at the end of the experiment. The wound 
was closed and analgesia, antibiotics and s.c. saline routinely administered as 
mentioned before. Animals recuperated in a warm environment in which easy 
access to food and water was provided. Animals were allowed to survive for 
approximately 3 months before electrophysiological assessment.  
3.2.5 Electrophysiology 
3.2.5.1 Anaesthesia 
Animals were anaesthetised as described in Chapter 2 during the preparatory 
surgery and electrophysiological assessment.  
3.2.5.2 Preparatory surgery 
The preparations for surgery and electrophysiological assessment were exactly 
the same as described in Chapter 2.  
3.2.5.3 Recordings of cord dorsum potentials  
To assess spinal cord function in the region of the lesion and the effect of OEC 
transplants, CDPs evoked by electrical stimulation of the radial nerve and/or 
corticospinal tract were recorded. Recordings of CDPs were made while 
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stimulating either the radial nerve or within the pyramids at supramaximal 
stimulus intensity. The procedures for stimulation and recording were the same 
as described in chapter 2. Throughout the recording of CDPs, great care was 
taken to remove fluid from the surface of the cord to avoid inaccuracy of 
recordings. 
All recordings of electrical potentials were digitised (Cambridge Electronic 
Design 1401+ interface, Cambridge, UK) and stored on a computer at a sampling 
rate of 20 kHz, without filtering. Averaging and measurements of the amplitudes 
of electrical potentials were performed using Signal software (Cambridge 
Electronic Design, Cambridge, UK). 
3.2.5.4 Conditioning of radial CDPs with pyramidal stimulation  
As an additional way of assessing the function of the corticospinal projection 
below the level of a lesion we applied conditioning stimuli in the pyramids and 
looked at their effect on CDPs evoked by radial-nerve afferents below the level 
of the lesion. The detailed procedure was described in Chapter 2. 
3.2.5.5 Field potential recording 
To assess possible changes in the areas of terminations of corticospinal fibres, 
systematic mapping of the field potentials evoked by pyramidal stimulation was 
performed in cervical segments above and below the dorsal column lesion. 
The recordings were made using microelectrodes attached to a stepping motor 
which was mounted on a micromanipulator.  In early experiments a carbon fibre 
electrode was used (Carbostar-1, tip size 5µm, impedance 0.5-2MΩ, Kation 
Scientific, USA) but this was found to be affected by the stimulus artefact 
leading to distortion of the early part of the record. We therefore changed to 
using glass microelectrodes (Tip size of 1-2µm; impedance 2MΩ) which were 
pulled from 1mm diameter filamented glass capillary tubing (GC 150TF-10, 
Harvard Apparatus LTD, UK) using a microelectrode puller (PE-2, Narishige, 
Japan), and then filled with 2M sodium chloride. The glass microelectrodes 
provided less distorted recordings than the carbon fibre electrodes. Recordings 
from both types of microelectrodes provided reliable information but the 
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recordings made using the carbon fibre electrodes required more careful 
interpretation. 
Recordings of field potentials were made in normal animals and in lesioned 
animals both above and below the level of the lesion (Figure 3-2). For lesioned 
animals, recordings above the lesion were made at sites as close as possible to 
where the largest pyramidal-evoked CDPs had been recorded earlier in the 
experiment. This was generally from 2.5 mm to 4 mm above the level of the 
lesion. Recordings in normal animals were made within comparable locations. 
Recordings below the lesion were usually made within a few mm of the lesion 
where small pyramidal-evoked CDPs were often recordable. In lesioned animals 
where recordings were to be made below the lesion there was little to record. 
Therefore, before recording below the lesion, recordings were first made with 
the same electrode at a position above the lesion to make sure that the 
electrode and other equipment and settings were appropriate and everything 
was in working order.  
The electrode was mounted with the tip pointing rostral 20 degrees in order to 
provide a clearer view of the spinal cord using the binocular microscope. 
Electrode tracks were then made using a vertical medio-lateral angle at regular 
intervals of 100 or 200µm to cover the full medio-lateral width of the grey 
matter (Figure 3-2B). Sometimes the spacing of the tracks had to be adjusted to 
avoid blood vessels. The first track was usually made at, or close to midline. 
Midline was identified by moving the electrode so that it was pointing directly to 
the left dorsal root entry zone and then the right dorsal root entry zone and 
noting the distance between them. This was then divided in two and this 
position taken as the midpoint. 
A small opening was made in the pia using watch makers forceps through which 
the electrode could be inserted. At each track location, recordings were made 
at regular intervals of 100µm from the surface to at least 2.4mm deep. The 
manipulator was zeroed at the surface of the first track and this setting was 
then kept throughout all subsequent tracks. That is, the manipulator was not 
reset for surface at the top of each recording track. This was done in order that 
the depth would be aligned in all electrode tracks so forming a grid which could 
be used for subsequent reconstruction of the field potential maps (Figure 3-2B). 
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Recordings at each location were made while stimulating the pyramids with 
single shocks (0.2ms duration up, usually supramaximally). Between 25 and 50 
sweeps were recorded and averaged at each position. Sometimes several 
recordings were made at the same position using different strengths of 
stimulation to obtain further information about the strength of pyramidal 
stimulation required to elicit the response. The recordings were made using an 
Axoprobe-1A microelectrode amplifier (Axon Instruments, UK). They were 
further amplified and filtered (NL824, Digitimer Ltd, UK). The signals were then 
digitised using a CED 1401 interface (Cambridge Electronic Design Ltd, UK) for 
off line analysis.  
At the end of the experiment, empty glass microelectrodes were inserted into 
the spinal cord to mark the position at which field potentials were recorded. The 
electrodes were mounted on the stepping motor and driven into the spinal cord 
at a known position relative to the electrode tracks. The blank electrodes were 
cut and left in the cord and their position noted. The positions of these marking 
electrodes were determined histologically and used to align the map of the field 
potential recordings with the outline of the grey matter at the recording level. 
3.2.5.6 Perfusion 
Most of the animals were transcardically perfused at the end of the 
electrophysiological experiment for histology as described in chapter 2.  
3.2.6 Histological processing 
3.2.6.1 Histological processing of spinal cord for lesion and cell distribution 
Animals receiving transplants of OECs the sections were cut sagittaly in order to 
preserve information about the distribution of OECs in the rostro-caudal axis. 
Three 4mm blocks were prepared carefully from each animal: rostral block (from 
6mm to 2mm above lesion), lesion block (from 2mm above lesion to 2mm below 
lesion), and caudal block (from 2mm to 6mm below lesion). A rostro-ventral 
notch was made on each block. Blocks were cut into 70µm parasagittal sections 
on a freezing microtome, washed in phosphate buffered saline 0.3M (PBS double 
salt), and then incubated for 30min in 50% ethanol. After washing 3 times for 10 
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minutes each in PBS sections were treated with fluorescence histochemestry 
techniques. 72h incubation of sections with anti-NF200 (1:1000 Sigma), anti-GFP 
(1:1000) and anti-GFAP (1:1000 Sigma) primary antibodies at 4°C which label 
respectively the axons, the OECs, and the astrocytes (lesion boundaries) was 
followed by secondary antibodies of appropriate species conjugated to 
fluorophores (Alexa 488 1:500, Cy5 1:100, Rodamine 1:100) (2 hrs at room 
temperature or overnight at 4°C). After washing 3 times for 10 minutes in PBS, 
sections were mounted on plain glass slides in anti-fade medium (Vectashield; 
Vector Laboratories, UK), and coverslipped and the edges of the coverslip sealed 
with nail varnish and then stored at –20°C. 
3.2.6.2 Histological processing of brainstem for stimulation sites 
Brainstem tissue containing the stimulating electrode tracks were carefully 
processed as described in chapter 2. Slides were stored at -20°C.  
3.2.6.3 Histological processing of spinal cord for field potential recording 
sites 
After washing in 0.1MPB, the marking electrodes or recording sites were 
identified. Blocks containing the marking electrodes or encompassing the 
recording sites were carefully prepared to avoid damaging the electrode tracks if 
present. A notch was made at the ventral aspect of the cord on the right corner. 
Sections were cut transversely (approximately parallel with marking electrode if 
present in order to reconstruct a clear electrode track) at 70µm using a freezing 
microtome (Ernst Leitz Wetzlar, Germany). Sections were mounted on plain glass 
slides in Vectashield mounting medium, coverslipped and the edges of the 
coverslip sealed with nail varnish, and then stored at -20°C.  
3.2.7 Microscopy 
3.2.7.1 Reconstruction of stimulation sites in the Pyramids 
Sections containing the stimulating electrode tracks were reviewed under 
microscopy (Zeiss Axioplan 2 Imaging), and the stimulating electrode tracks were 
reconstructed by using Camera lucida drawings as described in chapter 2.  
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3.2.7.2 Verification of dorsal column lesion  
Sections containing the lesion cavity were observed using phase contrast light 
microscopy to determine the perimeter of the cavity and the relationship to the 
boundaries between grey and white matter as described in chapter 2. 
3.2.7.3 Quantification of lesion size  
The length of the lesion cavity was measured as described in chapter 2. 
3.2.7.4 Distribution of OECs 
Sections from animals transplanted with OECs were examined using 
epifluorescence microscopy (Nikon Eclipse E600) to confirm the survival of the 
transplanted cells and to document their distribution. Confocal microscope 
images of sagittal sections through dorsal column lesions and cell transplants 
were taken to illustrate the distribution of transplanted cells.  
3.2.7.5 Reconstruction of field potential recording sites 
Sections containing tracks left by the marking electrodes or, if the marking 
electrode was not located, sections from close to the recording sites were 
reviewed by microscopy with a dark field condenser, and then photographed 
using a digital camera (4X objective Axiocam Zeiss, Germany). 4 photos were 
taken if necessary to show the whole field view of the section, and then 
montaged using Adobe Photoshop CS2 software. Each montaged image of the 
section from the recording site was then traced using a graphics tablet (Wacom 
pen tablet, Japan) to outline the section and grey and white matter border 
together with the position of the electrode track if present. 
3.2.8 Off-line analysis of electrophysiology 
3.2.8.1 Off-line analysis of CDPs 
CDP recordings were inspected and analysed by using Signal software as 
described in chapter 2. The data was noted in excel spreadsheets then imported 
to Prism 4 software (GraphPad Software Inc, USA) to create potential plots. 
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3.2.8.2 Off-line analysis of CDP conditioning 
Averaged records were inspected and analysed offline using Signal software as 
described in chapter 2.  
3.2.8.3 Off-line analysis of field potentials 
Averaged records were inspected offline using Signal software. The amplitudes 
of field potentials at each location were measured by using Signal software. The 
measurement of field potential of each location was noted in excel 
spreadsheets, and then imported to 3D field software to create potential plots. 
An outline of the section from field potential recording site and isopotential 
plots were both imported into a graphics program (Coreldraw version 12; Corel 
USA) and properly scaled (adjusted to matching scale). No adjustment was made 
for shrinkage of tissue after perfusing. The Isopotential plot was then accurately 
overlaid on the outline of the spinal cord using information about the electrode 
surface, midline, and visible marking electrode tracks. 
3.2.9 Statistical analysis   
The following statistical tests were carried out on the electrophysiological data 
(GraphPad Software Inc, USA). Analysis of variance (ANOVA), the Dunnett Post-
hoc test, and Student’s t-test were used to reveal the differences among 
different groups. 
3.3 Results 
3.3.1 Distribution of OECs in cervical spinal cord 
OECs were transplanted into the cervical spinal cord using two methods: by 
injecting into the lesion cavity made by the wire knife or by injecting directly 
into the spinal cord above the lesion. A cavity surrounded by an area of spinal 
cord tissue containing reactive astrocytes (labelling densely for GFAP) developed 
at the wire knife lesion site as described in chapter 2.  
 Figure 3-3 shows examples of confocal images obtained from three 
representative animals of the group which received transplants of cells into the 
lesion cavity. Very few cells remained within the lesion cavity apart from a few 
distributed around the rim. However, there was an extensive distribution of cells 
caudal to the lesion in the form of a continuous track occupying the ventral half 
of the dorsal columns and medial most aspects of the dorsal horns. The cells 
were extended for at least 6mm below the lesion and therefore provided a 
convenient region within which to test sensory pathways using radial nerve 
afferents. Relatively few cells were observed rostral to the lesion in these 
animals.  
Figure 3-4 shows examples of confocal images obtained from three animals 
which received OEC transplants made at separate injection sites spanning from 
0.5 to 5mm above the lesion. Labelled cells were observed throughout the dorsal 
columns and medial most aspects of the dorsal horn but were less dense than 
the caudally distributed cells in animals with cells injected into the lesion 
cavity. However, a lower proportion of the cells injected into these animals 
expressed GFP so that the precise distribution and density of cells is also more 
difficult to judge than in the lesion transplanted animals.   
3.3.2 Spinal cord function assessed by electrophysiology 
CDPs evoked by stimulating the corticospinal tract and/or radial nerve were used 
to assess function in the cervical spinal cord as in the previous chapter. 
Recordings were made from animals with OECs transplanted into the lesion site 
 182
(n=16), OECs transplanted into the cord above the lesion site (n=14), and 
medium injected into the cord above the lesion site (n=12). Recordings from 
normal animals (n=24) and animals in the three month survival lesioned group 
(n=18) presented in chapter 2 are also referred to for comparison.  
3.3.2.1 Cord dorsum potentials evoked by pyramidal stimulation 
Potentials evoked by pyramidal stimulation were recorded with a silver ball 
electrode positioned on the dorsal columns at 1mm intervals from 8mm rostral 
to 8mm caudal to the C4/5 segmental border as described in chapter 2. 
OEC below group 
CDPs evoked by stimulation in the pyramidal tract were investigated in 10 
lesioned animals three months after OECs were transplanted into the lesion site 
resulting in caudally distributed cells. Examples of CDPs recorded from two 
representative animals of this group are shown in Figure 3-5 and the distribution 
of averaged CDPs in all animals of this group is shown in Figure 3-6. In the OEC 
below group, CDPs recorded both above and below the lesion were similar to 
those in three month survival animals which were lesioned but did not receive 
any treatment. At some locations above the lesion, CDPs had a tendency to be 
larger than in the 3 month animals. CDPs above the lesion were significantly 
larger than those recorded in normal animals, as in the 3 month survival animals 
(Table 3-1).  
Medium above group 
CDPs evoked by stimulation in the pyramidal tract were investigated in 10 
lesioned animals three months after medium was injected into the cord above 
the lesion site. Examples of CDPs recorded from two representative animals of 
this group are shown in Figure 3-7 and the distribution of averaged CDPs in all 
animals of this group is shown in Figure 3-8. CDPs recorded both above and 
below the lesion were similar in amplitude to those recorded in the 3 month 
survival dorsal column lesioned animals and did not differ significantly at any 
location. Like the 3 month animals, CDPs recorded above the lesion were 
significantly larger than those recorded in normal animals. 
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OEC above group 
CDPs evoked by stimulation in the pyramidal tract were investigated in 14 
lesioned animals three months after OECs were transplanted into the cord above 
the lesion site. Examples of CDPs recorded from two representative animals of 
this group are shown in Figure 3-9 and the distribution of averaged CDPs in all 
animals of this group is shown in Figure 3-8. CDPs recorded both above and 
below the lesion did not differ significantly from those recorded from animals 
injected with medium above the lesion or 3 month dorsal column lesioned 
animals (Table 3-1). There was some tendency for potentials recorded in the 
OEC above group to be slightly smaller between +2 and +4mm where the cells 
were injected, but this was not significant. 
3.3.2.2 Cord dorsum potentials evoked by radial nerve stimulation 
Potentials evoked by radial nerve stimulation were recorded with a silver ball 
electrode positioned on the dorsal columns at 1mm intervals from 8mm rostral 
to 8mm caudal to the C4/5 segmental border as described in chapter 2. 
OEC below group 
CDPs evoked by radial nerve stimulation were investigated in 16 lesioned animals 
three months after OECs were transplanted into the lesion site leading to 
subsequent spread of the cells up to 6mm caudal to the lesion. Examples of CDPs 
recorded from two representative animals of this group are shown in Figure 3-11 
and the distribution of averaged CDPs in all animals of this group is shown in 
Figure 3-10. CDPs recorded in this group were almost identical to those recorded 
in the three month survival animals which received dorsal column lesions only. 
CDPs recorded above the lesion were still very small while CDPs recorded below 
the lesion were significantly larger than those recorded in normal animals from -
4mm to -8mm (Table 3-2).  
Medium above group 
CDPs evoked by radial nerve stimulation were investigated in 12 lesioned animals 
three months after medium injected into the cord above the lesion site. 
Examples of CDPs recorded from two representative animals of this group are 
shown in Figure 3-12 and the distribution of averaged CDPs in all animals of this 
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group is shown in Figure 3-13. CDPs recorded in the animals with medium 
injected rostral of the lesion site were almost identical to those in three month 
survival animals which were not transplanted.  
OEC above group 
CDPs evoked by radial nerve stimulation were investigated in 13 lesioned animals 
three months after OECs were transplanted into the cord above the lesion site. 
Examples of CDPs recorded from two representative animals of this group are 
shown in Figure 3-14 and the distribution of averaged CDPs in all animals of this 
group is shown in Figure 3-13. The CDPs recorded from this group were broadly 
similar to those of the 3 month survival dorsal column lesioned animals and 
those injected with medium above the lesion. However, the difference between 
the CDPs recorded below the lesion and those recorded from normal animals was 
less marked and failed to reach significance between -2 and -6mm. 
3.3.2.3 Field potentials 
Extracellular field potentials recorded within the spinal grey matter are negative 
potentials that reflect current flow at synapses between afferent systems and 
spinal cord neurones. They therefore reflect the same process as CDPs except 
that by recording at different locations in the grey matter information can be 
obtained about the spatial distribution of the synapses generating the fields. In 
order to assess the possible changes in the areas of termination of the 
corticospinal fibres, field potentials evoked by pyramidal stimulation were 
recorded above and below the C4/5 border in normal animals and above and 
below the lesion site in lesioned animals.  
Normal animals 
Recordings of field potentials evoked by pyramidal stimulation were made from 
4 normal animals, all at a position 4mm above the C4/5 border. Examples of 
field potential recordings from a normal animal are shown in Figure 3-15. The 
field potentials were recorded 4mm rostral of the C4/5 border. Small negative 
field potentials usually appeared close to the surface and were usually distinct 
by 0.2mm. The biggest negative fields were observed at the medial edge of the 
deep dorsal horn at a depth of 1.0-1.2mm. At some locations, an afferent volley 
 185
could be detected before the onset of the field potential. The peak amplitudes 
were around 0.6mV-1.1mV. The field potentials started to reverse and become 
positive at a depth of about 1.4-1.5mm.  
Dorsal column lesioned animals 
Recordings of field potentials evoked by pyramidal stimulation were made from 
17 animals with dorsal column lesions; three 1 week survival animal, six 3 month 
survival animals, four animals with medium injected above the lesion, and four 
animals with OECs injected above the lesion. Recordings were made above the 
lesion in 8 animals and from below the lesion in 9 animals. 
For recordings above the lesion the field potentials were recorded as close as 
possible to the location where the largest pyramidal-evoked CDPs were 
recorded, which was generally from 2.5mm to 4mm above the lesion site. 
Examples of field potential recordings made 3.5mm above the lesion in one of 
these animals are shown in Figure 3-16. The distributions of the fields in lesioned 
animals were broadly similar to that seen in normal animals. There was 
considerable variation in the shape, area, and size of the isopotential plots 
obtained from different animals in both normal and lesioned groups so that it 
was considered difficult to safely interpret this data. 
Field potentials below the level of the lesion were often absent or very small. 
The fields were only large enough and common enough in two animals to allow 
full mapping and construction of an isopotential plot. Examples of field potential 
recordings made 3mm below the lesion from one of these animals is shown in 
Figure 3-17. Attempts to record field potentials below the lesion often failed to 
disclose any action at the locations sampled or resulted in very occasional 
recordings. Some of the potentials recorded below the lesion were located in 
more lateral and ventral parts of the grey matter and sometimes required 
stimulus intensities at the upper end of the range activating corticospinal fibres. 
They were also often shorter in latency than corticospinal evoked activity should 
be indicated that a small amount of spread to reticulospinal fibres had occurred. 
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3.3.3 Lesion size 
The appropriate locations of the dorsal column lesion (i.e. C4/5 segmental 
border) were confirmed in all the lesioned animals included in this study. The 
lesions made by the wire knife approach were consistent and accurate across 
and within groups of animals. 
Examples of sections containing lesion cavities from different animal groups are 
presented in Figure 3-18. The wire knife lesion interrupted the full width of the 
dorsal columns. The lesion site of the transplanted animal groups appeared 
similar to that of three months survival animals. The lesion cavities were 
developed rostro-caudally and occupied the dorsal columns and varying amounts 
of grey matter.   
Table 3-3 shows the quantitative comparison of the lengths of the lesion cavities 
in the lesioned animal groups: three month survival group, OEC below group, 
OEC above group, and medium above group. The ranges of the lengths of the 
cavities in all the groups vary. The means of the lengths of the cavity are similar 
among the groups. 
3.4 Discussion 
Cell transplants 
Previous studies from this lab using OECs have shown that when transplanted 
into lumbar level wire knife lesions of the dorsal columns the cells survive well 
within the lesion site and to a large extent fill the lesion cavity (Toft et al. 
2007). When we attempted to make perform similar transplants (as described in 
Toft et al. 2007) into wire knife lesions at the cervical level the cells rarely 
remained within the lesion site in any significant numbers. The reason for this 
technical failure is not clear but may be related to a greater flow of 
cerebrospinal fluid from the cervical level lesions or to the greater movement 
that occurs at the cervical compared to lumbar region when the animals recover 
and become mobile again. Despite the absence of cells in the lesion cavity itself, 
inspection of blocks of spinal cord taken from below the lesion site showed that 
in nearly every case there was an extensive caudally directed distribution of the 
cells and that these cells remained 3 months after transplantation. The cells 
were so numerous that they formed a continuous column spread through out the 
ventral half of the dorsal columns and most lateral aspects of the dorsal horn. 
Earlier studies of olfactory ensheathing cell transplants suggested that these 
cells have migratory properties and that these were an important aspect of their 
ability to support extended axonal regeneration (Ramon-Cueto and Nieto-
Sampedro, 1994; Li et al. 1997; 1998; Ramon-Cueto et al. 1998, 2000). However, 
at least in the case of wire knife lesions, it is likely that much of the spread of 
cells occurs as an artifact of the lesioning and injecting technique at the time of 
transplantation. In a detailed study by Lu et al. (2006), OECs and other cell types 
were transplanted both within the lesion and at nearby sites and the distribution 
of the cells studied at different time points by detection of GFP expressed in the 
transplanted cells. Extensive movement of the cells was seen within hours of the 
injections suggesting that most of the dispersion was explained by passive spread 
from the injection site, possibly along tears in the neuropil created by the lifting 
action of the wire knife.  
Spread of cells from the injection lesion site rarely occurred in the rostral 
direction. For this reason cells were directly injected into the spinal cord above 
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the lesion. The cells spread from the injection sites with time so that this 
process also resulted in continuously distributed cells extending from the lesion 
to 4 or 5mm more rostral. However, the cells were less densely distributed than 
below the lesion where the distribution occurred by “natural” processes. 
Lack of electrophysiological evidence for sprouting 
The rationale of the experiments reported in this chapter was to test whether 
enhancement of corticospinal and radial nerve-evoked actions matched the 
distribution of transplanted cells. That is, if the presence of OECs within the 
spinal cord adjacent to the lesion induced sprouting of ascending and descending 
pathways, then in animals with cells distributed above the lesion, CDPs evoked 
by corticospinal fibres above the lesion should be larger in lesioned controls. 
Similarly if the presence of OECs distributed below the lesion induced plasticity 
in sensory afferents, the CDPs evoked by the radial nerve should be larger below 
the lesion than in lesioned controls. However, in each case the actual results 
observed showed that the presence of OECs had little detectable effect on the 
amplitude of CDPs evoked by either ascending or descending fibre pathways. The 
electrophysiological evidence therefore suggests that OECs do not induce 
sprouting of either corticospinal or sensory afferent terminals after dorsal 
column lesions. 
Sensitivity of electrophysiological recording for detecting 
plasticity  
This negative finding is not likely to be due to a lack of sensitivity of the 
electrophysiological assessment because it was shown in the previous chapter 
that changes in the amplitude of CDPs can be detected in response to lesioning 
and these involve not just detection of the direct interruption of ascending and 
descending fibres by axotomy but also the more subtle changes in function that 
occur in the intact proximal sections of the axotomised axons where collateral 
arbours form connections with spinal cord neurones. Furthermore, it will be 
shown in the next chapter that the same electrophysiological assessment 
procedures can detect changes in function induced by administration of 
antibodies that block myelin inhibitory proteins. It therefore seems reasonable 
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to presume that if OECs induced plasticity then this would have been detected 
using the electrophysiological methods adopted here. 
Are the cells optimally located? 
Little is known about the extent to which OECs directly stimulate axonal growth 
or the mechanisms by which they do so. OECs promote neurite outgrowth from 
DRG neurones in culture. They have also been shown to support axonal 
regeneration of various fibre types in the spinal cord (Richter and Roskams, 
2007). However, it is not clear from the in vivo experiments to what extent OECs 
actively promote axonal regeneration and to what extent they simply provide a 
growth supportive substrate. It has even been suggested that Schwann cells 
infiltrating the transplant may be responsible for most of the growth promoting 
effects (Lu et al. 2006). Nor is there much known about the mechanisms that are 
involved in any growth promoting effects that OECs might have. One possibility 
is that soluble factors are released by the transplanted cells (Au et al. 2007) and 
that these induce collateral sprouting. Signalling by this mechanism could 
potentially occur at some distance. Another possibility is that some form of 
contact signalling occurs either between OECs and the regenerating growth 
cones of axotomised fibres near the lesion site or by contact of parent fibres or 
their axon collaterals. In ongoing anatomical studies of OEC transplants in the 
lab, an association between transplanted cells and regenerating fibres is 
sometimes seen but is rather infrequent.  
The distribution of the transplanted cells was assessed by microscopical 
examination of GFP labelled cells. In the spinal cord caudal to the lesion the 
cells were thickly distributed so that a continuous column of cells filled the 
dorsal columns and the adjacent lateral most aspect of the dorsal horn. These 
cells are well placed for inducing plasticity in radial afferent fibres by the 
release of soluble factors since they are close to the parent fibres in the dorsal 
columns and also adjacent to their termination site in the dorsal horn. However, 
they are arguably less well placed for any contact mediated actions since some 
radial afferents may be more dorsally located in the dorsal columns and the cells 
are not in the main area targeted by axon collaterals. The distribution of cells 
above the lesion was similarly targeted on the dorsal columns and adjacent 
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lateral white matter. In this case the cells are well placed in close proximity to 
the corticospinal fibres and their local axon collaterals. Sprouting of radial fibres 
above the lesion was not expected since few if any fibres are spared by the 
dorsal column lesion. Sprouting of corticospinal fibres below the lesion was also 
not expected because few if any of the main dorsal column fibres are spared by 
the dorsal column lesion and the transplanted cells are not in an appropriate 
location to interact with the minor components which project in the lateral and 
ventral funiculi (Casale et al. 1988; Rouiller et al. 1991; Brosamle and Schwab 
1997). 
Comparison with previous evidence for sprouting 
There has been only one previous direct investigation of the potential of OEC 
transplants to produce sprouting. Chuah et al. (2004) made lesions of the main 
dorsal column component of the corticospinal tract into which they then 
transplanted OECs. Examination of the density of tract-traced corticospinal fibre 
collateral branches below the level of the lesion revealed more in transplanted 
animals than in non-transplanted controls. Chuah et al attributed this to 
sprouting of the minor corticospinal components projecting through the ventral 
white matter. However, these observations would be equally consistent with a 
neuroprotective action of the OECs since the number of collateral branches in 
transplanted animals did not exceed that in normal animals. In this study we did 
not examine plasticity in spared fibres as in the Chuah et al. (2004) study. 
Instead we investigated whether OECs would induce sprouting in fibres that had 
been axotomised. The rationale for this was that axotomised fibres might be 
better primed for plasticity and that the actions of intact fibres would be easier 
to assess functionally than the much smaller populations of spared fibres. OECs 
have been reported to support regeneration of both corticospinal (Li et al. 1997; 
1998) fibres and dorsal column fibres (Toft et al. 2007). To the extent that 
similar mechanisms may be involved in axonal regeneration and in sprouting, 
both fibres types are therefore suited to the study.  
Several potential therapies for spinal cord injury, although originally devised 
with the intention of removing inhibitory influences on regenerating axons and 
so stimulating axonal regeneration, also appear to induce plasticity and may in 
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fact produce most of their functional effects by this mechanism (Bradbury and 
McMahon, 2006). However, the fact that OECs support regeneration of 
axotomised fibres within a transplant but do not promote sprouting of the 
undamaged collaterals of the same fibres is not necessarily a surprise.  It is 
possible that entirely different signalling mechanisms are involved. It is also 
possible that OEC transplants in vivo have very little direct influence on the 
regeneration of axons and that rather than stimulating axonal regeneration they 
are mainly passive providers of a growth permissive scaffold. The regeneration 
of axotomised branches is driven by growth programmes and expression of 
various growth associated proteins (Bouquet and Nothias, 2007) so that these 
mechanisms alone may be sufficient to drive regeneration when OECs provide 
appropriate conditions within the lesion. In support of this possibility, ongoing 
work in the lab has shown that substantial axonal regeneration occurs in 
transplants of many different cells types in addition to OECs, including 
fibroblasts which are not considered to have specific axonal outgrowth 
promoting properties (Riddell, Barnett, Toft unpublished).   
Does the injection process or presence of OECs have any 
detrimental effect? 
As a control for the possibility that the injection process itself might cause some 
damage to the spinal cord, a group of animals was injected with medium above 
the lesion and corticospinally-evoked CDPs assessed. When compared to lesioned 
animals without any injections above the lesion, CDPs from the medium injected 
animals were entirely comparable, suggesting that the injection process itself 
does not have any detrimental effect on the spinal cord. When corticospinally-
evoked CDPs recorded in animals injected with OECs above the lesion were 
compared with the lesion only animals CDPs from the two animals were again 
very similar though there was a tendency towards smaller CDPs in the region (0 
to +4mm) where OECs were injected. This suggests that OEC transplants may be 
associated with a very modest disruption of function and since the injection of 
medium alone had no effect, the cells themselves may be responsible. It is 
possible that damage simply results from the physical process of accommodating 
the volume (¾ to 1µl) of the cells within the normal spinal cord tissue where 
there is no natural space to accommodate them. It is known that the cells 
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themselves readily mingle with astrocytes and induce minimal astrocytic 
hypertrophy (Santos-Silva et al. 2007). 
Significance of findings in relation to previous 
electrophysiological observations on OEC transplanted animals 
In previous work from the lab (Toft et al. 2007) OECs were transplanted into a 
lumbar dorsal column lesion similar to the cervical lesions used here. However, 
in this study the cells were shown to remain within the lesion cavity and to limit 
the usual expansion of the cavity which is seen with time. Electrophysiological 
assessment showed that this was associated with an enhancement of the CDPs 
evoked by sensory afferents in the region of the injury. It was suggested that this 
might be explained by OECs promoting sprouting of afferent fibres or 
neuroprotection of afferent fibre collaterals. The current results do not support 
the idea that OECs promote sprouting of damaged fibre systems and the 
explanation for the enhanced CDPs seen in the previous study therefore more 
likely involves neuroprotection. OEC transplants may reduce the die back of 
dorsal column axons and therefore preserve more of the local axon collaterals 
which branch profusely to provide connections with spinal cord neurones. 
Preservation of these connections is probably the main explanation for the larger 
potentials in OEC transplanted animals.  
 
 
 
Table 3-1 Statistical analysis of the differences between pyramidal-evoked 
CDPs recorded in different animal groups at each recording location 
ANOVA with post-hoc Dunnett’s test was first applied and where a significant difference 
was found the P value threshold is given. Where no significance was detected with 
ANOVA, Student’s t-test was used and where a significant difference was detected the P-
value is given. Comparison where no significance was detected with either test is indicated 
by NS.  
 
Normal Normal Normal 3month 3month 3month OEC above 
 
OEC below OEC above Medium OEC below OEC above Medium Medium 
+8 P=0.034 P=0.0306 P=0.003 NS NS NS NS 
+7 NS NS P=0.0131 NS NS NS NS 
+6 P=0.0366 P=0.0083 P=0.0006 NS NS NS NS 
+5 P<0.01 P=0.0407 P<0.05 NS NS NS NS 
+4 P<0.01 NS P<0.05 NS NS NS NS 
+3 P<0.05 NS P=0.0275 NS NS NS NS 
+2 P=0.0406 NS NS NS NS NS NS 
+1 NS P<0.01 P<0.01 NS NS NS NS 
0 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-1 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-2 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-3 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-4 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-5 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-6 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-7 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-8 P<0.01 P<0.01 P<0.01 NS NS NS NS 
 
 
 
Table 3-2 Statistical analysis of the differences between radial nerve-evoked 
CDPs recorded in different animal groups at each recording location 
ANOVA with post-hoc Dunnett’s test was first applied and where a significant difference 
was found the P value threshold is given. Where no significance was detected with 
ANOVA, Student’s t-test was used and where a significant difference was detected the P-
value is given. Comparison where no significance was detected with either test is indicated 
by NS.  
 
Normal Normal Normal 3month 3month 3month OEC above  
OEC below OEC above Medium OEC below OEC above Medium Medium 
+8 P<0.01 P<0.01 P<0.01 NS NS NS NS 
+7 P<0.01 P<0.01 P<0.01 NS NS NS NS 
+6 P<0.01 P<0.01 P<0.01 NS NS NS NS 
+5 P<0.01 P<0.01 P<0.01 NS NS NS NS 
+4 P<0.01 P<0.01 P<0.01 NS NS NS NS 
+3 P<0.01 P<0.01 P<0.01 NS NS NS NS 
+2 P<0.01 P<0.01 P<0.01 NS NS NS NS 
+1 P<0.01 P<0.01 P<0.01 NS NS NS NS 
0 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-1 P<0.01 P<0.01 P<0.01 NS NS NS NS 
-2 P<0.01 NS NS NS NS NS NS 
-3 NS NS NS NS NS NS NS 
-4 P=0.0296 NS NS NS NS NS NS 
-5 P<0.05 NS P<0.05 NS NS NS NS 
-6 P<0.01 NS P<0.01 NS NS NS NS 
-7 P<0.01 P=0.0315 P<0.05 NS NS NS NS 
-8 P<0.05 P=0.022 P<0.01 NS NS NS NS 
 
 
 
 
 
 
 
 
Table 3-3 Quantification of lesion cavity size in different groups 
The lengths of the cavities in lesioned groups were assessed and compared (see methods) 
using Students’ t-test which showed no significant difference in mean cavity length among 
the groups.  
 
 
 
 3 month group (n=15) 
OEC below 
group (n=18) 
OEC above 
group (n=16) 
Medium above 
group (n=12) 
Length of cavity 
(Range) 1260-3920µm 1750-3360µm 1050-3360 µm 1820-2800µm 
Length of cavity 
(Mean) 2511µm 2423µm 2389µm 2293µm 
Figure 3-1 18-day OECs in culture
P75 (red, A), GFP (green, B) and merge (C). Blue is DAPI. Scale bar = 50µm.
A B C
Stimulating electrode
Recording electrode
C4/5  lesionPyramid Corticospinal tract
A
B
Field potential recording sites
0.5mm
Figure 3-2  Experimental setup for field potential recording
Schematic diagram of experimental preparation show location of lesion and of stimulating 
and recording electrodes for assessing corticospinally-evoked field potentials. A, the 
dorsal columns were lesioned bilaterally at the C4/C5 junction which interrupts the main 
component of the corticospinal tract which runs in the ventral aspect of the dorsal 
columns. A stimulating electrode was inserted in the medullary pyramid dorsally and a 
micro-electrode was inserted into the spinal cord at locations above and below the C4/5. 
B, recordings were made at regular intervals of 100 or 200µm medio-laterally up to 
900µm and normally 100µm intervals ventrodorsally from the surface to at least 2.4mm 
deep. In the transverse view of the spinal cord, dots represent recording sites.
+2 0 -2 -4 -6
A
OECs injected to lesion
(mm) GFP%
73%
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70%
Figure 3-3 Distribution of OECs 3 months after injections into the dorsal column 
lesion site 
A, schematic diagram of distribution of cells following injection into a dorsal column 
lesion. Few cells remained in the lesion cavity but a continous track of cells had formed in 
the dorsal column extending caudal from the injection site for 6mm; B, confocal images 
from three transplanted animals showing the lesion cavity largely devoid of cells and the 
extensive distribution of OECs (green) from 2mm above the lesion to 6mm below the 
lesion. The percentage of transplant cells that were GFP positive is indicated to the right.
B
CaudalRostral
AFigure 3-4 Distribution of OECs 3 months after injections above the lesion site 
A, schematic diagram of the distribution of cells following injection above the lesion. The 
cells were transplanted in the cord at a depth corresponding to the corticospinal pathway at 
between 4 and 5 sites between the lesion and 4mm more rostrally. They were observed 
rostrally for more than 5mm along the dorsal columns; B, confocal images from three 
transplanted animals showing the distribution of OECs (green) from 1mm to 5mm above 
the lesion. The percentage of transplant cells that were GFP positive is indicated to the 
right.
B
 OECs injected at several sites above lesion
50%
63%
63%
+5 +3(mm) +1 GFP%
CaudalRostral
Figure 3-5 Examples of CDPs evoked by pyramidal stimulation in the OEC below 
group 
Each column of traces shows recordings made from one animal. The recordings were 
made at 1mm intervals from 8mm rostral to 8mm caudal to the lesion level (C4/5 border) 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate 
stimulus artifacts. 
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Figure 3-6 Amplitudes of pyramidal-evoked CDPs recorded in the OEC below group
The plot shows the distributions of the amplitudes of CDPs recorded from the OEC below 
group (n=10). The previous plots for the normal group and for the three month survival 
group are also shown for comparison. CDP amplitudes are averaged for all animals in each 
group, each data point showing mean +/- SEM. The recordings were made over the 
cervical spinal cord. Recording positions are shown relative to the C4/5 border (0 mm) 
where dorsal column lesions were made. CDPs recorded in the OEC below group were 
similar to those in three month survival animals both above and below the lesion. There is 
an increasing tendency from the lesion site to 5mm rostral of the lesion, but not 
statistically different from those recorded in the three month survival group. 
Figure 3-7 Examples of CDPs evoked by pyramidal stimulation in the medium above 
group 
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the lesion level (C4/5 border) as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. 
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Figure 3-8 Amplitudes of pyramidal-evoked CDPs recorded in the medium above and 
OEC above groups
Plots show the amplitudes of CDPs recorded over the cervical spinal cord in response to 
pyramidal stimulation in the medium above (n=10) and OEC above (n=14) groups. The 
previous plots for the normal group and for the three month survival group are also shown 
for comparison. CDP amplitudes are averaged for all animals in each group, each data 
point showing mean +/- SEM. Recording positions are shown relative to the C4/5 border 
(0 mm) where dorsal column lesions were made. In the medium above group, CDPs below 
the lesion were larger than those recorded in three month survival lesioned animals but not 
significantly different. Compared to CDPs in the medium above group, CDPs recorded 
around the lesion were similar. Above the lesion, CDPs were smaller than those recorded 
in the medium above group but not significantly different.  
Figure 3-9 Examples of CDPs evoked by pyramidal stimulation in the OEC above 
group 
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the lesion level (C4/5 border) as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. 
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Figure 3-10 Amplitudes of radial nerve-evoked CDPs recorded in the OEC below 
group
The plot shows the amplitudes of CDPs recorded over the cervical spinal cord in response 
to radial nerve stimulation in the OEC below group (n=16). The previous plots for the 
normal group and for the three month survival group are also shown for comparison. CDP 
amplitudes are averaged for all animals in each group, each data point showing mean +/- 
SEM. Recording positions are shown relative to the C4/5 border (0 mm) where dorsal 
column lesions were made. CDPs recorded in the OEC below group were almost identical 
with those recorded in three month survival lesioned animals. CDPs recorded below the 
lesion were significantly larger than those recorded in normal animals from -4mm to -
8mm. 
Figure 3-11 Examples of CDPs evoked by radial nerve stimulation in the OEC below 
group 
Each column of traces shows recordings made from one animal. The recordings were 
made at 1mm intervals from 8mm rostral to 8mm caudal to the lesion level (C4/5 border) 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate 
stimulus artifacts.
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Figure 3-12 Examples of CDPs evoked by radial nerve stimulation in the medium 
above group
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the lesion level (C4/5 border) as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. 
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Figure 3-13 Amplitudes of radial nerve-evoked CDPs recorded in the medium above 
and OEC above groups
Plots show the amplitudes of CDPs recorded over the cervical spinal cord in response to 
radial nerve stimulation in the medium above (n=12) and OEC above (n=13) groups. The 
previous plots for the normal group and for the three month survival group are also shown 
for comparison. CDP amplitudes are averaged for all animals in each group, each data 
point showing mean +/- SEM. Recording positions are shown relative to the C4/5 border (0 
mm) where dorsal column lesions were made. CDPs in the medium above group were 
almost identical to those in the three month group. In the OEC above group, CDPs 
recorded from 8mm to -3mm were similar to those recorded in the 3 month survival group. 
CDPs from -4mm to -8mm were smaller but not significantlly different. 
Figure 3-14 Examples of CDPs evoked by radial nerve stimulation in the OEC above 
group 
Each column of traces shows recordings made from one animal. The recordings were made 
at 1mm intervals from 8mm rostral to 8mm caudal to the lesion level (C4/5 border) as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. 
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Figure 3-15 Field potential recordings from a normal animal
Field potential recordings were made at 4mm above the C4/5 reference location in a 
normal animal (9308). A, examples of field potential recordings made in the track indicated 
by an open arrow head in B (400µm to the left of midline). The top trace shows a CDP 
recording from the same level of the cord. The negative potential reached a peak amplitude 
at 1.2mm deep, then reversed; B, schematic diagram showing all recording sites. Solid line 
represents the track from which the recordings in A were made; C, isopotential plot 
computed from the recordings made at all locations and accurately overlaid on an outline 
of the spinal cord. Solid lines represent negative potentials, dashed lines represent positive 
potentials.
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Figure 3-16 Field potential recordings from above the lesion in a 3 month dorsal 
column lesioned animal
Field potential recordings were made at 3.5mm above the lesion (C4/5 reference location) 
(R6508). A, examples of field potential recordings made in the track indicated by an open 
arrow head in B (500µm to the left of midline). The top trace shows a CDP recording from 
the same level of the cord. The negative potential reached a peak amplitude at 1.0mm 
deep, then reversed; B, schematic diagram showing all recording sites. Solid line 
represents the track from which the recording in A were made; C, isopotential plot 
computed from the recordings made at all locations and accurately overlaid on an outline 
of the spinal cord. Solid lines represent negative potentials, dashed lines represent positive 
potentials.
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Figure 3-17 Field potential recordings from below the lesion in a 3 month dorsal 
column lesioned animal
Field potential recordings were made at 3mm below the lesion level (C4/5 reference 
location) (R6508). A, examples of field potential recordings made in the track indicated by 
an open arrow head in B (400µm to the left of midline). The top trace shows a CDP 
recording from the same level of the cord. The negative potential reached a peak amplitude 
at 0.8mm deep, then reversed; B, schematic diagram showing all recording sites. Solid line 
represents the track from which the recordings in A were made; C, isopotential plot 
computed from the recordings made at all locations and accurately overlaid on an outline of 
the spinal cord. Solid lines represent negative potentials, dashed lines represent positive 
potentials.
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Figure 3-18 Lesion morphology of transplanted animals
Light microscopy images taken with a dark field view condenser from 
transvers/parasagittal sections of different animal groups. The lesion interrupted the whole 
dorsal columns. Lesion cavities were observed in all the transplanted groups. Varying 
amouts of the dorsal horn grey matter were also affected by the lesion. Scale bar 1mm 
applies to all images.
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Effects of anti-Nogo and anti-MAG on 
sensorimotor pathways following injury 
 215
4.1 Introduction  
Axonal regeneration following injury is limited by neurite growth inhibitors 
present in CNS myelin such as Nogo-A and MAG. However, these proteins may 
normally serve to restrict axonal plasticity and sprouting in the adult nervous 
system once mature neuronal circuits have developed. Consistent with this 
hypothesis, treatment with antibodies directed at the NOGO-A-specific terminal 
of NOGO-A or interference with NOGO-R signalling has been shown to lead to 
sprouting in several fibres systems (Li et al. 2004; Schnell and Schwab 1990; 
Fouad et al. 2004; Liebscher et al. 2005; Freund et al. 2006; 2007) and to 
promote improved functional recovery (Liebscher et al 2005, Freund et al 2007). 
MAG also has the capacity to inhibit neurite outgrowth (McKerracher et al. 1994; 
Mukhopadhyay et al. 1994). Although its effects on plasticity have not been 
investigated, treatment with anti-MAG antibody is reported to have 
neuroprotective effects in a model of stroke. Improved functional recovery was 
accompanied by smaller lesion volumes and better tissue sparing in animals 
receiving anti-MAG antibody (Irving et al. 2005; Thompson et al. 2006). 
The aim of this study was to use an electrophysiological approach to directly 
assess the effect of two antibodies targeting inhibitory myelin proteins on the 
function of sensorimotor pathways following spinal cord injury. The antibodies 
were supplied by GSK and included a mouse monoclonal antibody directed to a 
fragment of the amino terminal region of human NOGO-A (GSK577548) and a 
humanised antibody to MAG (GSK249320A).  
4.2 Methods 
4.2.1 Animals 
The observations reported in this chapter are based on investigation of 61 
Sprague Dawley rats (Harlan, Loughborough, UK). Figure 4-1 shows the overall 
plan for this study. Twelve rats were naïve non-lesioned animals from which 
normal data was obtained in an acute electrophysiological experiment. Forty six 
rats were subjected to cervical dorsal column lesions and were allowed to 
recover for 8 weeks. Of these animals, 14 were implanted with pumps delivering 
vehicle, 10 animals with pumps delivering anti-Nogo antibody and 9 with pumps 
delivering anti-MAG antibody. The other 13 animals received lesions only to 
provide a control for any effects of the implanted intrathecal cannulae. 
Furthermore, three animals were sacrificed 5 weeks after lesioning and pump 
implantation in order to assess antibody distribution following intrathecal 
delivery (two animals for anti-Nogo antibody, one for anti-MAG antibody). Rats 
used for the naïve group weighed 380 –460g at the time of electrophysiology to 
approximately match the weight of animals which had been lesioned and 
allowed to survive for 8 weeks. At the time of surgery, rats used for the lesioned 
group weighed 243-295g. 
4.2.2 Antibodies 
4.2.2.1 Antibody preparation 
Antibodies were prepared and supplied by GSK pharmaceuticals as part as a 
collaborative contract. 
Immunisation strategy    In order to generate monoclonal antibodies directed 
against the sequences unique to the CNS restricted Nogo-A isoform (A-splice) 
two female mice (SJL) were immunised subcutaneously with a mixture of human 
and rat NOGO-A-splice-GST proteins purified from E.Coli (5ug per injection). The 
RIMMS schedule used was designed to generate high affinity monclonal 
antibodies by rapid immunisation at multiple sites (day 0, 2 sites using CFA plus 
4 sites using RIBI adjuvant, days 4 and 8, 4 sites using just RIBI).  After three 
immunisations over 11 days, lymph node cells were harvested from 2 mice and 
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fused with Bcl2 expressing P3X myeloma cells. Cells were seeded into twenty 96 
well plates. Wells displaying growing cells were progressed into the screening 
assay detailed below.  
Screening strategy    A large panel of anti-Nogo-A antibodies was generated. 
These antibodies were progressed on the basis of binding to cleaved human 
Nogo-A splice (to eliminate GST reactive clones) and then for cross-reactivity 
with both human and rat Nogo-A splice. Antibodies were further filtered using a 
competition assay with those antibodies showing the best inhibition of binding to 
immobilised Nogo-A following the addition of increasing quantities of soluble 
Nogo-A. These selected antibodies were screened as hybridoma supernatants for 
their ability to reverse the inhibitory activity of GST-human Nogo-A splice in 
neurite-outgrowth assays.  
Monoclonals selected for progression   These selected antibodies (53) were 
screened initially as hybridoma supernatants for their ability to reverse the 
inhibitory activity of GST-human Nogo-A splice in neurite-outgrowth assays. An 
automated neurite-outgrowth assay was configured using the Cellomics 
Arrayscan machine in which fluorescently labeled neuronal processes stained 
using anti-beta-tubulin are quantitated. Wells of poly-d-lysine coated 96 well 
plates were coated using a spot of recombinant purified protein at 3pmol/ul. 
Baseline growth was assessed by measuring neuronal growth on the GST alone 
protein, inhibition was assessed in wells coated with GST-Nogo-Asplice or GST-
Nogo-A5+6 pretreated with HBSS. Reversal of inhibition was determined in wells 
coated with Nogo-A pretreated with hybridoma supernatant or purified IgG 
diluted in HBSS. Four antibodies were identified with function blocking activity 
in this assay (2A10, 2C4, 15C3 and 4E2). 4E2 could not be revived from frozen 
stocks but the remaining three lines were grown in Cell Factories under serum 
free conditions and antibodies were purified using immobilised Protein G 
columns. These purified antibodies were shown to be able to neutralise the 
inhibitory activity of GST-NogoAregion 5+6. From these purified antibodies 2A10 
appeared to be the most efficacious antibody with both 2C4 and 15C3 requiring 
higher concentrations to inhibit Nogo. 2A10 was manufactured from the mouse 
hybridoma using standard tissue culture conditions. Antibody was purified using 
protein-A sepharose and further processed by ion-exchange chromatography. 
The identity of the antibody was confirmed by N-terminal sequencing and 
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activity was confirmed by ELISA and Biacore assays relative to a reference batch 
with neurite-outgrowth inhibition blocking activity.  
4.2.2.2 Pumps 
Two different osmotic mini-pumps were used to deliver vehicle or antibodies in 
this study. The 2 week pumps (2ML2, ALZET, USA) were implanted into the 
animals, and then swapped for 4 weeks pumps (2ML4, ALZET, USA) after 2 weeks 
so that vehicle/antibody was delivered for 6 weeks in total. 
4.2.2.3 Dosing and antibody delivery 
Pumps were filled and primed overnight in sterile saline at 35 oC with the 
cannulae attached. For the vehicle treated animals the pumps were filled with 
Phosphate buffered saline (PBS, Ca2+ and Mg+ free, invitrogen, UK) diluent in 
which the Nogo antibody was prepared. For anti-Nogo treatment, 2 week pumps 
(2ML2) were filled with anti-Nogo antibody (anti-Nogo 2A10 mouse monoclonal) 
at a concentration of 3mg/ml. Since the 4 week pumps (2ML4) pump at a rate 
half that of the 2 week pumps, they were filled with anti-Nogo at a 
concentration of 6mg/ml. This concentration was chosen based on previous 
studies (Liebscher T et al. 2005). For anti-MAG treatment, 2-week pumps were 
filled with anti-MAG (GSK249320A humanised IgG1 antibody in phosphate buffer) 
at a concentration of 0.7mg/ml and 4-week pumps at a concentration of 1.4 
mg/ml. This concentration was designed to deliver anti-MAG antibody at a dose 
of 100µg/24hrs and was chosen based on previous studies performed at GSK. The 
diluent used to prepare working strength solutions was the same as that in which 
the antibody was supplied. 
4.2.3 Lesioning, intrathecal cannulation and pump implantation 
All the dorsal column lesions and pump implantations in this study were carried 
out by Dr. John Riddell. 
4.2.3.2 Dorsal column lesion procedure 
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The dorsal columns were lesioned bilaterally at the C4/C5 junction. The 
lesioning procedure was the same as described in the methods section of chapter 
2. Surgical materials and instruments were sterilised and precautions were taken 
to minimise the risk of infection. Animals routinely received the peri-operative 
medication described previously in chapter 2.  
4.2.3.2 Intrathecal cannulation and pump implantation 
At the same operation a fine cannula (ReCathco) was introduced through a slit in 
the dura at the atlanto-occipital junction and passed caudally until it appeared 
within the laminectomy opening (see Figure 4-2). The tip of the cannula was 
positioned just rostral to the lesion. The cannula was then secured to bone (C1 
vertebra) with Vetbond cyanoacrylate adhesive and secured by suture thread 
more distally. The pump was placed in a subcutaneous pocket over the back at 
the thoraco-lumbar level. The positioning and continuity of intrathecal cannulae 
was determined at the electrophysiological experiment and the completeness of 
lesions after histological processing at the end of the experiment. 
4.2.3.3 Pump swap 
Two weeks after the lesion operation, animals were re-anaesthetised with 
halothane and the 2 week pumps swapped for the 4 week pumps being careful 
not to introduce air bubbles when re-attaching to the cannula. 
4.2.3.4 Distribution of anti- Nogo and anti-MAG at 5 weeks and 8 weeks 
To determine the distribution of the antibodies after intrathecal delivery, 
animals were lesioned and implanted with pumps exactly as for the 
electrophysiological experiments except that the animals were sacrificed at 5 
weeks post-implantation. This time point was chosen because it is towards the 
end of the normal total delivery period of six weeks (3 weeks after implantation 
of the second minipump) and is before significant degradation of the antibodies 
would be expected. Two animals were implanted with pumps delivering anti-
Nogo antibody and one animal with a pump delivering anti-MAG.  
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Immunolabelling for anti-Nogo (n=3) and anti-MAG (n=6) was also performed at 
the 8 week post-lesion time point i.e. 2 weeks after delivery of antibodies had 
ceased.  
4.2.4 Electrophysiology 
4.2.4.1 Anaesthesia 
Animals were anaesthetised as described in chapter 2 during the preparatory 
surgery and electrophysiological assessment.  
4.2.4.2 Preparatory surgery 
The preparation for surgery and electrophysiological assessment were exactly the 
same as described in chapter 2. During the surgery, the positioning and continuity 
of intrathecal cannulae were confirmed, and then the cannula was carefully 
removed.  
4.2.4.3 Recordings of cord dorsum potentials  
To assess spinal cord function in the region of the lesion and the effects of 
antibody treatments, cord dorsum potentials (CDPs) evoked by electrical 
stimulation of the radial nerve and/or the corticospinal tract were recorded. 
The procedures for stimulation and recording were the same as described in 
chapter 2. Recordings were made while stimulating the radial nerve or the 
pyramids at supramaximal intensities (typically 50-100µA for radial nerve and 
200-350µA for pyramidal stimulation). Responses to 25 stimuli were recorded at 
each recording location and averaged using a CED 1401+ interface and Signal 
software.  
4.2.4.4 Perfusion 
Most of the animals were transcardically perfused at the end of the 
electrophysiological experiment for histology as described in chapter 2.  
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4.2.5 Histological processing 
4.2.5.1 Histological processing of brainstem for stimulation sites 
Brainstem tissue containing the stimulating electrode tracks were carefully 
processed as described in chapter 2. Slides were stored at -20°C.  
4.2.5.2 Histological processing of spinal cord for lesions 
The procedure for the histological processing of tissue containing the lesion 
cavity was the same as described in chapter 2. Slides were stored at -20°C.  
4.2.6 Microscopy 
4.2.6.1 Reconstruction of stimulation sites in the Pyramids 
Sections containing stimulating electrode tracks were reviewed under 
microscopy (Zeiss Axioplan 2 Imaging), and the stimulating electrode tracks were 
reconstructed by using Camera lucida drawings as described in chapter 2.  
4.2.6.2 Verification of dorsal column lesion  
Sections containing the lesion cavity were observed using phase contrast light 
microscopy to determine the perimeter of the cavity and the relationship to the 
boundaries between grey and white matter as described in chapter 2.   
4.2.7 Off-line analysis of electrophysiology 
CDP recordings were inspected and analysed by using Signal software as 
described in chapter 2. The data was noted in excel spreadsheets then imported 
to Prism 4 software (GraphPad Software Inc, USA) to create potential plots. 
4.2.8 Statistical analysis   
The following statistical tests were carried out on the electrophysiological data 
(GraphPad Software Inc, USA). Analysis of variance (ANOVA); Tukey-Kramer Post-
hoc; The Dunnett Post-hoc test; Student’s t-test was used to reveal the 
differences among different groups. 
4.3 Results 
4.3.1 Distribution of antibodies 
The distribution of the antibodies following intrathecal delivery was investigated 
using immunocytochemistry and fluorescence and confocal microscopy.  
4.3.1.1 Anti-Nogo antibody at 5 weeks  
Anti-Nogo immunolabelling could be detected at high levels around the rim of 
the lesion cavity and within the neuropil of the dorsal spinal cord above and 
below the lesion (Figure 4-3). Labelling was strongest within the more superficial 
aspects of the dorsal columns above the lesion, close to where the cannula tip 
was located (Figure 4-3D). Anti-Nogo labelling of blood vessels within the spinal 
cord, both in the dorsal aspects and the ventral aspects was also common 
(arrows in Figure 4-3B, C and D). There was no obvious co-localisation with 
neurofilament labelled structures (Figure 4-3) or with GFAP (not illustrated).    
One of the anti-Nogo treated animals examined in this way appeared to have an 
unusually high density of large calibre blood vessels within the spinal cord close 
to the delivery site. This observation may reflect an angiogenic effect of the 
Nogo antibody or may simply be a response to the presence of an intrathecal 
cannula. 
4.3.1.2 Anti-MAG antibody at 5 weeks 
Humanized anti-MAG immunolabelling could be detected at high levels within 
the spinal segments close to the intrathecal delivery. The immunolabelling was 
strongest around the edge of the lesion cavity but penetrated deep into the 
spinal cord parenchyma and was evident particularly in the dorsal columns (see 
Figure 4-4). There was evidence for preferential binding within degenerating 
white matter. The dotted white lines in Figure 4-4A indicate the upper and 
lower borders of the corticospinal tract within the ventromedial dorsal columns. 
As can be seen, above the lesion (left hand end of section), immunolabelling is 
seen mainly dorsal to the corticospinal tract within the degenerating white 
matter of the ascending dorsal column system. This pattern was also evident in 
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transverse sections taken from a block rostral to the parasaggital section (Figure 
4-4E): immunolabelling here is seen particularly in the ascending dorsal column 
tract, avoiding the intact corticospinal tract. On the other hand, below the 
lesion (Figure 4-4A, right hand end of section) the immunolabelling was mainly 
within the degenerating corticospinal tract in the ventral aspect of the dorsal 
columns. Some evidence of binding to dorsal roots was also observed (Figure 4-
4E and G). Co-localisation with APC was investigated but none seen (Figure 4-
4F). Humanized MAG antibody labelling was, however, seen in blood vessels 
(Figure 4-4B) and in occasional cells (Figure 4-4C and D). Anti-MAG labelling was 
occasionally co-localised with endogenous MAG (arrows in Figure 4-4D) though 
endogenous MAG was not obviously increased around the lesion site or in 
degenerating white matter tracts at 5 week post-lesion in MAG antibody treated 
animals. 
4.3.1.3 Anti-Nogo and anti-MAG at 8 weeks 
Immunolabelling for anti-Nogo (n=3) and anti-MAG (n=6) was also performed at 
the 8 week post-lesion time point i.e. 2 weeks after delivery of antibodies had 
ceased. Immunolabelling at this time point was very much reduced compared to 
the 5 week time point and was only detectable in the most superficial aspects of 
the cord and around the lesion cavity where the intensity was also greatest at 5 
weeks (see Figure 4-5). 
4.3.2 Spinal cord function assessed by electrophysiology 
As in the previous chapters, CDPs evoked by stimulating the corticospinal tract 
and/or radial nerve were used to assess function in the cervical spinal cord. 
Because Sprague-Dawley rats were used for this study rather than the F344 
strain of the earlier studies, recordings were made again from normal animals 
(n=12). A further 33 animals were subjected to dorsal column lesions and 
implanted with a pump and intrathecal cannula. These were divided into three 
groups: one treated with vehicle (n=14), one with anti-Nogo (n=10), and one 
with anti-MAG (n=9). 
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4.3.2.1 Cord dorsum potentials evoked by pyramidal stimulation 
Potentials evoked by pyramidal stimulation were recorded with a silver ball 
electrode positioned on the dorsal columns at 1mm intervals from 8mm rostral 
to 8mm caudal to the C4/5 segmental border as described in chapter 2. 
Because of the use of a different strain of animals for the work in this chapter, 
and the possibility of anatomical or other differences that could affect the 
protocol we developed for maximal unilateral pyramidal stimulation, brain stem 
stimulation sites were histologically verified for 6 animals. Figure 4-6 shows 
reconstructions of the electrode positions and the corresponding stimulus-
recruitment curves for 4 of these animals. These showed the same characteristic 
features as the F344 animals so that the same protocol was used to select 
animals. 
Normal animal group 
CDPs evoked by pyramidal tract stimulation were investigated in 11 normal 
animals. Examples of CDPs recorded from two representative animals of this 
group are shown in Figure 4-7. The recordings show that clear surface potentials 
are evoked by pyramidal stimulation at all of the recording locations examined. 
This is from 8mm rostral to 8mm caudal to the C4/5 border of the cervical 
segments. Cervical segments are about 3mm long in the rat so that this 
corresponds to approximately C2 to C7. The recordings show clear afferent 
volleys rostrally which become more dispersed and show a longer latency at 
progressively more caudal recording locations due to the longer conduction 
distance. The mean CDP amplitude for all animals in this group at each recording 
location is shown in Figure 4-8. In normal SD rats, the distribution of CDP 
amplitudes evoked by pyramidal stimulation was fairly flat over most of the 
cervical cord but declined in amplitudes at further caudal locations. Compared 
to the amplitudes in normal F344 rats, the amplitudes tended to be higher at 
around 0.35mV, but these were not statistically significantly different (Table 4-
1).  
Vehicle group 
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CDPs evoked by pyramidal stimulation were investigated in 13 animals implanted 
with a pump delivering vehicle. Examples of CDPs recorded from two 
representative animals of this group are shown in Figure 4-9 and the distribution 
of averaged CDPs in all animals of this group is shown in Figure 4-10. CDPs below 
the lesion were greatly reduced compared to those in normal animals as 
expected following interruption of the main component of the corticospinal 
tract. However, small CDPs were detectable at these levels. On average these 
were about half the size seen in F344 animals 3 months following a dorsal 
column lesion. CDPs above the lesion were also smaller than those recorded in 
normal animals (by some 25-40%). The amplitudes above the lesion were around 
0.25mV in vehicle treated animals compared to around 0.35mV in normal 
animals and this is significantly different (Table 4-1).  
Anti-Nogo group 
CDPs evoked by pyramidal stimulation were investigated in 10 animals with 
pumps delivering anti-Nogo antibody. Examples of CDPs recorded from two 
representative animals of this group are shown in Figure 4-11 and the 
distribution of averaged CDPs in all animals of this group was shown in Figure 4-
12. CDPs below the lesion tended to be larger than those recorded in the vehicle 
group but this difference was not significant (Table 4-1). CDPs above the lesion 
also tended to be larger in the anti-Nogo treated animals than those in the 
vehicle group (by about 30%) and the difference was significant at some 
locations (Table 4-1). They were almost same as those recorded in normal 
animals. The amplitudes above the lesion level were larger than 0.3mV. Because 
intrathecal cannulation-vehicle treatments profoundly reduced the amplitudes 
of CDPs, the effect of the anti-Nogo treatment was to restore the CDPs to their 
normal amplitudes. 
Anti-MAG group 
CDPs evoked by pyramidal stimulation were investigated in 8 animals with pumps 
delivering anti-MAG antibody. Examples of CDPs recorded from two 
representative animals of this group are shown in Figure 4-13 and the 
distribution of averaged CDPs in all animals of this group is shown in Figure 4-14. 
The amplitudes of CDPs in the anti-MAG treated group were very similar to those 
recorded in the vehicle group.  
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4.3.2.2 Cord dorsum potentials evoked by radial nerve stimulation 
Potentials evoked by radial nerve stimulation were recorded with a silver ball 
electrode positioned on the dorsal columns at 1mm intervals from 8mm rostral 
to 8mm caudal to the C4/5 segmental border as described in chapter 2. 
Normal animal group 
CDPs evoked by radial nerve stimulation were investigated in 9 normal animals. 
Examples of CDPs recorded from two representative animals of this group are 
shown in Figure 4-15. The recordings show that clear surface potentials are 
evoked by radial nerve stimulation at all of the recording locations examined. 
The recordings show clear afferent volleys close to the entry of the stimulated 
root which was 3 to 4mm below C4/5 segmental border, and become more 
dispersed at progressively more rostral and caudal recording locations due to the 
longer conduction distance. The rostro-caudal distribution of averaged CDPs in 
all animals of this group is shown in Figure 4-16. In normal animals, the largest 
potentials were produced between 0 and -5 mm which corresponds to the C5 and 
C6 segments. CDPs of gradually declining amplitude were, however, evoked for 
several segments above and below this. The amplitudes of the biggest CDPs were 
around 0.8mV. The amplitudes of CDPs recorded in SD rats showed a slight 
tendency to be bigger than those recorded in F344 rats but the difference was 
not significant (Table 4-2). 
Vehicle group 
CDPs evoked by radial nerve stimulation were investigated in 14 animals with 
pumps delivering vehicle. Examples of CDPs recorded from two representative 
animals of this group are shown in Figure 4-17 and the distribution of averaged 
CDPs in all animals of this group is shown in Figure 4-18.  Above the lesion level, 
CDPs in the vehicle treated group were almost abolished due to the dorsal 
column lesion. Below the lesion, CDPs recorded from vehicle treated animals 
were almost the same as those recorded in normal animals at positions between 
-3 and -8mm. Nearer to the lesion, however (-1 and -2mm) they were 
significantly smaller. 
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Anti-Nogo group 
CDPs evoked by radial nerve stimulation were investigated in 10 animals treated 
with anti-Nogo. Examples of CDPs recorded from two representative animals of 
this group are shown in Figure 4-19 and the distribution of averaged CDPs in all 
animals of this group is shown in Figure 4-20. In the anti-Nogo group, CDPs above 
the lesion were of negligible amplitudes as in the vehicle treated group. 
However, CDPs below the lesion were larger than those recorded in the vehicle 
group (by 35-40%) and the difference was significant at some locations (Table 4-
2). They also tended to be larger even when compared to CDPs in normal 
animals although in this case the difference did not reach significance (Table 4-
2).  
Anti-MAG group 
CDPs evoked by radial nerve stimulation were investigated in 9 anti-MAG treated 
animals. Examples of CDPs recorded from two representative animals are shown 
in Figure 4-21 and the distribution of averaged CDPs in all animals of this group 
is shown in Figure 4-22. CDPs recorded in these animals were very similar to 
those of the vehicle treated group. 
4.4 Discussion 
Distibution of antibodies 
The dose chosen for the delivery of anti-Nogo was the same as has been used 
previously for the intrathecal delivery of similar anti-Nogo antibodies to that 
used here (Liebscher et al. 2005; Maier et al. 2009). The duration of the 
treatment was, however, prolonged beyond the four weeks delivery used in 
previous studies by swapping osmotic pumps to provide a total delivery period of 
six weeks. When the distribution of the antibody was investigated after 5 weeks 
of administration, it was found to be distributed mainly superficially within the 
neuropil and was enriched in the region of the lesion cavity as has been reported 
for similar antibodies directed against the Nogo-A-specific region of Nogo-A 
delivered icv (Weinmann et al. 2006). The choice of concentration for anti-MAG 
was based on previous studies performed by GSK in a stroke model (Irving et al. 
2005). In this earlier study anti-MAG was given as bolus injections by icv or iv 
administration within a period of 72 hours following the induction of stroke but 
the distribution of the antibody was not examined. In the current study the 
antibody was delivered intrathecally for a continuous period of 6 weeks as for 
the anti- Nogo. When the distribution of the antibody was investigated after 5 
weeks of administration, it was found to be distributed mainly within the dorsal 
half of the neuropil and was enriched around the lesion cavity but also in regions 
corresponding to degenerating white matter tracts in the dorsal columns.  
Corticospinal and sensory CDPs in Sprague-Dawley compared to 
Fisher 344 animals 
For investigation of the effect of anti- Nogo and anti-MAG antibodies, Sprague-
Dawley animals were preferred to Fischer 344s because SDs are more robust, less 
nervous animals and use of an inbred strain was not required. Because we were 
using a different strain and strain related differences are know to occur it was 
necessary to repeat recordings from normal animals. Corticospinally and sensory-
evoked CDPs were very similar in both strains of animals although corticospinal 
CDPs tended to be slightly, though not significantly, bigger in SD animals. This 
may be related to reports of differences in the area of the sensorimotor cortex 
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in different strains of rats described by Whishaw and colleagues (Whishaw et al. 
2003). 
Effect of intrathecal cannulae and vehicle treatment 
One surprising finding was that pyramidal-evoked CDPs above the lesion in 
animals in which vehicle alone was delivered via an implanted intrathecal 
cannula were smaller in amplitude than those recorded from normal animals. 
This contrasts with the results obtained with F344 animals where at both 1 week 
and 3 months following a dorsal column lesion CDPs were larger than in normal 
animals of the same strain. CDPs evoked below the lesion by radial nerve 
afferents were not as affected since they were similar in size to normal animals, 
but this again contrasts with enhanced CDPs seen in F344 animals 1 week and 3 
months after a dorsal column lesion. These observations suggest that either the 
presence of the cannula or the delivery of the vehicle from the pump had a 
detrimental effect on the spinal cord. Even though the cannula used was of the 
smallest possible diameter it was evident during placement that it was a tight fit 
between the pia and the dura. It was also sometimes possible to see a groove in 
the dorsal surface of the spinal cord where the cannula had rested. There have 
been previous reports of inflammation around chronically indwelling intrathecal 
cannulae. However, this is the first time that a functional assessment of the 
effect of an intrathecal cannula has been made. The result suggests that it 
would be preferable to use an alternative method of drug delivery where 
possible.  
Effect of anti- Nogo treatment 
The results obtained from animals treated with anti- Nogo show a significant 
enhancement of both corticospinal and sensory afferent evoked CDPs compared 
to vehicle treated controls. Interpretation of the effects of anti- Nogo on 
corticospinal CDPs above the lesion are complicated by the negative effects of 
vehicle/intrathecal cannulation which meant that the CDPs following anti- Nogo 
treatment were increased towards that seen in normal animals rather than 
exceeding them. Corticospinally–evoked CDPs below the lesion also tended to be 
larger in anti-Nogo treated animals but this effect did not reach significance. 
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The results for CDPs evoked by sensory afferents of the radial nerve were clear 
cut. Treatment with anti-Nogo resulted in CDPs that exceeded not just those of 
the vehicle treated controls but also of normal animals. This evidence strongly 
suggests that anti-Nogo enhances plasticity in sensorimotor pathways, the 
functions of which are thereby enhanced.  
Effect of anti-MAG treatment 
The results obtained from animals in which anti-MAG was delivered over the 
spinal cord are unequivocal. Anti-MAG treatment had no effect on either 
corticospinally evoked or sensory afferent evoked CDPs. The CDPs evoked by 
both pathways were neither suppressed nor enhance but remained almost 
identical to those of the vehicle treated controls. The fact that CDPs recorded 
from anti-MAG treated animals are so similar to the vehicle treated animals 
does, however, provide reassurance the CDP assessment method employed is 
consistent and therefore that the enhanced CDPs observed in the anti-Nogo 
treated controls are genuine. 
The lack of effect of anti-MAG is not likely to be due to poor penetration of the 
antibody since immunocytochemical detection of the antibody showed it to be 
distributed throughout the relevant area of the spinal cord as discussed above. It 
therefore seems unlikely that anti-MAG treatment has any plasticity promoting 
effect, at least in this laceration model of spinal cord injury. This does not 
preclude the possibility that anti-MAG may have a neuroprotective function as 
has been reported in a stroke model (Irving et al. 2005) and suggested recently 
by in vitro studies (Nguyen et al. 2009). The wire knife dorsal column lesion 
model used in this study is not a model suited to disclosing neuroprotective 
actions as axons in the white matter are acutely axotomised and there is 
minimal collateral damage to neurones in the grey matter. Studies in a contusion 
injury model will be necessary to determine whether anti-MAG treatment has 
any neuroprotective actions following spinal cord injury. 
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Mechanisms of Nogo-induced plasticity - anatomical vs synaptic 
plasticity 
This study shows an increased efficacy of corticospinal and sensory pathways in 
response to anti-Nogo treatment. Previous investigations using similar antibodies 
to the amino-Nogo terminal have suggested that some axonal regeneration can 
occur (Brosamle et al. 2000; Freund et al. 2009) but also that there is 
widespread anatomical sprouting (Raineteau and Schwab, 2001; Raineteau et al. 
2002; Bareyre et al. 2002). Sprouting has been reported for a number of 
different fibre systems including the corticospinal tract after interruption within 
the spinal cord or by pyramidotomy (Bareyre et al. 2002), in the rubrospianl 
tract after corticospinal tract lesions (Raineteau et al. 2002). The larger 
amplitude potentials seen below the lesion on stimulation of the pyramidal tract 
in Nogo-ab treated animals could theoretically be due either to regeneration or 
to sprouting. However, clearly the enhancement of corticospinal actions above 
the dorsal column lesion and the enhancement of sensory transmission below the 
lesion cannot be explained by axonal regeneration since they are the “wrong 
side” of the lesion. This, together with the fact that the CDPs evoked by sensory 
afferents are actually larger following anti-Nogo treatment than in normal 
animals indicates that a mechanisms involving plasticity is involved. Given the 
evidence discussed above, anatomical sprouting of the corticospinal tract is a 
strong possibility. Sprouting of large diameter sensory fibres has not been 
reported following anti-Nogo treatment so the mechanism by which the efficacy 
of sensory pathways is enhanced remains to be investigated.  
Does plasticity occur in spared fibres or only axotomised fibres? 
We have shown that anti-Nogo treatment produces an increase in the 
effectiveness of corticospinal actions above a dorsal column lesion and of 
sensory afferents below a dorsal column lesion. Although both the corticospinal 
and sensory potentials are produced by intact sections of these fibres proximal 
to the lesion, most are likely to have been axotomised more distally by the 
dorsal column lesion. Stimulation of the corticospinal tract also produces larger 
potentials below the level of the lesion. While these are likely to be produced by 
intact fibres belonging to the minor lateral component which pass the lesion, 
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this is not definitive since corticospinal connections above the lesion are made 
partly onto propriospinal neurones with axons passing the lesion. It therefore 
remains uncertain as to whether the plasticity-inducing effects of anti-Nogo 
treatment work only on axotomised fibres or also on non-damaged fibres. It is 
also possible that direct damage to the fibres in which plasticity is induced is not 
necessary but that some damage to the system as a whole is sufficient to render 
them responsive to anti-Nogo treatment (Raineteau et al. 2002). This would be 
important if anti-Nogo treatment was to enhance activity in spared pathways. As 
discussed earlier in the context of spontaneous plasticity, it is not possible to 
tell whether the plasticity induced by anti-Nogo treatment occurs in the 
corticospinal projection to the lumbar cord or the projection to the cervical 
segments but this could potentially be investigated further by using 
microstimulation in the forelimb and hindlimb areas of the sensorimotor cortext 
to determine the involvement of projections from these two areas or by tract 
tracing if anatomical sprouting is involved. 
Does anti-Nogo treatment induce plasticity in contusion models 
of spinal cord injury? 
Transection models of spinal cord injury are the most suitable for investigating 
the mechanisms underlying experimental treatments for spinal cord injury but 
contusion injuries most closely model clinical injuries. The effect of anti-Nogo 
treatments have not yet been investigated in this model and this will be 
important to understand how effective the treatment is in maximising function 
following this type of injury and therefore how useful it may be clinically where 
most injuries are contusion type injuries. 
Over what distance is plasticity induced following intrathecal 
delivery of anti-Nogo? 
Nogo-abs have been delivered by injections of hybridoma cells into the brain 
ventricles or icv injection (Bareyre et al. 2002) or intrathecally via osmotic 
minipumps (Liebscher et al. 2005; Maier et al. 2009). Intrathecal delivery of 
Nogo-ab is generally made with the tip of the cannula close to the site of injury. 
Sprouting of the corticospinal system has been reported within the spinal cord 
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but also for collateral branches within the brain. How this sprouting relates to 
function is not known since the behavioural changes usually used to assess 
recovery of function could result from plasticity at any level of the neuraxis and 
could involve systems not investigated anatomically. It is also unclear how close 
delivery of Nogo-ab would need to be to the terminals in which induction of 
plasticity is desired. Signalling of plasticity might be very local within the axon 
i.e. only terminals close to Nogo-ab binding may be induced to sprout) or binding 
of Nogo-ab at one set of terminals may induce plasticity in all of the terminals of 
that axon even where they are at some distance from the antibody binding.  
In the treatment of spinal cord injury, inducing plasticity at all levels below the 
lesion, not just close to the lesion site would be of greatest potential benefit 
since spared fibres may travel for long distances below the lesion and many fibre 
types will give rise to collaterals connecting with spinal cord neurones over 
several segments. It would therefore be valuable to determine whether the 
plasticity we can detect electrophysiologically when testing pathways 
terminating close to the level at which the Nogo antibody is delivered would also 
occur at a greater distance from the delivery site or whether the effects of anti-
Nogo diminish rapidly with distance. A better understanding of how Nogo-ab 
treatment induces plasticity at a molecular and cellular level may also 
illuminate these issues. 
Is anti-Nogo treatment as effective after a delay? 
Treatments for spinal cord injury that depend critically on treatment 
commencing within a short time of the injury will be more difficult to implement 
than treatments that are not time-critical. Furthermore, treatments that are 
effective when initiated some time after the injury could be useful not only for 
the treatment of new injuries but also for chronic injuries. In this study the anti-
Nogo treatment was administered acutely i.e. from the time the lesion was 
made. The question of whether plasticity is induced only in axotomised fibres o 
also in spared fibres has a bearing on this question. If only axotomised fibres are 
influenced then this implies a mechanism that interacts with signalling 
mechanisms triggered by axotomy. Since these change with time then the effect 
of anti-Nogo treatment might also be time limited. If on the other hand anti-
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Nogo treatment induces plasticity in non-damaged fibres, and in the absence of 
collateral injury, then it is more likely that the plasticity inducing effects can be 
produced by treatment at any time point. Preliminary evidence from the Schwab 
group suggests that delayed treatment for spinal cord injury is less effective 
while delayed treatment remains effective in stroke models (Seymour et al. 
2005). It is not clear why there should be such a discrepancy and further 
investigation of anti-Nogo effects at different time points may be useful.  
Duration of anti-Nogo induced plasticity 
In the current experiments, electrophysiological assessment was performed two 
weeks after anti-Nogo delivery by the implanted pumps was exhausted. This 
indicates that, after a six 6 week treatment with anti-Nogo, the effects of the 
treatment persist for at least a further two weeks. Furthermore, this occurs 
despite a marked reduction in the amount of bound antibody detectable in the 
spinal cord at 8 weeks compared to 5 weeks. However, it remains uncertain as to 
whether the plasticity induced is permanent or reduces with time when 
treatment is stopped and if it reduces, how soon. The answers to these questions 
have clear implications for any treatment regime. If the plasticity induced is 
permanent then this would mean that only a single treatment would be 
necessary to bring about the desired plasticity and once the effects were 
maximised, treatment could be stopped. On the other hand it would also mean 
that any undesirable effects, once established would be permanent, and would 
not resolve if treatment were ceased. Studies using different durations of 
treatment and following the functional changes over a long time course would 
therefore be desirable. 
Does Nogo-ab induced plasticity translate into improved 
sensorimotor function? 
Synaptic plasticity (strengthening existing connections) would enhance existing 
pathways while sprouting (new connections) may either enhance existing 
pathways or result in the formation of entirely new pathways. These new 
connections may or may not be functionally appropriate and integrated in a 
useful way. It is far from clear which, if either mechanism of plasticity, would 
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provide the best prospects for improving function after spinal cord injury but 
there are several reports that treatments with anti-Nogo antibodies or with 
agents that interfere with Nogo-R signalling can provide modest improvements in 
function. Functional recovery reported following IN-1 antibody treatment or 
delivery of other monoclonal antibodies directed against the Nogo-A-specific 
terminal of Nogo-A includes improvements of locomotion in rats (Liebscher et al. 
2005) and of grasping movements in monkeys (Freund et al. 2006).  
 
 
 
 
 
 
 
 
Table 4-1 Statistical analysis of the differences between pyramidal-evoked 
CDPs recorded in different animal groups at each recording location 
ANOVA with post-hoc Dunnett’s test was first applied and where a significant difference 
was found the P value threshold is given. Where no significance was detected with 
ANOVA, Student’s t-test was used and where a significant difference was detected the P-
value is given. Comparison where no significance was detected with either test is indicated 
by NS.  
 
 
 
 
SD Normal 
 
Normal 
 
Normal 
 
Vehicle 
 
Vehicle 
 
Anti-Nogo 
  
F344 Vehicle Anti-Nogo Anti-MAG Anti-Nogo Anti-MAG Anti-MAG 
+8 NS P=0.0040 NS NS NS NS NS 
+7 NS P=0.0083 NS NS P=0.0500 NS P=0.0433 
+6 NS P=0.0327 NS P=0.0127 NS NS NS 
+5 NS P=0.0305 NS P=0.0015 P=0.0416 NS P=0.0462 
+4 NS P=0.0124 NS P=0.0101 NS NS NS 
+3 NS P=0.0022 NS P=0.0090 NS NS NS 
+2 NS P<0.05 P<0.05 NS NS NS NS 
+1 NS P<0.01 P<0.01 P<0.01 NS NS NS 
0 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-1 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-2 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-3 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-4 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-5 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-6 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-7 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-8 NS P<0.01 P<0.01 P<0.01 NS NS NS 
 
 
 
 
 
 
Table 4-2 Statistical analysis of the differences between radial nerve-evoked 
CDPs recorded in different animal groups at each recording location 
ANOVA with post-hoc Dunnett’s test was first applied and where a significant difference 
was found the P value threshold is given. Where no significance was detected with 
ANOVA, Student’s t-test was used and where a significant difference was detected the P-
value is given. Comparison where no significance was detected with either test is indicated 
by NS.  
 
 
 
SD Normal Normal Normal Vehicle Vehicle Anti-Nogo 
 
F344 Vehicle Anti-Nogo Anti-MAG Anti-Nogo Anti-MAG Anti-MAG 
+5 NS P<0.01 P<0.01 P<0.01 NS NS NS 
+4 NS P<0.01 P<0.01 P<0.01 NS NS NS 
+3 NS P<0.01 P<0.01 P<0.01 NS NS NS 
+2 NS P<0.01 P<0.01 P<0.01 NS NS NS 
+1 NS P<0.01 P<0.01 P<0.01 NS NS NS 
0 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-1 NS P<0.01 P<0.01 P<0.01 NS NS NS 
-2 NS NS NS NS NS NS NS 
-3 NS NS NS NS P<0.01 NS P=0.0321 
-4 NS NS NS NS P<0.05 NS NS 
-5 NS NS NS NS NS NS P=0.0133 
-6 NS NS NS NS NS NS P=0.0386 
-7 NS NS NS NS NS NS NS 
-8 NS NS NS NS NS NS NS 
Figure 4-1 Schematic diagram of study design 
Schematic diagram to show the overall plan of the experiment. The timing of individual 
experimental procedures is indicated relative to the operation to lesion the dorsal columns 
and implant pumps (Week 0). Behavioural testing although carried out, is not included in 
the present report.
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Figure 4-2 Localisation of intrathecal cannulae for antibody delivery
A, cannulae were inserted via the atlanto-occipital opening and routed intrathecally to 
localise the tip close to the C4/5 junction. B, the cannula tip was typically sited ca. 1 mm 
rostral of the C4/5 lesion site. A 10-0 surgical suture was stitched to the dura to mark the 
lesion site.
Figure 4-3 Distribution of anti-Nogo within the spinal cord after intrathecal delivery 
at 5 weeks 
A, confocal microscope image of parasaggital section of spinal cord at the level of a dorsal 
column lesion where anti-Nogo was delivered intrathecally for five weeks. In this and other 
panels, immunolabelling for anti-Nogo is shown in green and immunolabelling for NF200 
is shown in red. Anti-Nogo was detected mainly around the rim of the lesion cavity and 
dorsal surface of the cord but also penetrated into the dorsal aspects of the cord, especially 
rostral to the lesion where the cannula tip was situated; B, C, and D show selected areas 
from this and an additional section (D) to illustrate anti-Nogo binding to blood vessels 
(arrows), including within the ventral aspect of the cord (D). Scale bars: A, 500µm, B,C, D, 
200µm.
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Figure 4-4 Distribution of anti-MAG within the spinal cord after intrathecal delivery 
at 5 weeks 
A, confocal microscope image of parasaggital section of spinal cord at the level of a dorsal 
column lesion where anti-MAG was delivered for five weeks. Anti-MAG immunolabelling 
(green) is distributed around the periphery of the lesion cavity and dispersed more widely 
within the dorsal columns. Anti-MAG was distributed preferentially within areas of 
degenerating white matter: above the lesion (left hand side of section) immunolabelling 
occurs mainly dorsal to the intact corticospinal tract (dashed lines) within the degenerating 
ascending dorsal column tracts. Below the lesion (right hand side of section), 
immunolabelling is distributed mainly within the corticospinal tract (within dashed lines). 
E, transverse section from spinal cord several mm above the lesion showing the 
preferential distribution of anti-MAG within the region of dorsal columns containing 
degenerating ascending sensory fibres, and the absence of labelling within the corticospinal 
tract (within dashed lines); B and C show higher power views from an area of the 
ascending dorsal column (B) and the corticospinal tract (C). Note occasional anti-MAG 
labelled cells. The cellular labelling in C is shown in more detail in D where some 
examples of colocalisation of anti-MAG with structures labelled with endogenous MAG 
are also illustrated (arrows); F, high power image of an area of the dorsal columns (of the 
section shown in E) showing the anti-MAG was not co-localised with APC labelled cells; 
G, high power image of the dorsal root entry zone (from the section shown in E) showing 
the anti-MAG labelling within the dorsal root. Green = anti-MAG, Red (A-D) = 
endogenous MAG, (E-G) = APC. Scale bars: A, 500µm, B, C, E, 200µm, D, F, G, 50µm.
Figure 4-5 Distribution of antibodies within the spinal cord at 8 weeks 
A and B, confocal images of parasaggital sections from animals treated with anti-Nogo (A) 
and anti-MAG (B). The antibodies were delivered continuously by intrathecal cannula for 
6 weeks and the animals perfused 2 weeks after delivery had ceased. Both antibodies were 
stained less intensely than at the 5wk time-point. A, anti-Nogo (green) was found 
distributed around the edges of the lesion cavity and on the surface of the cord but little 
remained within the parenchyma; B, more of the anti-MAG (green) remained within the 
spinal cord. Blue, GFAP, Red (A), NF200, (B), endogenous MAG. Scale bar: 500µm.
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Figure 4-6 Examples of pyramidal stimulus-recruitment curves and corresponding 
electrode positions for SD animals
The diagrams to the left show reconstructions of stimulating electrode tracks. The plots to 
the right show corresponding stimulus-recruitment curves, one for stimulation up to 1mA 
and another up to 5mA. 
Middle
Stimulus recruitment curve to 1mA Stimulus recruitment curve to 5mA
Figure 4-7 Examples of CDPs evoked by pyramidal stimulation in normal animals
Each column of traces shows recordings made from one animal. The recordings were 
made at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border as 
indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate 
stimulus artifacts.
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Figure 4-8 Amplitudes of pyramidal-evoked CDPs recorded in the normal group 
The plot shows the amplitudes of CDPs recorded over the cervical spinal cord in response 
to pyramidal stimulation in the normal SD animals (n=11). The plot for normal F344 
animals (n=18) from chapter 2 is shown for comparison. CDP amplitudes are averaged for 
all animals in each group, each data point showing mean +/- SEM. Recording positions are 
shown relative to the C4/5 border (0 mm) where dorsal column lesions were made in 
lesioned groups. In both SD and F344 rats, the distributions of CDP amplitudes evoked by 
pyramidal stimulation were fairly flat over most of the cervical cord but declines in 
amplitudes at further caudal locations. The amplitudes were around 0.3 mV in F344 rats 
and 0.35mV in SD rats. The difference are not significant.
Figure 4-9 Examples of CDPs evoked by pyramidal stimulation in the vehicle treated 
group 
Each column of traces shows recordings made from one animal. The recordings were 
recorded at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate 
stimulus artifacts. 
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Figure 4-10 Amplitudes of pyramidal-evoked CDPs recorded in the vehicle treated 
group 
The plot shows the amplitudes of CDPs recorded over the cervical spinal cord in response 
to pyramidal stimulation in the vehicle group (n=13). The previous plot for the normal 
group is also shown for comparison. CDP amplitudes are averaged for all animals in each 
group, each data point showing mean +/- SEM. Recording positions are shown relative to 
the C4/5 border (0 mm) where dorsal column lesions were made in lesioned groups. 
Compared to those recorded in normal animals, CDPs above the lesion were significantly 
smaller in the vehicle group. Small CDPs were detectable below the lesion. 
Figure 4-11 Examples of CDPs evoked by pyramidal stimulation in the anti-Nogo 
treated group 
Each column of traces shows recordings made from one animal. The recordings were 
recorded at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts.
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Figure 4-12 Amplitudes of pyramidal-evoked CDPs recorded in the anti-Nogo treated 
group 
The plot shows the amplitudes of CDPs recorded over the cervical spinal cord in response 
to pyramidal stimulation in the anti-Nogo group (n=10). The previous plots for the normal 
group and for the vehicle group are also shown for comparison. CDP amplitudes are 
averaged for all animals in each group, each data point showing mean +/- SEM. Recording 
positions are shown relative to the C4/5 border (0 mm) where dorsal column lesions were 
made in lesioned groups. CDPs below the lesion tended to be larger in the anti-Nogo 
treated animals than vehicle treated but the difference was not significant. CDPs above the 
lesion were larger compared to those recorded in the vehicle group and the difference was 
significant at some locations. 
Figure 4-13 Examples of CDPs evoked by pyramidal stimulation in the anti-MAG 
treated group 
Each column of traces shows recordings made from one animal. The recordings were 
recorded at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 50 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. 
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Figure 4-14 Amplitudes of pyramidal-evoked CDPs recorded in the anti-MAG 
treated group 
The plot shows the amplitudes of CDPs recorded over the cervical spinal cord in response 
to pyramidal stimulation in the anti-MAG group (n=8). The previous plots for the normal 
group and for the vehicle group are also shown for comparison. CDP amplitudes are 
averaged for all animals in each group, each data point showing mean +/- SEM. Recording 
positions are shown relative to the C4/5 border (0 mm) where dorsal column lesions were 
made in lesioned groups. In the anti-MAG group, the distribution of CDPs was almost 
identical to those recorded in the vehicle group. 
Figure 4-15 Examples of CDPs evoked by radial nerve stimulation in the normal 
animal group
Each column of traces shows recordings made from one animal. The recordings were 
recorded at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts.
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Figure 4-16 Amplitudes of radial nerve-evoked CDPs recorded in normal SD animals 
compared to F344’s 
The plots show the amplitudes of CDPs recorded over the cervical spinal cord in response 
to radial nerve stimulation in the normal animal groups. Recordings were made from 
normal SD (n=9) and F344 (n=22) rats. CDP amplitudes are averaged for all animals in 
each group, each data point showing mean +/- SEM. Recording positions are shown 
relative to the C4/5 border (0 mm) where dorsal column lesions were made in lesioned 
groups. In both SD and F344 rats, the largest potentials are produced between 0 and -5mm 
which corresponds to the C5 and C6 segments where radial nerve afferents enter the cord. 
CDPs of gradually declining amplitude are, however, evoked for several segments above 
and below this. The amplitudes of the biggest CDPs were 0.7mV in F344 rats and around 
0.8mV in SD rats. 
Figure 4-17 Examples of CDPs evoked by radial nerve stimulation in the vehicle 
treated group 
Each column of traces shows recordings made from one animal. The recordings were 
recorded at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. 
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Figure 4-18 Amplitudes of radial nerve-evoked CDPs recorded in the vehicle treated 
group 
The plot shows the amplitudes of CDPs recorded over the cervical spinal cord in response 
to radial nerve stimulation in the vehicle group (n=14). The previous plot for the normal 
group is also shown for comparison. CDP amplitudes are averaged for all animals in each 
group, each data point showing mean +/- SEM. Recording positions are shown relative to 
the C4/5 border (0 mm) where dorsal column lesions were made in lesioned groups. CDPs 
above the lesion in the vehicle group were almost abolished. CDPs below the lesion were 
almost same as those in normal animals.
Figure 4-19 Examples of CDPs evoked by radial nerve stimulation in the anti-Nogo 
treated group 
Each column of traces shows recordings made from one animal. The recordings were 
recorded at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. 
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Figure 4-20 Amplitudes of radial nerve-evoked CDPs recorded in the anti-Nogo 
treated group 
The plot shows the amplitudes of CDPs recorded over the cervical spinal cord in response 
to radial nerve stimulation in the anti-Nogo group (n=10). The previous plots for the 
normal group and for the vehicle group are also shown for comparison. CDP amplitudes 
are averaged for all animals in each group, each data point showing mean +/- SEM. 
Recording positions are shown relative to the C4/5 border (0 mm) where dorsal column 
lesions were made in lesioned groups. Below the lesion, CDPs were larger in the anti-Nogo 
treated group than those recorded in the vehicle group. The differences were significant at -
3mm and -4mm. They were also larger than CDPs in normal animals at these caudal 
locations but the difference did not reach significance.
Figure 4-21 Examples of CDPs evoked by radial nerve stimulation in the anti-MAG 
treated group 
Each column of traces shows recordings made from one animal. The recordings were 
recorded at 1mm intervals from 8mm rostral to 8mm caudal to the C4/5 segmental border 
as indicated. Traces recorded at +7, +5, -5, and -7mm are omitted. The traces represent 
averages of 25 sweeps and the calibrations apply to all traces. The arrows indicate stimulus 
artifacts. 
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Figure 4-22 Amplitudes of radial nerve-evoked CDPs recorded in the anti-MAG 
treated group 
The plot shows the amplitudes of CDPs recorded over the cervical spinal cord in response 
to radial nerve stimulation in the anti-MAG group (n=9). The previous plots for the normal 
group and for the vehicle group are also shown for comparison. CDP amplitudes are 
averaged for all animals in each group, each data point showing mean +/- SEM. Recording 
positions are shown relative to the C4/5 border (0 mm) where dorsal column lesions were 
made in lesioned groups. In the anti-MAG group, CDPs were almost identical to those 
recorded in the vehicle group. 
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Final discussion and future directions 
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Functional recovery following SCI can be assessed by behavioural tests and 
electrophysiological approaches. Behavioural tests can provide evidence of 
improved performance in the ability of animals to fulfil sensorimotor tasks. 
However, the mechanisms underlying the improved function can not be 
elucidated and the level at which these mechanisms operate (supraspinal or 
spinal) are also undetermined. To investigate the mechanisms underlying 
recovery of function, many studies combine behavioural tests of function with 
anatomical assessments and draw conclusions based on correlation between the 
two. For example, improved functional recovery and ‘sprouting’ have been 
observed in the same animals leading to the idea that sprouting is one 
mechanism supporting functional recovery. However, ‘sprouting’ reported using 
tracer labelling might not always be genuine. It is possible that injury could 
change the properties of axons and consequently enhance their ability to 
transport tracers. In other words, an apparently greater density of axons may be 
due to enhanced labelling rather than new sprouting. Even if there is genuine 
sprouting following the injury, anatomical methods can not show whether 
functional connections have been formed. An advantage of the 
electrophysiological approach is that it can evaluate the function of specific 
spinal pathways and has the potential to provide reliable information about 
changes in functional connections with target pathways. A limitation of the 
electrophysiological approach is that some spinal pathways are difficult to study. 
The corticospinal and sensory pathways studied in this thesis are among the most 
convenient. These same pathways are also relatively accessible to study in man 
using non-invasive approaches. For example, intraoperative somatosensory 
evoked potentials and motor evoked potentials have been monitored during 
spine surgery and have been used for assessing changes in function in patients 
with SCI (Hyun et al. 2009; Sykova et al. 2006).  
Electrophysiological results in this project support previous evidence that a 
lesion to the spinal cord alone can induce a modest degree of spontaneous 
plasticity in the terminations of sensorimotor pathways. As mentioned before, 
one of the main underlying mechanisms for plasticity is anatomical sprouting. 
However, synaptic plasticity is another alternative mechanism and has been 
shown to occur even as partial normal brain function. Long-term potentiation in 
the hippocampus is an example (DeFelipe 2006). Synaptic plasticity can include 
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changes in the quantity of neurotransmitter released at a synapse and changes in 
how effectively cells respond to those neurotransmitters. There are two known 
molecular mechanisms for synaptic plasticity. The first mechanism involves 
modification of existing synaptic proteins resulting in altered synaptic function 
(Shi et al. 1999). The other mechanism depends on second messenger 
neurotransmitters regulating gene transcription and changes in the levels of key 
proteins at synapses. This second mechanism can be triggered by protein 
phosphorylation but takes longer and lasts longer, providing the mechanism for 
long-lasting memory storage. The strength of a synapse also depends on the 
number of ion channels it has. Several facts suggest that neurons change the 
density of receptors on their postsynaptic membranes as a mechanism for 
changing their own excitability in response to stimuli. In a dynamic process that 
is maintained in equilibrium, alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPA receptor) is added to the membrane by 
exocytosis and removed by endocytosis (Pérez-Otaño et al. 2005). These 
processes, and by extension the number of receptors on the membrane, can be 
altered by synaptic activity. Since long-term potentiation relies on the influx of 
Ca2+ through NMDAN-methyl D-aspartate (NMDA) channels, synaptic plasticity 
may be due to changes in NMDA receptors, for example changes in their subunits 
to allow the concentration of Ca2+ in the cell to be lowered more quickly (Shi et 
al. 1999; Pérez-Otaño et al. 2005). 
One strategy for treating spinal cord injury is to enhance spontaneous plasticity. 
Apart from the use of cell transplantation and antibodies to myelin inhibitors as 
investigated in this thesis, other pharmacological interventions are reported to 
induce plasticity. These include neurotrophins and chondroitinase. Neurotrophic 
factors can promote axonal plasticity in the sensorimotor cortex and spinal cord 
(Zhou and Shine, 2003). The inhibitory effects of CSPGs can be degraded by 
ChABC which removes GAG chains from the protein core. ChABC has been shown 
to stimulate the sprouting of injured and uninjured fibres and promote improved 
recovery (Bradbury et al. 2002; Barritt et al. 2006). Electrophysiological data 
also suggest that an improved functional performance in the ChABC treated 
animals is consequent to reorganization of intact primary afferent terminals 
after SCI (Cafferty et al. 2008). There are therefore several potential means by 
which plasticity following spinal cord injury might be enhanced to maximise the 
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function of spared pathways. Our results show that the presence of OECs within 
the spinal cord does not enhance spontaneous plasticity. On the other hand, 
transmission in both corticospinal and sensory pathways was significantly 
enhanced by anti-Nogo antibody treatment.  
In addition to the intervention and treatments described above there is evidence 
that rehabilitation training can augment functional outcome in the clinic 
(Forrest et al. 2008; Schubert et al. 2008). The underlying mechanisms of this 
are under investigation in animal models. A number of studies suggest that an 
enriched environment that promotes locomotion after SCI is beneficial for 
stepping performance in rats and mice (Iankhorst et al. 2001; Van Meeteren et 
al. 2003; Engesser-Cesar et al. 2005). Other studies have focused on task-specific 
training such as reaching training and treadmill training to improve specific 
functions. For example, step training improves stepping and stand training 
improves standing (De Leon et al. 1998). Reaching training promotes plasticity 
and task specific recovery in rats (Girgis et al. 2007). Edgerton and colleagues 
have intensively investigated the effects of treadmill training on functional 
recovery following SCI and confirmed that improved stepping performance can 
be achieved following task-specific training (Ichiyama et al. 2009; Cai et al. 
2006). However, the location and nature of the changes in neural substrates 
underlying the behavioural improvements are not well understood. Plasticity 
after training could be induced by an increase in the amount of trophic factors. 
For example, voluntary exercise can maintain the level of BDNF (Ying et al. 
2005). Repetitive patterns of activation at a synapse could change the properties 
of that synapse (Petruska et al. 2007; Wolpaw and Tennissen, 2001) or reinforce 
spinal pattern generators (Bradbury and McMahon, 2006).  
There is some evidence that directly relates to the corticospinal tract. Thomas  
and Gorassini (2005) have reported that corticospinal tract function is increased 
by treadmill training after incomplete injury, although their assessment of the 
corticospinal tract used transcranial magnetic stimulation which is probably not 
specific for the corticospinal tract in the rat (Nielsen et al. 2007). It has also 
been reported that electrical stimulation of spared corticospinal axons augments 
their connection below an injury (Brus-Ramer et al. 2007). Finally, Girgis et al. 
(2007) have reported an increased collateral sprouting of corticospinal fibres at 
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the spinal level and expansion of part of the forelimb cortical area in animals 
with cervical spinal cord injuries when they were subjected to reaching training. 
However, training has not always resulted in positive improvements. There is 
evidence that training in one task may interfere with performance of another. 
Studies show that task-specific training might potentially diminish some 
functions while augmenting others. For example, when a spinal cat is trained to 
stand it learns to stand, but steps very poorly (De Leon et al. 1998).  Therefore, 
the mechanisms of rehabilitative training have to be investigated and clearly 
understood in order to design the most appropriate form of training.  
Spinal cord injury is a multifaceted problem and successful treatment may 
eventually involve strategies that combine targeting of one or more of the 
strategies of neuroprotection, axonal regeneration, plasticity, and 
rehabilitation. It might also be possible to combine several plasticity promoting 
treatments. For example, anti-Nogo antibody treatment could be combined with 
ChABC treatment if different mechanisms are involved so that a synergistic 
effect is obtained. Combining treatments that promote plasticity with 
rehabilitative training is a combination which is increasingly being investigated. 
In a recent study, the effect of combination of ChABC treatment and physical 
rehabilitation was investigated and it was found that ChABC treatment opens a 
window during which rehabilitation can enhance functional recovery (Garcia-
Alias et al. 2009). 
However, although plasticity plays a role in functional recovery following SCI, it 
does not always result in a beneficial outcome. For instance, sprouting following 
SCI is thought to contribute to autonomic dysreflexia and pain (Weaver et al. 
2006; Finnerup and Jensen, 2004). Some potential treatments have the 
possibility to enhance the ‘bad’ plasticity. Treadmill training has been reported 
to exaggerate autonomic dysreflexia through a combination of enhanced 
vascular reactivity and central plasticity (Laird et al. 2009; Fawcett and Curt, 
2009).  
Combinations of individual beneficial treatments do not always provide better 
recovery following injury. Furthermore, adverse effects of a combinatorial 
treatment have been reported by a number of studies. Maier and colleagues 
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(2009) compared the effects of anti-Nogo antibody treatment and treadmill 
training in rats with incomplete SCI. Even though functional recovery was 
observed in both groups, axonal regeneration and sprouting of descending 
systems was seen only in rats with antibody treatment. Surprisingly, 
combinatorial treatment with both antibody and training produced a poorer 
locomotor performance, compared to individual treatments. It was suggested 
that the mechanisms underlying these changes with each treatment are not only 
different but possibly competitive. Therefore, a full understanding of the 
mechanism underlying each individual treatment as well as their potential 
interactions will be crucial to finding the most effective combination for future 
therapies. 
This thesis has focused, as does much of spinal cord injury research, on the 
changes that occurred in the spinal cord following SCI and potential treatments. 
However, changes at a supraspinal level are substantial and can not be ignored 
(Curt et al. 2002; Corbetta et al. 2002).  Changes at a supraspinal level including 
the cortical level may play an important role in functional recovery (Fouad et al. 
2001) and modulating plasticity at a supraspinal level may prove just as 
important in promoting better functional recovery. 
In the future, enhancing beneficial plasticity at both supraspinal and spinal cord 
levels should be a feasible strategy for improving sensorimotor functions based 
on maximising the function of spared tracts. However, this strategy is likely to 
be most beneficial in patients with a certain degree of spared neuronal 
hardware as only then can plasticity effectively translate into functional 
recovery. Future research in this area will need to focus on obtaining a better 
understanding of how different plasticity inducing treatments actually bring 
about improved function and perhaps better understand how treatments can be 
optimally combined and/or linked to rehabilitation training to maximize 
functional recovery while avoiding the potential adverse effect of innappropriate 
neural re-organization. Appropriate combinatorial treatment of pharmacological 
and rehabilitative training will potentially maximize the spontaneous plasticity 
so that better functional recovery can be attained.  
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